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Macrophages	  are	  an	  important	  class	  of	  cell	  involved	  in	  host	  defence	  and	  homeostasis	  
that	  are	  able	   to	  alter	   their	  phenotype	   in	   response	   to	   their	   surroundings	  and	  affect	  a	  
wide	   range	   of	   biological	   processes.	   These	   properties	   make	   them	   critical	   to	   host	  
function	   in	   normal	   and	   disease	   settings,	   leading	   to	   their	   utility	   as	   targets	   to	   inform	  
upon	  functional	  status	  of	  an	  organ/tissue	  as	  well	  as	  for	  therapeutic	  intervention.	  Thus	  
the	   development	   of	   macrophage-­‐specific	   imaging	   agents	   has	   potential	   clinical	  
applications	  in	  the	  diagnosis	  and	  measuring	  response	  to	  treatment	  of	  disease.	  
This	  thesis	  sets	  forth	  the	  development	  of	  novel	  antibody-­‐based	  nuclear	  imaging	  agents	  
99mTc-­‐SER4,	   64Cu-­‐NOTA-­‐SER4,	   and	   99mTc-­‐ED3	   targeting	   the	   antigen	   sialoadhesin	   and	  
111In-­‐DTPA-­‐ED2	  targeting	  CD163,	  of	  which	  both	  antigens	  are	  macrophage-­‐restricted.	  All	  
the	   agents	   described	   herein	   exhibit	   tracking	   to	   endogenous	   sialoadhesin-­‐expressing	  
macrophage	   populations	   with	   exceptionally	   fast	   blood	   clearance	   times.	   In	   a	  
heterotopic	   cardiac	   transplantation	   model	   of	   acute	   rejection	   the	   tracer	   99mTc-­‐SER4	  
demonstrated	  enhanced	  targeting	  to	  the	  rejected	  organ,	  whilst	   following	  recovery	  to	  
localised	   bone	  marrow	   radioablation	   preliminary	   data	   showed	   increased	   64Cu-­‐NOTA-­‐
SER4	   in	   the	   ablated	   bone	   marrow.	   The	   tracers	   111In-­‐DTPA-­‐ED2	   and	   99mTc-­‐ED3	   also	  
demonstrated	   the	   feasibility	   of	   imaging	   distinct	   macrophage	   populations	  
simultaneously.	  
In	   this	   thesis,	   we	   present	   sialoadhesin	   as	   a	   candidate	   target	   for	   the	   imaging	   of	  
macrophage	  populations	  in	  vivo,	  with	  the	  potential	  for	  translation	  into	  the	  clinic.	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  1:	  	  The	  Macrophage	  Marker	  Sialoadhesin	  and	  Imaging	  
	  
1.1 Introduction	  
Macrophages	   (Mφ)	   are	   an	   important	   class	   of	   cell	   involved	   in	   host	   defence	   and	  
homeostasis.	  Mφ	  are	  able	  to	  alter	  their	  phenotype	  in	  response	  to	  their	  surroundings,	  
affecting	  a	  wide	  range	  of	  biological	  processes.	  These	  properties	  make	  them	  critical	  to	  
host	  function	  in	  normal	  and	  disease	  settings,	  leading	  to	  their	  utility	  as	  targets	  to	  inform	  
upon	   functioning	   as	   well	   as	   for	   therapeutic	   intervention.	   The	   development	   of	   Mφ-­‐
specific	   imaging	   agents	   has	   potential	   clinical	   applications	   in	   the	   diagnosis	   and	  
measuring	  response	  to	  treatment	  of	  disease,	  in	  accordance	  with	  the	  current	  trend	  for	  
personalised	   medicine.	   Additionally,	   non-­‐invasive	   imaging	   of	   Mφ	   populations	   also	  
offers	  researchers	  a	  novel	  means	  of	  studying	  Mφ	  behaviour	  in	  vivo.	  
	  
1.2 An	  Overview	  of	  Mφ-­‐Biology	  	  
Mφ	  are	  present	  in	  virtually	  all	  the	  tissues	  of	  the	  body,	  and	  arise	  from	  the	  recruitment	  
of	   circulating	   monocytes	   (Gordon	   and	   Taylor	   2005).	   As	   immune	   cells,	   they	   are	  
principally	   recognised	   by	   their	   function	   as	   professional	   phagocytes	   in	   which	   they	  
remove	   invading	  pathogens	  via	  the	  array	  of	  germ-­‐line	  encoded	  cell	  surface	  receptors	  
with	  which	  they	  use	  to	  sense	  their	  environment.	  This	  action	  in	  innate	  immunity	  is	  also	  
accompanied	   by	   their	   ability	   to	   secrete	   a	   variety	   of	   cytotoxic	   intermediates	   and	  
cytokines	   to	   affect	   the	   immune	   response,	   and	   also	   to	   present	   antigenic	  material	   via	  
major	  histocompatibility	  complex	   (MHC)	  class	   II	   to	  T	  cells.	  They	   therefore	  participate	  
and	   form	   an	   important	   bridge	   between	   innate	   and	   adaptive	   immunity	   (Gordon	   and	  
Taylor	  2005;	  Pollard	  2009;	  Geissmann,	  Manz	  et	  al.	  2010)	  	  
Based	  on	  their	  anatomical	  location,	  Mφ	  populations	  display	  different	  phenotypes	  and	  




Mφ	  population	   in	   the	  body	  and	  are	   responsible	   for	   clearing	  antigens	   absorbed	   from	  
the	  gastrointestinal	  tract.	  They	  are	  also	  important	  for	  the	  maintenance	  of	  tolerance	  to	  
the	   antigenic	   products	   of	   digestion,	   which	   is	   characterised	   phenotypically	   by	   a	  
reduction	  in	  co-­‐stimulatory	  molecules	  and	  functionally	  by	  the	  release	  of	  interleukin	  10	  
(IL-­‐10)	   in	   response	   to	   lipopolysaccharide	   (Nemeth,	   Baird	   et	   al.	   2009).	   In	   contrast,	  
alveolar	   Mφ	   express	   high	   levels	   of	   pattern	   recognition	   receptors	   which	   permit	   the	  
uptake	  of	  non-­‐opsonised	  particles	  so	  as	  to	  manage	  the	  constant	  influx	  of	  particulates	  
and	   pathogens	   that	   invade	   the	   airways	   (Taylor,	   Martinez-­‐Pomares	   et	   al.	   2005).	  
However,	  to	  avoid	  damaging	  the	  fragile	  alveoli	  environment,	  alveolar	  Mφ	  also	  actively	  
suppress	  adaptive	  immunity	  and	  promote	  the	  secretion	  of	  transforming	  growth	  factor	  
beta	   (TGF-­‐β)	   in	   steady	  state	  conditions	   (Holt,	  Strickland	  et	  al.	  2008).	  Thus,	  Mφ	  serve	  
not	  only	  as	  effectors	  of	  the	  immune	  system	  but	  also	  play	  important	  homeostatic	  and	  
trophic	   roles.	   This	   latter	   point	   is	   exemplified	   by	  mice	   deficient	   in	   colony	   stimulating	  
factor	   1	   (CSF-­‐1),	   so-­‐called	   CSF-­‐1	   op/op	   mice,	   which	   leads	   to	   the	   development	   of	  
osteopetrosis.	  This	  disease	  is	  characterised	  by	  restricted	  bone	  marrow	  cavities	  due	  to	  
the	   failure	  of	  osteoclast	  development	  and	  thus	   failure	  of	  bone	  remodelling	   (Stefater,	  
Ren	  et	  al.	  2011).	  
In	  vivo	  and	  in	  vitro	  Mφ	  display	  considerable	  plasticity	  of	  phenotype,	  understood	  as	  an	  
ability	   to	  continuously	  adapt	   their	  behaviour	   to	   the	  surrounding	  environment	   (Stout,	  
Jiang	  et	  al.	  2005;	  Murray	  and	  Wynn	  2011).	  This	  feature	  is	  important	  as	  it	  allows	  Mφ	  to	  
sequentially	   carry	   out	   multiple,	   and	   sometimes	   disparate,	   functions.	   Attempts	   to	  
characterise	  Mφ	   functional	   status	   has	   led	   to	   the	   adoption	   of	   the	  M1/M2	   paradigm.	  
This	  mirrors	  the	  Th1/Th2	  nomenclature	  where	  M1	  Mφ	  are	  accorded	  an	  inflammatory	  
status	   (these	  are	  also	   sometimes	  known	  as	   classically	  activated	  Mφ)	   typically	  due	   to	  
exposure	  to	  cytokines	  such	  as	  interferon	  gamma	  (IFN-­‐γ);	  while	  M2	  Mφ	  are	  accorded	  an	  
anti-­‐inflammatory	   status	   following	   exposure	   to	   mediators	   such	   as	   IL-­‐4	   (Sica	   and	  







Figure	   1.2.1	   Mφ	   Polarization.	   In	   response	   to	   inflammatory	   stimuli,	   Mφ	   can	   adopt	   an	   M1	  
phenotype	  specialised	  for	  host	  defence	  and	  resulting	  in	  the	  release	  of	  inflammatory	  mediators.	  
M2	   phenotype	   may	   arise	   from	   exposure	   to	   anti-­‐inflammatory	   signals,	   promoting	   processes	  
such	   as	   wound	   repair	   during	   the	   resolution	   of	   inflammation.	   GF	   epidermanl	   growth	   factor,	  
RNS/ROS	   reactive	   nitrogen/oxygen	   species,	   TNFα	   tumor	   necrosis	   factor	   α,	   VEGF	   vascular	  
endothelial	   growth	   factor,	   TGF	  β	   transforming	  growth	   factor	  β.	   Figure	  adapted	   from	   (Laskin,	  
Sunil	  et	  al.	  2011)	  
The	  M2	  phenotype	  has	  since	  become	  a	  general	  pooling	  ground	  for	  any	  phenotype	  that	  
isn’t	  inflammatory,	  leading	  to	  the	  grouping	  of	  behaviours	  that	  aren’t	  well	  related,	  such	  
as	   anti-­‐inflammatory	   behaviour	   with	   wound	   remodelling	   behaviour.	   It	   is	   now	  
commonly	   acknowledged	   that	  Mφ	  do	  not	   adopt	   strict	   phenotypes,	   but	   instead	  exist	  
within	  a	  spectrum	  of	  phenotypes,	  permitting	  them	  to	  subtly	  alter	  their	  actions(Mosser	  
and	   Edwards	   2008).	   However,	   M1/M2	   is	   still	   a	   convenient	   tool	   for	   understanding	  
immunological	  function,	  and	  conveys	  an	  important	  phenomenon	  that	  it	  is	  the	  balance	  
between	   Mφ	   phenotypes	   rather	   than	   Mφ	   burden	   that	   correlates	   with	  
function/dysfunction.	  The	  development	  of	  cancer	  is	  often	  cited	  in	  this	  respect,	  where	  
the	   initiation	   of	   a	   tumour	   is	   the	   result	   of	   inflammatory	  Mφ	  promoting	   an	   abnormal	  
environment.	   Tumour	   progression	   is	   caused	   by	   the	   switch	   from	   inflammatory	   M1	  
phenotype	   to	   anti-­‐inflammatory	   M2	   phenotype,	   which	   provides	   and	  
immunosuppressive	   environment	   that	   enables	   the	   tumour	   to	   evade	   the	   immune	  
system	   (see	   Figure	   1.2)	   (Mantovani	   and	   Sica	   2010).	   In	   a	   converse	   scenario,	   the	  




maturation	   is	   marked	   by	   an	   increase	   of	   M1	   relative	   to	   M2	   Mφ	   numbers	   (Pello,	  
Silvestre	  et	  al.	  2011).	  
	  
	  
Figure	  1.2.2	  Mφ	  polarization	  during	   tumor	  progression.	  Hypothesised	  role	  for	   inflammatory	  
M1	   Mφ	   in	   tumor	   initiation,	   which	   undergo	   phenotypic	   switch	   to	   anti-­‐inflammatory	   M2	  
phenotype	   which	   promotes	   tumour	   expansion.	   Figure	   adapted	   from	   (Mantovani	   and	   Sica	  
2010)	  
	  
1.3 Mφ	  	  Markers	  
There	  are	  a	  variety	  of	  antigens	  used	  in	  the	  ex	  vivo	  identification	  of	  human	  Mφ	  and	  of	  
these	   the	  markers	   CD64,	   CD68	   (Macrosialin),	   CD163,	   CD169	   (Sialoadhesin	   (Sn))	   and	  
CD204	  (Mφ	  Scavenger	  Receptor	  A)	  represent	  the	  set	  of	  trans-­‐species	  pan-­‐Mφ	  markers	  
(Zola,	  Swart	  et	  al.	  2007).	  Due	  to	  the	  significant	  plasticity	  of	  Mφ	  phenotype,	  producing	  a	  
single	   Mφ	   marker	   has	   eluded	   researchers	   and	   none	   is	   uniquely	   expressed	   on	   Mφ.	  
CD64	   is	   expressed	   on	  monocytes	   and	   subsets	   of	   germinal	   and	   blood	   dendritic	   cells	  
(DCs);	  CD68	  on	  various	  leukocytes;	  CD163	  on	  monocytes;	  CD169	  on	  monocytes;	  CD204	  
on	  monocytes	  and	  DCs.	  CD68	   is	  Mφ-­‐restricted,	  however	   it	   is	   an	   intracellular	  antigen	  
and	   thus	   not	   suitable	   for	   non-­‐invasive	   imaging	   due	   to	   restricted	   access.	   Of	   the	  
remaining	  markers,	  CD163	  and	  sialoadhesin	  (Sn,	  CD169	  or	  Siglec	  1)	  represent	  the	  most	  
Mφ-­‐restricted	   of	   these	   markers,	   however	   because	   of	   significant	   levels	   of	   soluble	  
CD163	  (Van	  Gorp,	  Delputte	  et	  al.	  2010),	  access	  to	  cell-­‐bound	  CD163	  is	  compromised,	  






1.4 Siaoladhesin	  and	  the	  Siglec	  Family	  
The	   family	   of	   cell	   surface	   proteins	   known	   as	   the	   Siglecs	   (sialic	   acid	   binding	   Ig-­‐like	  
lectins)	   are	   characterised	   by	   the	   presence	   of	   an	   extracellular	   sialic	   acid-­‐binding	   N-­‐
terminal	  domain	   followed	  by	  up	   to	  16	   further	   immunoglobulin-­‐like	   (Ig-­‐like)	  domains.	  
Although	  no	  broad	  activities/functions	  of	  this	  family	  have	  been	  identified,	  conservation	  
in	  the	  cytoplasmic	  tails	  of	  Siglecs	  coupled	  with	  the	  recurring	  presence	  immunoreceptor	  
tyrosine-­‐based	  inhibitory	  motifs	  (ITIMs)	  in	  a	  majority	  of	  the	  Siglec	  family	  has	  suggested	  
an	   immunoregulatory	  role	   for	   these	  structures	   (Crocker,	  Paulson	  et	  al.	  2007;	  Crocker	  
and	  Redelinghuys	  2008;	  von	  Gunten	  and	  Bochner	  2008).	  As	  one	  of	  the	  first	  members	  
of	   this	   group	   (Kelm,	   Pelz	   et	   al.	   1994),	   the	   receptor	   Sn	  was	   originally	   identified	   on	   a	  
subset	  of	  Mφ	  that	  were	  able	  to	  bind,	  but	  not	  phagocytose,	  sheep	  red	  blood	  cells	  in	  a	  
sialic	  acid-­‐dependent	  manner	  (Crocker	  and	  Gordon	  1985;	  Crocker	  and	  Gordon	  1986).	  
Sequence	  analysis	  of	  mouse	  and	  human	  Sn	  has	  shown	  relatively	   less	  similarity	   in	  the	  
cytoplasmic	  domain	   (32%	  similarity	  with	  human	  Sn)	  as	  compared	  to	  the	  extracellular	  
region	  (72%	  similarity)	  ((Klaas	  and	  Crocker	  2012)).	  This	  observation,	  coupled	  to	  the	  lack	  
of	  an	  ITIM	  (Crocker,	  Mucklow	  et	  al.	  1994;	  Crocker	  and	  Redelinghuys	  2008)	  has	   led	  to	  
the	   speculation	   that	   Sn	   primarily	   serves	   extracellular	   functions,	   such	   as	   cell-­‐cell	   and	  
cell-­‐matrix	  interactions	  (Hartnell,	  Steel	  et	  al.	  2001).	  	  
Sn	   is	   a	   185kDa	   protein	   (Crocker,	   Kelm	   et	   al.	   1991)	   with	   an	   extracellular	   region	  
containing	   17	   Ig-­‐like	   domains	   (Crocker,	   Mucklow	   et	   al.	   1994)	   –	   by	   far	   the	   highest	  
number	   of	   domains	   of	   the	   known	   Siglecs.	   As	   with	   all	   Siglecs,	   sialic	   acid	   binding	   is	  
mediated	   by	   the	   V-­‐set	   terminal	   Ig-­‐like	   domain	   which	   is	   necessary	   and	   sufficient	   for	  
sialic	   acid	   binding	   (Nath,	   Vandermerwe	   et	   al.	   1995;	  May,	   Robinson	   et	   al.	   1998)	   and	  
shows	  a	  preference	  for	  5-­‐N	  acetylated-­‐neuraminic	  acid	  (Neu5Ac)	  which	  is	  α(2,3)-­‐linked	  
to	  preceding	  carbohydrates	  (Crocker,	  Mucklow	  et	  al.	  1994;	  Kelm,	  Schauer	  et	  al.	  1994).	  
Sn	  displays	  low	  affinity	  for	  monovalent	  ligands	  (kD	  in	  the	  range	  of	  1	  mM)	  (Blixt,	  Collins	  
et	   al.	   2003),	   and	   it	   is	   thought	   that	   simultaneous	  multivalent	   low-­‐affinity	  associations	  
create	  sufficient	  high	  avidity	  which	   lead	  to	  biologically	  meaningful	   interactions	  of	  Sn.	  
This	   is	   in-­‐line	  with	   in	   vitro	   data	  demonstrating	   increased	  binding	   capacity	  of	   Sn	  with	  




It	  has	  been	  postulated	  that	  the	  extracellular	  region	  of	  Sn	  may	  function	  to	  extend	  the	  V-­‐
set	  domain	  away	  from	  the	  glycocalyx	  so	  as	  to	  enable	  interaction	  with	  ligands	  in	  a	  trans	  
fashion	  (see	  Figure	  1.3)	   (Crocker,	  Hartnell	  et	  al.	  1997).	  A	  comparison	  of	  Sn	  activity	   in	  
rat	   splenic	   and	   lymph	   node	   (LN)	   Mφ	   has	   indicated	   that	   splenic	   Mφ	   are	   masked	  
considerably	  by	  endogenous	  sialylglycoconjugates	  through	  cis-­‐type	  interactions	  which	  
can	   be	   ablated	   by	   sialidase	   treatment,	   whilst	   LN	   Mφ	   are	   relatively	   unaffected	   by	  
masking	  (Nakamura,	  Yamaji	  et	  al.	  2002).	  In	  this	  way,	  cell	  expression	  of	  sialic	  acids	  may	  
be	  used	  to	  modulate	  functional	  Sn	  levels	  on	  cells,	  in	  effect	  fine	  tuning	  expression.	  
	  
Figure	  1.2.3	  Cis	  and	  Trans	  Sn	  binding.	   	  Cartoon	  of	  Sn	  extending	  beyond	  glycocalyx	  to	  interact	  















1.5 Sialoadhesin	  Expression	  
Of	  the	  species	  studied	  so	  far	  (human	  (Hartnell,	  Steel	  et	  al.	  2001),	  mouse	  (Crocker	  and	  
Gordon	  1989),	   rat	   (Dijkstra,	  Dopp	  et	  al.	  1985)	  and	  pig	   (Revilla,	  Poderoso	  et	  al.	  2009;	  
Poderoso,	  Martinez	  et	  al.	  2011)	  Sn	  has	  been	  found	  to	  be	  most	  abundantly	  expressed	  
by	  Mφ	  subsets	  occupying	  secondary	  lymphoid	  tissue	  (see	  Table	  1.1).	  	  
Sn	  Expression	  in	  Secondary	  Lymphoid	  Tissue	  
Tissue/Cell	  Type	   Rat	   Human	   Mouse	   Pig	  
MMM	   +	   n/a	   +	   /	  
MZM	   +	   -­‐	   +/-­‐	   +	  
PALS	   +/-­‐	   -­‐	   -­‐	   /	  
Splenic	  PFZM	   n/a	   +	   n/a	   n/a	  
PAMS	   n/a	   +	   n/a	   +B	  
Red	  Pulp	   +/-­‐	   +/-­‐	   +/-­‐	   -­‐	  
LN	  Supcapsular	  Sinus	   +	   +A	   +	   +	  
LN	  Medulla	   +	   +A	   +	   +	  
Table	   1.1	   Sn	   expression	   in	   Secondary	   Lymphoid	   Tissue.	   Key:	   n/a	   not	   applicable	   /	  
undetermined,	   -­‐	   undetected,	   +/-­‐	   low	   expression,	   +	   expression.	   PFZM:perifollicular	   zone	  Mφ,	  
PAMS:periartiolar-­‐associated	  Mφ,	   LN:	   lymph	   node,	  MMM:	  marginal	  metallophilic	  Mφ,	  MZM	  
marginal	   zone	  Mφ,	   PALS	   periarteriolar	   lymphoid	   sheath.	   A	  sinusoidal	   expression	   throughout	  
LN53,	  B	  ellipsoidal	  vessels	  associated	  with	  Sn	  expression,	  possibly	  equivalent	  to	  PAMS	  (Revilla,	  
Poderoso	  et	  al.	  2009).	  
	  
In	  all	  species	  studied,	  Mφ	  lining	  the	  subcapsular	  sinus	  (SCS)	  as	  well	  as	  the	  medulla	  of	  
the	   LN	   highly	   express	   Sn,	   whereas	   splenic	   distribution	   varies	   between	   species	   (see	  
Figure	   1.4).	  Marginal	  metallophilic	  Mφ	   (MMM),	   a	   population	   that	   lines	   the	  marginal	  
sinus	  at	   the	  periphery	  of	   the	  white	  pulp	   in	   rodents,	  express	  high	   levels	  of	  Sn.	   In	   rats	  
marginal	   zone	  Mφ	   (MZM)	   exhibit	   similar	   Sn	   levels	   to	  MMM,	  whereas	   in	  mice	  MZM	  
expression	  is	  relatively	  lower.	  Both	  species	  demonstrate	  low	  levels	  of	  Sn	  expression	  in	  
red	  pulp	  Mφ.	  With	  differing	  splenic	  architecture	  in	  primates	  (Mebius	  and	  Kraal	  2005)	  
sialoadhesin	  positive	  (Sn+)	  Mφ	  are	  located	  in	  a	  compartment	  found	  between	  the	  red	  
pulp	   and	   marginal	   zone	   identified	   as	   the	   perifollicular	   zone	   (Steiniger,	   Barth	   et	   al.	  





Figure	  1.2.4	  Comparison	  of	  the	  distribution	  of	  Sn+	  Mφ	  in	  the	  splenic	  microenvironment.	  	   	  A	  
framework	   of	   reticular	   fibroblasts	   (blue)	   forms	   the	   basis	   of	   the	   marginal	   zone	   and	   is	  
continuous	  with	  the	  reticular	  fibroblasts	  in	  the	  red	  pulp	  and	  the	  sinus-­‐lining	  cells	  (green)	  of	  the	  
marginal	  sinus.	  In	  all	  species,	  Sn+	  Mφ	  (red)	  are	  observed	  as	  a	  line	  of	  cells	  at	  the	  internal	  border	  
of	  the	  white	  pulp	  (the	  so	  called	  marginal	  metallophilic	  Mφ	  (MMM)).	  In	  rodents,	  the	  white	  pulp	  
is	  separated	  from	  the	  marginal	  zone	  (MZ)	  by	  a	  marginal	  sinus,	  and	  in	  the	  case	  of	  the	  rat	  spleen,	  
Sn+	  Mφ	  are	  observed	  in	  the	  marginal	  zone.	  In	  humans,	  the	  marginal	  zone	  is	  absent	  of	  Sn+	  Mφ,	  
but	  the	  unique	  structure	  known	  as	  the	  perifollicular	  zone	  contains	  Sn+	  Mφ	  both	  sporadically	  
and	  clustered	  around	  arteriolae	  (known	  as	  periartiolar-­‐associated	  Mφ	  (PAM)).	  Figure	  adapted	  
from	  (Mebius	  and	  Kraal	  2005).	  
	  
In	  the	  absence	  of	  a	  marginal	  sinus	  and	  MMM	  in	  primate	  spleens,	  the	  Mφ	  sheaths	  that	  
line	  capillaries	  of	  the	  perifollicular	  zone	  are	  speculated	  to	  be	  equivocal	  to	  MMM	  found	  
in	  rodents	  (Steiniger,	  Barth	  et	  al.	  1997).	  By	   immunohistochemistry,	  higher	  expression	  
levels	   of	   Sn	  have	  been	   reported	   in	   human	   versus	   chimpanzee	   spleens.	   The	  origin	   of	  
this	   remains	   to	  be	  elucidated,	  but	   could	  be	   the	   result	  of	   increased	  expression	  of	  Sn-­‐
ligand	  (Neu5Ac)	   in	  humans	  or	   increased	  cis-­‐inhibition	  due	  to	  sialic	  acid	  differences	   in	  
chimpanzees	   (Brinkman-­‐Van	   der	   Linden,	   Sjoberg	   et	   al.	   2000).	   In	   pigs,	   splenic	   Sn	  
expression	  is	  observed	  in	  the	  marginal	  zone	  and	  elliptical	  vessels	  (Revilla,	  Poderoso	  et	  
al.	   2009)	   which	   may	   be	   comparable	   to	   the	   periarterial	   Mφ	   sheaths	   observed	   in	  
humans.	  	  
The	   LNs	   and	   the	   white	   pulp	   area	   of	   the	   spleen	   function	   as	   focal	   centres	   where	  
microbial	  particles,	  antigen	  presenting	  cell	   (APCs)	   (which	  may	  carry	  antigen	   from	  the	  
periphery	   or	   acquire	   antigen	   locally)	   and	   their	   corresponding	   antigen-­‐specific	  
lymphocytes	   engage	   and	   initiate	   adaptive	   immune	   responses.	   The	   splenic	   marginal	  
zone/perifollicular	   region	  and	   the	  LN	  SCS	  are	  both	   transitional	  areas	  where	  cells	  and	  
molecules	  enter	   the	  white	  pulp	  or	   LN	  parenchyma	   (see	  Figure	  1.5).	  MMM	   lining	   the	  




anatomically	   analogous	  position	   to	  Mφ	   that	   form	  a	   rim	  under	   the	   LN	  SCS.	  Here,	   the	  
afferent	  lymph	  enters	  the	  tissue,	  which	  is	  consistent	  with	  the	  idea	  that	  these	  cells	  and	  
their	  Sn	  have	  a	  role	  in	  antigen	  capture/processing	  and	  in	  cell-­‐cell	  communication	  (Kraal	  
and	  Mebius	  2006).	  This	  conserved	  positioning	  of	  Sn+	  Mφ	  at	  the	  borders	  of	   lymphoid	  
tissue	   and	   circulating	   fluids	   strongly	   suggests	   a	   function	   as	   a	   mediator	   of	   adaptive	  
immunity.	  
	  
Figure	   1.2.5	   Diagram	   of	   Lymph	   Node	   and	   Schematic	   of	   Spleen.	   	   (A)	   The	   lymph	   node	   is	  
composed	   of	   a	   capsule	   into	   which	   afferent	   lymphatic	   vessels	   drain,	   and	   within	   resides	   the	  
lymph	  node	  cortex	  (containing	  all	  the	  immunological	  machinery)	  which	  is	  separated	  from	  the	  
capsule	   by	   the	   subcapsular	   and	   medullary	   sinuses.	   The	   lymph	   node	   is	   then	   drained	   via	   an	  
efferent	   lymphatic	   vessel.	   (B)	  On	  entry	   into	   the	   spleen,	   blood	   flow	  passes	   from	   the	   afferent	  
artery	   into	   the	  marginal	   zone	  where	   it	   comes	   into	   close	   contact	  with	   the	  white	   pulp.	   From	  
here,	   blood	   drains	   sequentially	   into	   the	   red	   pulp,	   the	   venous	   sinuses	   and	   exits	   the	   spleen	  
through	  the	  efferent	  veins.	  
	  
Lower	  levels	  of	  Sn	  expression	  can	  be	  found	  on	  Mφ	  in	  tissues	  other	  than	  lymphoid,	  with	  
varying	   degrees	   of	   cis-­‐masking	   shown	   to	   obscure	   apparent	   Sn	   levels	   (Nakamura,	  
Yamaji	   et	   al.	   2002;	   Ducreux,	   Crocker	   et	   al.	   2009).	   Both	   mice	   and	   humans	   express	  
relatively	  high	  levels	  of	  Sn	  on	  resident	  bone	  marrow	  Mφ	  (RBMM),	  whereas	  in	  rats	  Sn	  is	  
absent	  from	  this	  population.	  	  
	  
1.6 Sialoadhesin	  Regulation	  	  
It	  has	  been	  shown	  that	  Sn	   induction	  on	  PBMC	  and	  various	  Mφ	  subsets	   isolated	  from	  




2008),	  rats	  (Gessl,	  Boltznitulescu	  et	  al.	  1989;	  vandenBerg,	  vanDie	  et	  al.	  1996)	  and	  pigs	  
(Delputte,	  Van	  Breedam	  et	  al.	  2007)	  can	  be	  achieved	  by	  incubation	  with	  either	  type	  I	  
or	   II	   IFN.	   The	   exception	   to	   this	   has	   been	   mice,	   which	   despite	   being	   the	   most	  
extensively	  studied	  species	  for	  Sn,	  inducing	  factors	  have	  yet	  to	  be	  identified	  (Crocker,	  
Hill	   et	   al.	   1988;	  McWilliam,	   Tree	   et	   al.	   1992).	   Rat	   (Gessl,	   Boltznitulescu	   et	   al.	   1989;	  
vandenBerg,	  vanDie	  et	  al.	  1996)	  and	  human	  Sn	   induction	   (Hartnell,	  Steel	  et	  al.	  2001)	  
has	   also	   been	   shown	   following	   tumour	   necrosis	   factor	   alpha	   (TNF-­‐α)	   exposure,	   and	  
additionally	  ligation	  of	  human	  TLRs	  involved	  in	  viral	  and	  bacterial	  sensing	  (York,	  Nagai	  
et	   al.	   2007)	   (which	   also	   induce	   IFN-­‐α	   secretion)	   have	   been	   observed	   to	   increase	  
expression.	  	  
	  
In	  the	  case	  of	  both	  mice	  and	  pigs	  an	  unidentified	  component	  of	  autologous	  serum	  has	  
been	  shown	  to	  induce	  expression	  (Crocker,	  Hill	  et	  al.	  1988;	  Delputte,	  Van	  Breedam	  et	  
al.	  2007).	  This	  dependence	  of	  expression	  upon	  circulating	  factors	  may	  well	  explain	  the	  
observed	   changes	   in	   Sn	   expression	   on	   Mφ	   populations	   following	   disruption	   of	   the	  
blood-­‐brain	   barrier	   (Perry,	   Crocker	   et	   al.	   1992)	   and	   afferent	   lymphatics	   (Mebius,	  
Hendriks	   et	   al.	   1990).	   The	   factors	   negatively	   regulating	   Sn	   aren’t	   as	   unified.	   TH2	  
cytokines	   in	  mice	   (McWilliam,	   Tree	   et	   al.	   1992)	   and	   both	   viral	   and	   bacterial-­‐sensing	  
TLRs	   in	   humans	   (York,	   Nagai	   et	   al.	   2007)	   have	   been	   shown	   to	   down-­‐regulate	  
expression,	   whilst	   IL-­‐2	   and	   IFN-­‐γ	   demonstrated	   some	   inhibitory	   effect	   in	   rats	  
(Damoiseaux,	  Dopp	  et	  al.	  1989).	  
	  
1.7 Function(s)	  of	  Sialoadhesin	  Positive	  Mφ	  
To	   date,	   the	   functional	   roles	   of	   Sn	   expressing	   Mφ	   in	   the	   LN	   have	   been	   best	  
characterised.	   SCS	  Mφ	  border	   the	   lymphocyte-­‐rich	   LN	  and	   flowing	   lymph,	   leading	   to	  
the	  speculation	  that	  these	  resident	  cells	  perform	  a	  gate-­‐keeping	  role,	  restricting	  access	  
of	  lymphatic	  components	  including	  pathogens	  and	  soluble	  material	  to	  the	  LN.	  SCS	  Mφ	  
capture	   and	   secretion	   of	   IFN-­‐α	   in	   response	   to	   neurotropic	   viral	   infection,	   and	  
subsequent	  prevention	  of	  viral	  access	  to	  the	  central	  nervous	  system	  (CNS)	  exemplifies	  
this	   behaviour	   (Iannacone,	   Moseman	   et	   al.	   2010).	   As	   cells	   of	   the	   innate	   immune	  




activity,	   however	   further	   data	   illustrates	   Sn	   Mφ	   direct	   action	   in	   supporting	   the	  
adaptive	   immune	   response.	   Following	   subcutaneous	   injection	   of	   viral	   particles,	   SCS	  
Mφ	   have	   been	   shown	   to	   prevent	   the	   systemic	   dissemination	   of	   virus	   through	   its	  
capture	  followed	  by	  initiation	  of	  adaptive	  immunity	  directly	  by	  presentation	  of	  antigen	  
to	  B	  cells	  (Junt,	  Moseman	  et	  al.	  2007).	  Similarly,	  SCS	  Mφ-­‐mediated	  capture,	  processing	  
and	  presentation	  of	  antigenic	  material	  to	  invariant	  natural	  killer	  T	  cells	  (Barral,	  Polzella	  
et	  al.	  2010),	  CD8	  T	  cells	  (Asano,	  Nabeyama	  et	  al.	  2011)	  and	  B	  cells	  (Phan,	  Green	  et	  al.	  
2009)	   has	   demonstrated	   this	   connection	   between	   a	   classical	   scavenging	   role	   and	  
engaging	  adaptive	  immunity.	  	  
	  
This	  close	  relationship	  between	  sialoadhesin	  expressing	  Mφ	  and	  lymphocytes	  presents	  
a	  potential	  opportunity	  for	  pathogen	  transmission	  which	  has	  been	  exploited.	  SCS	  Mφ	  
capture	  of	  Toxoplasma	  gondii	  results	  in	  T	  cell	  recruitment	  and	  subsequent	  transfer	  of	  
parasite	   from	  Mφ	   to	   T	   cell,	   which	   then	   promotes	   host	   invasion	   of	   the	   pathogen	   by	  
trafficking	  (Chtanova,	  Han	  et	  al.	  2009).	  
	  
The	  spleen	  similarly	  locates	  sialoadhesin	  positive	  Mφ	  in	  the	  vicinity	  of	  lymphocyte-­‐rich	  
tissue	  and	  flowing	  fluid	  (in	  this	  case	  blood	  rather	  than	  lymph).	  Due	  to	  the	  difficulty	  of	  
isolation	  or	  selected	  depletion	  of	  either	  marginal	  metallophilic	  Mφ	  and	  marginal	  zone	  
Mφ	  subsets	  (the	  splenic	  Mφ	  populations	  that	  express	  high	  Sn	  depending	  upon	  species)	  
identifying	   specific	   roles	   for	   these	   subsets	  has	   so	   far	  proven	   troublesome	   (den	  Haan	  
and	   Kraal	   2012).	   Depletion	   of	   MZ	   Mφ	   (MMM	   +	   MZM)	   via	   clondronate	   liposomes	  
(McGaha,	   Chen	   et	   al.	   2011)	   or	   use	   of	   transgenics	   (Miyake,	   Asano	   et	   al.	   2007)	   and	  
exposure	   to	  apoptotic	   cells	  has	   revealed	   the	   importance	  of	  MZ	  Mφ	  debris	   clearance	  
and	  maintenance	  of	   tolerance,	  with	   their	   absence	   leading	   to	   autoimmunity.	  MZ	  Mφ	  
presence	  was	  also	  required	  in	  generating	  CD8	  T	  cell	  response	  to	  intravenous	  (IV)	  viral	  
infection	  (Backer,	  Schwandt	  et	  al.	  2010).	  This	  study	  showed	  that	  targeting	  of	  antigen	  
specifically	  to	  Sn+	  Mφ	  promoted	  CD8	  T	  cell	  response,	  involving	  cross	  presentation	  with	  
DCs	  but	  not	  eliminating	  a	  possible	  direct	  activation	  role	  for	  Sn+	  Mφ.	  More	  recently,	  an	  
effective	  humoral	   response	   to	  vesicular	   stromatitis	   virus	   (VSV)	  was	   shown	   to	   involve	  
Sn+	  Mφ	  capture	  and	  subsequent	  enforced	  replication,	  thought	  to	  enrich	  antigen	  load	  




as	   repositories	   for	  viral	   replication	   in	  a	   response	   to	  VSV	  challenge	   in	   the	  LN	  which	   is	  
thought	  to	  enhance	  immunity	  (Iannacone,	  Moseman	  et	  al.	  2010).	  These	  data	  all	  point	  
to	   the	   specialised	   role	   that	   Sn+	   Mφ	   play	   as	   scavengers	   and	   enforcers	   of	   adaptive	  
immunity.	  
	  
Analysis	  of	  Sn	  knock-­‐out	  (KO)	  mice	  has	  revealed	  decreased	  soluble	  IgM	  levels	  as	  well	  as	  
subtle	  alteration	  in	  CD8	  T	  cell	  and	  various	  B	  cell	  populations,	  furthering	  the	  notion	  of	  
Sn	   supporting	   immunoregulatory	   functions	   (Oetke,	   Vinson	   et	   al.	   2006).	   During	  
experimental	   allergic	   encephalitis	   (EAE),	   Sn	   KO	   mice	   have	   shown	   reduced	   disease	  
severity	   along	   with	   reduced	   numbers	   of	   infiltrating	   TH1	   and	   TH17	   cell	   in	   the	   CNS.	  
Additionally	  higher	  numbers	  of	   regulatory	  T	   cells	   (Treg)	  were	  observed	   in	   the	  CNS.	   In	  
vitro	  proliferation	  of	  CD4	  T	   cells	  using	  either	  Sn	  KO	  or	  wildtype	   (WT)	  CNS-­‐infiltrating	  
Mφ	  as	  APCs	  showed	  lower	  Treg	  proliferation	  using	  WT	  Mφ	  which	  could	  be	  ameliorated	  
by	  blocking	  of	  Sn	  (Wu,	  Rauch	  et	  al.	  2009).	  This	  was	  the	  first	  in	  vitro	  account	  of	  Sn	  Mφ	  
directly	   regulating	  T	  cell	  behaviour,	  opening	  the	  possibility	   that	   this	  proinflammatory	  
effect	  of	  Sn	   is	  corroborated	  by	  other	  autoimmune	  studies	   in	  which	  Sn	  KO	  mice	  have	  
exhibited	  reduced	  disease	  severity	  (Jiang,	  Hwenda	  et	  al.	  2006;	  Ip,	  Kroner	  et	  al.	  2007).	  
In	   a	   somewhat	   more	   artificial	   model	   of	   disease,	   Sn+	   Mφ	   in	   the	   liver	   have	   been	  
observed	  to	   form	  clusters	  with	  CD4	  and	  CD8	  T	  cells	  during	  a	  successful	  Graft-­‐versus-­‐
Leukaemia	   response.	   Following	   infusion	   of	   anti-­‐Sn	   antibody,	   Mφ-­‐T	   cell	   cluster	  
formation,	  along	  with	  survival	  rate,	  were	  reduced.	  Additionally,	   isolated	  Sn	  Mφ	  were	  
shown	   to	   present	   MHC	   I	   and	   MHC	   II	   restricted	   peptides	   to	   CD8	   and	   CD4	   T	   cells,	  
respectively	  (Rocha,	  Umansky	  et	  al.	  1997;	  Muerkoster,	  Rocha	  et	  al.	  1999).	  Altogether	  
these	  data	  show	  that	  Sn	  directly	  mediates	  effects	  of	  the	   immune	  system	  that	  can	  be	  
broadly	   classified	   as	   inflammatory.	   However,	   the	   exact	   nature	   of	   this	   effect,	   its	  
mechanism	   and	   whether	   it	   is	   affected	   centrally	   (i.e.	   in	   lymphoid	   structures)	   or	  
peripherally	  has	  yet	  to	  be	  determined.	  
	  
In	  vitro	  Sn	  has	  been	  shown	  to	  mediate	  binding	  to	  a	  variety	  of	  pathogens	  in	  a	  sialic	  acid-­‐
dependent	   manner	   (Jones,	   Virji	   et	   al.	   2003;	   Vanderheijden,	   Delputte	   et	   al.	   2003;	  
Monteiro,	   Lobato	   et	   al.	   2005;	   Heikema,	   Bergman	   et	   al.	   2010).	   This	   has	   led	   to	   the	  




from	  the	  lymph/blood	  using	  accessory	  receptors	  (the	  exception	  being	  porcine	  Sn	  which	  
exhibits	   endocytosis	   (Delputte,	   Van	   Gorp	   et	   al.	   2011)).	   In	   line	   with	   this,	   type	   I	   IFN	  
regulation	  of	  Sn	  may	  serve	  to	   increase	  recognition	  of	  sialic	  acid-­‐displaying	  pathogens	  
during	  infection.	  Based	  on	  the	  observation	  that	  Sn	  is	  non-­‐phagocytotic	  and	  possesses	  
an	  extensive,	  highly	  conserved	  extracellular	  domain	  that	  experiences	  considerably	  less	  
cis-­‐masking	   than	   other	   Siglecs,	   another	   hypothesis	   is	   that	   Sn	   mediates	   cell-­‐cell	  
interactions	   (Crocker,	  Paulson	  et	  al.	   2007).	   In	   line	  with	   this,	   Sn	  has	   shown	   to	  display	  
binding	  to	  various	  cell	  populations	   (Hartnell	  2001;	  Crocker	  1995;	  van	  den	  Berg	  1992)	  
with	   one	   study	   recording	   differential	   binding	   according	   to	   T	   cell	   maturity	   in	   which	  
authors	  reasoned	  this	  assisted	  in	  T	  cell	  homing	  to	  lymphoid	  tissue	  (Vandenberg,	  Breve	  
et	   al.	   1992).	   During	   EAE	   (see	   above)	   it	   was	   noted	   that	   Treg	   in	   the	   afflicted	   tissue	  
displayed	  increased	  Sn	  ligand.	   In	  vitro,	   isolated	  Treg	  were	  then	  shown	  to	  proliferate	  in	  
the	  absence/blocking	  of	  Sn	  expression	  on	  Mφ	  which	  were	  acting	  as	  APC,	  establishing	  
the	  link	  between	  Sn-­‐mediated	  interaction	  and	  lymphocyte	  behaviour	  (Wu,	  Rauch	  et	  al.	  
2009).	  Counter	  receptors	  for	  Sn	  including	  CD43	  (van	  den	  Berg,	  Nath	  et	  al.	  2001),	  MUC-­‐
1	  (Nath,	  Hartnell	  et	  al.	  1999),	  Mφ	  galactose	  c-­‐type	  lectin	  1	  (Martinez-­‐Pomares,	  Crocker	  
et	  al.	  1999)	  and	  chimeric	  mannose	  receptor	  binding	  protein	  	  (Kumamoto,	  Higashi	  et	  al.	  
2004)	  contribute	   to	  our	  understanding	   that	  Sn	  can	  mediate	   interactions	  with	  various	  
cell	   surface	   proteins.	   It	   has	   been	   speculated	   that	   to	   meet	   this	   requirement	   in	  
identifying	   self-­‐structures,	   Sn	   expression	   in	   humans	   is	   significantly	   higher	   than	   in	  
primates.	   The	   reasoning	   for	   this	   is	   based	   on	   the	   increase	   burden	   of	   the	   Sn	   ligand	  
Neu5Ac	  in	  humans	  due	  to	  loss	  of	  Neu5Gc	  synthesis,	  leading	  to	  increased	  Sn	  expression	  
in	  order	  to	  maintain	  efficient	  screening	  for	  self	   (Brinkman-­‐Van	  der	  Linden,	  Sjoberg	  et	  
al.	  2000).	  
	  
From	   the	   finding	   that	  MZM	  and	   SCS	  Mφ	  participate	   in	   the	   induction	   of	   an	   adaptive	  
immune	   response,	   targeting	   antigen	   to	   Sn+	   Mφ	   has	   been	   explored	   as	   a	   means	   of	  
inducing	   immunity.	  Delivery	  of	  antigen	  to	  Sn	  using	  a	  monoclonal	  antibody	  (mAb)	  has	  
been	  shown	  to	  strongly	  inhibit	  tumour	  growth	  in	  mice	  (Backer,	  Schwandt	  et	  al.	  2010)	  
whilst	   a	   humoral	   response	   and	   increased	   reactivity	   of	   PBMC	   was	   observed	   in	   pigs	  
(Poderoso,	  Martinez	   et	   al.	   2011).	  Without	   specifically	   targeting	   Sn+	  Mφ,	   an	   efficient	  




This	   effect	   was	   abolished	   by	   selective	   depletion	   of	   Sn+	   Mφ	   in	   LN,	   illustrating	   the	  
importance	  of	  this	  subset	  in	  vaccination	  (Asano,	  Nabeyama	  et	  al.	  2011).	  Coupled	  to	  the	  
data	  concerning	  that	  MZ	  Mφ	  maintain	  self-­‐tolerance	  following	  exposure	  to	  apoptotic	  
material,	  it	  is	  clear	  that	  Sn+	  Mφ	  represent	  important	  links	  in	  the	  induction	  of	  tolerance	  
and	  in-­‐tolerance	  (i.e.	  vaccination).	  	  
	  
1.8 Sialoadhesin	  in	  Disease	  Settings	  
Sialoadhesin	  positive	  Mφ	  have	  been	  identified	  in	  a	  variety	  of	  disease	  settings,	  and	  the	  
following	  collates	  the	  known	  data	  in	  separate	  models.	  
1.8.1 Cancer	  
Mφ	  	  play	  an	  important	  role	  in	  the	  pathophysiology	  of	  cancer,	  displaying	  both	  pro-­‐	  and	  
anti-­‐tumorcidal	  behaviours	   	  (Mantovani,	  Allavena	  et	  al.	  2008).	  Clinically,	   increased	  Sn	  
expression	  has	  been	  recorded	  in	  splenic	  marginal	  cell	  lymphoma	  (Marmey,	  Boix	  et	  al.	  
2006)	   as	  well	   as	   identification	  of	   Sn	  positive	  Mφ	   infiltrates	   in	  MUC-­‐1	  positive	  breast	  
carcinoma	  (Nath,	  Hartnell	  et	  al.	  1999).	  
In	  mice,	  splenic	  and	   liver	  Sn	  expression	  has	  been	  shown	  to	  correlate	  with	   lymphoma	  
stasis/regression	  in	  a	  model	  of	  Graft-­‐versus-­‐Leukaemia	  reactivity	  (Umansky,	  Beckhove	  
et	   al.	   1996;	   Rocha,	   Umansky	   et	   al.	   1997;	   Muerkoster,	   Wachowski	   et	   al.	   1998).	  
Following	  adoptive	  immunotherapy	  in	  this	  model,	  donor	   lymphocytes	  were	  shown	  to	  
cluster	   with	   Sn+	   Mφ	   and	   isolated	   Mφ	   were	   able	   act	   as	   a	   professional	   APC	   by	  
presenting	  antigen	  to	  CD4	  and	  CD8	  T	  cells	   (Rocha,	  Umansky	  et	  al.	  1997;	  Muerkoster,	  
Wachowski	  et	  al.	  1998).	  Furthermore,	  in	  vivo	  administration	  of	  a	  non-­‐depleting	  anti-­‐Sn	  
mAb	  resulted	  in	  reduced	  accumulation	  of	  CD8	  T	  cells	  and	  cluster	  formation,	  as	  well	  as	  
reduced	  survival	  rates.	  In	  vitro	  Sn	  blocking	  showed	  reduced	  proliferation	  of	  cytotoxic	  T	  
lymphocytes	  in	  the	  presence	  of	  Sn+	  Mφ	  pulsed	  with	  antigen	  (Muerkoster,	  Rocha	  et	  al.	  
1999).	  These	  Sn+	  Mφ	  were	  later	  shown	  to	  express	  increased	  levels	  of	  CD40,	  a	  receptor	  
which	   is	   involved	   in	   T	   cell	   priming,	   activation	   and	   differentiation	   as	   well	   as	   in	   the	  
mediation	  of	  Mφ	  effector	  functions	  suggesting	  that	  Sn+	  Mφ	  activate	  recruited	  T	  cells	  
and	   hence	   promote	   a	   tumoricidal	   response	   (Muerkoster,	   Laman	   et	   al.	   2000).	  
Altogether,	  these	  data	  point	  to	  immunologically	  active	  role	  for	  Sn	  in	  promoting	  tumour	  




Analysis	   of	   rat	   tumours	   has	   shown	   Sn+	   Mφ	   to	   be	   present	   in	   hepatic	   metastatic	  
carcinoma	   (Heuff,	   Vanderende	   et	   al.	   1993),	   adenocarcinoma	   of	   the	   prostate	  
(Landstrom	   and	   Funa	   1997)	   and	   transplanted	   xenografts	   (Yamashiro,	   Takeya	   et	   al.	  
1994;	  Yamashiro,	  Takeya	  et	  al.	  1998).	  In	  prostate	  adenocarcinoma	  the	  number	  of	  Sn+	  
Mφ	   has	   shown	   a	   strong	   positive	   correlation	   with	   tumour	   apoptosis	   and	   negative	  
correlation	   with	   tumour	   growth.	   As	   with	   mice,	   rat	   Sn	   expression	   was	   found	   to	   be	  
concomitant	  with	  lymphocyte	  recruitment.	  	  
	  
1.8.2 Arthritis	  
As	   inflammatory	  cells,	  Mφ	  constitute	  a	  significant	  proportion	  of	   the	  cellular	   infiltrate	  
during	  rheumatoid	  arthritis	  and	  contribute	  to	  both	  tissue	  destruction	  and	  remodelling	  
during	  disease	  progression	   (Kinne,	   Stuhlmueller	  et	  al.	   2007).	   In	  keeping	  with	   this,	   Sn	  
positive	  Mφ	   have	   been	   identified	   in	   the	   joints	   of	   RA	   patients	   (Hartnell,	   Steel	   et	   al.	  
2001).	  
In	   the	   rat,	   accumulation	   of	   Sn+	  Mφ	   into	   the	   arthritic	   synovium	   and	   joint	   space	   has	  
been	   shown	   to	   occur	   within	   a	   day	   following	   induction	   and	   along	   with	   lymphocyte	  
influx	   (Dijkstra,	   Dopp	   et	   al.	   1987;	   Verschure,	   Vannoorden	   et	   al.	   1989;	   Kool,	  
Gerritsboeye	  et	  al.	  1992).	  Following	  arthritic	  induction,	  increased	  Sn	  expression	  in	  the	  
LN	   SCS,	   splenic	  MZ	   and	   red	   pulp	   has	   been	   found	  which	  may	   be	   a	   reflection	   of	   the	  
increased	  serum	  levels	  of	  relevant	   inflammatory	  cytokines	   (Carol,	  Pelegri	  et	  al.	  2000)	  
(see	   Section	   1.8).	   Similarly	   a	   systemic	   increase	   in	   TNF-­‐α	   has	   been	   observed	   after	  
arthritis	  induced	  by	  intraperitoneal	  (IP)	  injection	  with	  streptococcal	  cell	  wall	  fragments	  
in	  which	  elevated	  Sn	  expression	  was	  found	  on	  isolated	  peritoneal	  Mφ	  (Chou,	  Dong	  et	  
al.	  1998).	  Treatment	  with	  clodronate-­‐laden	  small	  unilamellar	  vesicles	  (SUVc)	  has	  been	  
shown	   to	   reduce	   overall	   Mφ	   burden	   (including	   Sn+	   Mφ)	   and	   arthritic	   severity	  
(Richards,	  Williams	  et	  al.	  1999),	  although	  whether	  this	  effect	  resulted	  specifically	  from	  
the	   Sn+	   Mφ	   subset	   was	   undetermined.	   The	   sum	   of	   this	   data	   strongly	   correlates	  
inflammation	  with	  the	  presence	  of	  Sn	  positive,	  furthering	  the	  notion	  of	  Sn	  as	  a	  marker	  






Glomerulonephritis	   is	   an	   inflammatory	   renal	   disease	   in	  which	  Mφ	   accumulation	   is	   a	  
prominent	  feature,	  and	  where	  increased	  burden	  correlates	  to	  poorer	  clinical	  prognosis	  
(Nikolic-­‐Paterson	   and	   Atkins	   2001).	   Analysis	   of	   kidney	   tissue	   from	   patients	   with	  
glomerulonephritis	  has	  shown	  that	  Sn+	  Mφ	  accumulation	  correlated	  with	  glomerular	  
injury	   and	   following	   glucocorticoid	   therapy	   Sn	   expressing	   Mφ	   numbers	   dropped	  
(Ikezumi,	   Suzuki	   et	   al.	   2005).	   Sn	   expressing	  Mφ	  have	   been	  widely	   studied	   in	   rodent	  
models	   of	   glomerulonephritis,	   principally	   as	   an	   indicator	   of	   Mφ	   maturity/activation	  
during	   nephritis	   (Lan,	   Nikolicpaterson	   et	   al.	   1993;	   Lan,	   Nikolicpaterson	   et	   al.	   1995;	  
Erwig	  and	  Rees	  1999;	  Lai,	  Cook	  et	  al.	  2001;	  Kluth,	  Erwig	  et	  al.	  2004;	  Yamate,	  Machida	  
et	   al.	   2004;	   Ricardo,	   van	   Goor	   et	   al.	   2008).	   As	   with	   humans,	   anti-­‐inflammatory	  
treatment	   (IL-­‐4	   (Cook,	   Singh	   et	   al.	   1999),	   IL-­‐6	   (Karkar,	   Smith	   et	   al.	   1997),	   IL-­‐11	   (Lai,	  
Cook	  et	  al.	  2001),	  has	  resulted	  in	  depletion	  of	  Sn	  Mφ	  	  recruitment	  and	  amelioration	  of	  
disease	  severity.	  	  
	  
1.8.4 CNS	  Inflammation	  
The	  recent	  development	  of	  Sn	  KO	  mice	  has	  allowed	  the	  study	  of	  these	  Mφ	  in	  various	  
autoimmune	   settings,	  which	   has	   provided	   further	   evidence	   of	   an	   immunoregulatory	  
role.	   Sn	   KO	   mice	   display	   reduced	   disease	   severity	   in	   experimental	   autoimmune	  
uveoretinitis	   (EAU)	   (Jiang,	   Hwenda	   et	   al.	   2006),	   and	   myelin	   degeneration	   models	  
(Kobsar,	   Oetke	   et	   al.	   2006;	   Ip,	   Kroner	   et	   al.	   2007)	   in	   which	   reduced	   lymphocyte	  
invasion	  was	  observed	  in	  KO	  strains.	  	  During	  EAE	  increased	  Treg	  and	  decreased	  effector	  
T	  cell	  numbers	  were	  detected	  in	  the	  CNS	  of	  KO	  compared	  to	  wild	  type	  (WT)	  mice,	  with	  
in	   vitro	   data	   showing	   Sn	   expression	   to	   directly	   influence	   Treg	   proliferative	   responses	  
(see	  Section	  1.6)	  (Wu,	  Rauch	  et	  al.	  2009).	  
Monocytes	   cultured	   from	   rat	   strains	   which	   are	   more	   susceptible	   to	   experimental	  
autoimmune	  disease	  induction	  have	  demonstrated	  higher	  levels	  of	  Sn	  expression	  than	  
less	  susceptible	  strains	  (Damoiseaux,	  Huitinga	  et	  al.	  1992).	  This	  mirrors	  KO	  data	  from	  
mice,	   insofar	   as	   Sn	   expression	   correlates	  with	   disease	   severity.	   Also	   similar	   to	  mice,	  
induction	  of	  experimental	  allergic	  encephalomyelitis	  resulted	  in	  the	  recruitment	  of	  Sn+	  




Once	   again	   lymphocyte	   recruitment	   was	   positively	   correlated	   with	   increased	   Sn	  
however	  no	  causal	  relationship	  was	  shown.	  Taken	  together,	  these	  data	  point	  towards	  
the	  presence	  of	  Sn	  strongly	  associates	  with	  an	  adaptive	  immune	  response.	  
	  
1.9 Expression	  of	  Sn	  in	  other	  Myeloid-­‐lineage	  cells	  
Under	  homeostatic	  conditions,	  Sn	  expression	  is	  restricted	  to	  mature	  Mφ	  populations,	  
although	  there	  is	  evidence	  that	  a	  subset	  of	  DC	  in	  the	  LN	  may	  perhaps	  also	  express	  Sn	  
(Crocker	   and	   Gordon	   1989;	   Berney,	   Herren	   et	   al.	   1999;	   den	   Haan	   and	   Kraal	   2012).	  
However,	   under	   pathological	   circumstances	   expression	   has	   also	   been	   shown	   to	   be	  
elevated	  on	  circulating	  monocytes	  in	  a	  variety	  of	  clinical	  conditions	  including	  coronary	  
artery	   disease	   (CAD)	   (Xiong,	   Zhou	   et	   al.	   2009),	   Systemic	   Lupus	   Erythematosus	   (SLE)	  
(Biesen,	   Demir	   et	   al.	   2008),	   HIV	   (Pulliam,	   Sun	   et	   al.	   2004)	   and	   systemic	   sclerosis	  
patients	  (York,	  Nagai	  et	  al.	  2007).	  For	  CAD	  and	  SLE,	  expression	  of	  Sn	  on	  monocytes	  was	  
correlated	   to	  disease	   severity.	  Additionally	   in	   SLE,	   Sn	   levels	  were	   strongly	   correlated	  
with	  IFN-­‐α,	  indicating	  the	  dependence	  of	  expression	  upon	  inflammatory	  stimuli,	  which	  
is	   consistent	   with	   in	   vitro	   type	   I	   IFN	   regulation	   of	   Sn	   (see	   Section	   1.6).	   Whether	  
expression	   is	   a	   factor	   in	  disease	  progression	  or	   is	   simply	   symptomatic	   is	   unresolved,	  
with	   some	   speculating	   on	   a	   role	   in	   monocyte	   recruitment	   to	   sites	   of	   inflammation	  
(Xiong,	  Zhou	  et	  al.	  2009).	  An	  interesting	  observation	  has	  been	  in	  HIV	  upregulation	  of	  Sn	  
on	  circulating	  monocytes,	  in	  which	  Sn	  may	  offer	  a	  means	  for	  HIV	  to	  gain	  access	  to	  the	  
CNS.	   In	   this	   scenario,	   it	   has	   been	   speculated	   that	   the	   increased	   infection	   of	   Sn+	  
monocytes	  serves	  to	  promote	  HIV-­‐associated	  dementia	  (Rempel,	  Calosing	  et	  al.	  2008).	  
When	  considering	  the	  expression	  of	  Sn	  on	  DC,	  it	  has	  been	  shown	  in	  vitro	  that	  Sn	  can	  be	  
induced	  following	  exposure	  to	  human	  rhinovirus	  and	  that	  potent	  T	  cell	  anergy	  can	  be	  
affected	  in	  mixed	  leukocyte	  reaction	  coculture	  experiments	  (Kirchberger,	  Majdic	  et	  al.	  
2005).	   It	   was	   speculated	   that	   synapse	   formation	   during	   T	   cell	   activation	   could	   be	  
inhibited	  by	  Sn	  liganding	  to	  CD43,	  and	  later	  on	  shown	  that	  the	  inhibitory	  factor	  was	  IL-­‐
35	  specifically	  released	  from	  CD4+	  and	  CD8+	  T	  effector	  cells	  (Seyer,	  Kirchberger	  et	  al.	  





1.10 Molecular	  Imaging	  
Molecular	   imaging	   has	   been	   described	   as	   the	   visual	   representation,	   characterisation	  
and	  quantification	  of	  biological	  processes	  at	  the	  cellular	  and	  subcellular	  level	  in	  a	  living	  
host	   (Massoud	   and	   Gambhir	   2003).	   This	   technology	   relies	   on	   the	   use	   of	   molecular	  
probes	   in	   conjunction	   with	   various	   imaging	   modalities	   (e.g.	   positron	   emission	  
tomography	   (PET),	  magnetic	   resonance	   imaging	   (MRI),	   etc.)	   to	   non-­‐invasively	   detect	  
biological	   events.	   For	   research	   purposes,	   the	   value	   of	   molecular	   imaging	   is	   in	   the	  
analysis	   of	   intact	   living	   subjects.	   This	   permits	   repeated	   studies	   on	   the	   same	   subject	  
(reducing	  both	  subject	  numbers	  and	  variability	  from	  using	  multiple	  subjects),	  analysis	  
of	  processes	  in	  an	  in	  vivo	  setting	  (more	  biologically	  meaningful	  than	  an	  in	  vitro	  setting),	  
as	  well	  as	  whole	  body	  visualisation	  of	  processes	  rather	  than	  sampled	  regions	  (such	  as	  
with	   histological	   approaches).	   In	   clinical	   terms,	   molecular	   imaging	   represents	   a	  
significant	   technological	   advance	  as	  earlier	   techniques	  have	   relied	  upon	  detection	  of	  
morphological	   and	   structural	   changes	   in	   order	   to	   infer	   diagnose	   and	   monitor	  
pathology.	   As	   such	   changes	   typically	   occur	   during	   the	   advanced	   stages	   of	   disease,	  
molecular	  imaging	  allows	  for	  earlier	  detection	  (and	  with	  it	  earlier	  medical	  intervention)	  
as	   well	   as	   inform	   upon	   a	   patients	   response	   to	   treatment.	   Additionally,	   molecular	  
imaging	   can	   assist	   in	   the	   prediction	   of	   a	   patients	   response	   to	   therapy	   (e.g.	   a	   radio-­‐
labelled	   therapeutic	   can	   inform	  upon	  whether	   the	   therapeutic	  will	   target	   the	   site	  of	  
disease	   in	   an	   individual	   sufficiently)	   and	   is	   also	   used	   in	   radio-­‐immunotherapy	   for	  
dosing	   calculations,	   which	   are	   critical	   for	   optimising	   treatment	   (James	   and	   Gambhir	  
2012).	  	  
	  
1.10.1 Nuclear	  Imaging	  
Nuclear	  imaging	  is	  the	  process	  of	  detecting	  an	  administered	  radioactive	  compound	  in	  
order	   to	   non-­‐invasively	   visualise	   physiological	   processes	   (in	   both	   disease	   and	  
homeostasis).	  This	   technique	  relies	  upon	  the	   inclusion	  of	  a	   radioactive	  nuclide	   into	  a	  
targeting	   vector	   which	   shows	   specificity	   for	   a	   desired	   structure/process	   as	   well	   as	  
instrumentation	  able	  to	  detect	  the	  appropriate	  source	  of	  radiation.	  
The	   two	   technologies	   used	   for	   detecting	   an	   administered	   radiotracer	   both	   depend	  




systems	   are	   single	   photon	   emission	   computed	   tomography	   (SPECT)	   and	   PET.	   SPECT	  
involves	   the	   detection	   of	   γ	   radiation	   released	   from	   the	   nuclear	   rearrangement	   of	   a	  
radionuclide.	   This	   is	   driven	   by	   a	   radioisotope	   changing	   its	   nuclear	   structure	   from	   a	  
higher	  energy	  configuration	  to	  a	  lower,	  more	  stable	  one,	  with	  the	  difference	  in	  energy	  
between	   these	   states	   released	   as	   γ	   radiation	   Rather	   than	   detecting	   γ	   radiation	  
released	   from	   nuclear	   rearrangement,	   PET	   detects	   radiation	   released	   from	   the	  
annihilation	  of	  a	  positron	  with	  an	  electron,	  which	  produces	  two	  photons	  at	  180°	  to	  one	  
another.	  The	  origin	  of	  the	  positron	  is	  a	  radioisotope	  with	  an	  overabundance	  of	  protons	  
in	   its	   nucleus	  which	   achieves	   greater	   stability	   through	   the	   decay	   of	   a	   proton	   into	   a	  
neutron	  and	  a	  positron	  (and	  a	  neutrino)	  (see	  Figure	  1.6).	  	  
	  
Figure	   1.2.6	   Positron	   Annihilation.	   	   Atoms	   with	   an	   overabundance	   of	   protons	   can	   achieve	  
greater	   stability	   by	   the	   conversion	   of	   a	   proton	   into	   a	   neutron	   along	   with	   the	   release	   of	   a	  
positron.	  An	  annihilation	  event	  results	  from	  a	  positron	  encountering	  an	  electron	  which	  results	  
in	   the	   release	   of	   two	   photons	   with	   a	   fixed	   energy	   (511	   KeV)	   at	   180°	   from	   each	   other.	   PET	  
systems	  are	  designed	  to	  detect	  these	  events.	  
	  
These	  two	  different	  sources	  of	  γ	  radiation	  result	  in	  slightly	  different	  scanners	  designed	  
for	   their	   detection.	   Both	   designs	   include	   a	   basic	   γ	   camera	   that	   is	   composed	   of	   a	  
scintillator,	   which	   fluoresces	   in	   response	   to	   incoming	   γ	   radiation,	   coupled	   to	   a	  
photomultiplier,	  which	  amplifies	  and	  digitises	  this	  fluorescent	  signal.	  The	  systems	  then	  
diverge	  in	  terms	  of	  how	  they	  collect	  incident	  radiation.	  SPECT	  scanners	  typically	  use	  a	  
rotating	   set	   of	   cameras	  which	   include	   collimators	   to	   eliminate	   photons	   that	   are	   not	  
perpendicular	   to	   the	   scintillator.	   A	   series	   of	   planar	   images	   are	   then	   made	   from	  
multiple	  angles	  which	  are	  then	  reconstructed	  into	  a	  3D	  image	  of	  activity	  distribution.	  
PET	   systems	   instead	   utilise	   a	   360°	   arrangement	   of	   cameras	   which	   only	   detect	   180°	  
photons	  that	  arrive	  within	  a	  short	  time	  of	  one	  another	  (these	  being	  photons	  produced	  
from	   positron	   annihilation).	   The	   origin	   of	   radiation	   can	   then	   be	   derived	   from	   the	  





Figure	  1.2.7	  Schematic	  of	  SPECT	  and	  PET	  scanners.	  	  A)	  SPECT	  scanners	  employ	  γ	  cameras	  on	  a	  
rotating	  axis	  which	  collect	  photons	  that	  arrive	  perpendicular	  to	  the	  camera’s	  scintillator	  (a)	  to	  
produce	   a	   series	   of	   planar	   images	   that	   are	   reconstructed	   into	   a	   3D	   image	   of	   activity	  
distribution.	  Non-­‐perpendicular	  photons	  are	  eliminated	  by	  the	  presence	  of	  a	  collimator	  (b).	  B)	  
PET	   scanners	   contain	   a	   360°	   ring	  of	   cameras	  which	   identify	   annihilation	   events	   by	  detecting	  
the	  near	  simultaneous	  arrival	  of	  180°	  photons.	  PET	  scanners	  dispense	  with	  collimators	  hence	  
have	  greater	  sensitivity	  as	  compared	  to	  SPECT	  systems.	  
	  
As	   PET	   systems	   do	   not	   require	   collimators,	   far	   more	   incident	   radiation	   reaches	   the	  
scintillator	  compared	  to	  SPECT	  hence	  PET	   is	  a	  more	  sensitive	  technique.	  Additionally,	  
attenuation	  correction	  (the	  process	  of	  correcting	  for	  signal	  loss	  due	  to	  interaction	  with	  
the	  matter	   it	   passes	   through,	   i.e.	   the	   patient)	   is	  much	   simplified	   in	   PET	   than	   SPECT	  
which	  improves	  image	  quality	  (Garcia	  2012).	  The	  reliance	  on	  positron	  annihilation	  for	  
PET	  results	   in	  an	  inherent	  limit	  to	  accuracy	  as	  the	  origin	  of	  radiationis	  the	  location	  of	  
the	   annihilation	   event,	   which	   can	   be	   in	   excess	   of	   a	   1mm	   from	   the	   tracer	   (which	   is	  
radioisotope	  dependent).	  Also	  as	  the	  radiation	  released	  from	  annihilation	  is	  always	  the	  
same	  wavelength,	  distinctions	  between	  radionuclides	  cannot	  be	  made	  in	  PET	  whereas	  
in	   SPECT	   different	   nuclides	   emitting	   different	   wavelength	   radiation	   permit	   multiple	  
tracers	   to	   be	   administered	   and	  detected	   simultaneously.	   The	  high	   cost	   of	   producing	  
PET	  nuclides	  in	  cyclotrons	  as	  compared	  to	  generator	  produced	  SPECT	  isotopes	  has	  also	  
provided	  economic	  obstacles	  to	  PET	  development.	  However,	  the	  greater	  availability	  of	  
non-­‐metallic	  PET	  radioisotopes	  (alongside	  metallic	  PET	  isotopes)	  permits	  the	  synthesis	  





1.10.2 Imaging	  Mφ	  
To	   date	   in	   vivo	   imaging	   of	   Mφ	   has	   largely	   focussed	   upon	   either	   exploiting	   their	  
phagocytotic	   activity	   by	   engulfment	   of	   particulate	   agents	   (such	   as	   ultrasmall	  
superparamagnetic	  ironoxide	  nanoparticles	  (USPIOs)	  (Tang,	  Muller	  et	  al.	  2009;	  de	  Roos	  
2012)	   and	   perfluorocarbon	   emulsions	   (Temme,	   Boenner	   et	   al.	   2012))	   or	   by	   the	  
targeting	   of	   structures	   (such	   as	   vascular	   cellular	   adhesion	   protein-­‐1)	   and	   products	  
(such	   as	   reactive	   oxygen	   species)	  which	   are	   not	   exclusive	   to	   this	   cell	   type	   (Quillard,	  
Croce	   et	   al.	   2011).	   The	   widespread	   use	   of	   nanoparticle-­‐based	   imaging	   agents	   is	   as	  
much	  an	  exploitation	  of	  Mφ	  	  phagocytotic	  activity	  as	  it	  is	  a	  response	  to	  a	  lack	  of	  Mφ	  -­‐
restricted	  antigens,	  this	  being	  a	  consequence	  of	  their	  considerable	  plasticity.	  The	  lack	  
of	   specificity	   of	   nanoparticles	   is	   observed	   in	   USPIOs	   uptake	   where	   despite	   the	  
significant	   role	   that	   Mφ	   	   scavenger	   receptor	   A	   plays	   (Lunov,	   Zablotskii	   et	   al.	   2011)	  
USPIOs	  uptake	  is	  also	  seen	  in	  rapidly	  proliferating	  cells	  (Moore,	  Weissleder	  et	  al.	  1997).	  
Furthermore	  the	  presence	  of	  Mφ	  is	  not	  necessarily	  indicative	  of	  disease	  prognosis	  as	  it	  
is	   often	   the	   balance	   of	   Mφ	   phenotypes	   that	   determines	   outcome	   (see	   1.1)	   and	   so	  
agents	  that	  can	  reveal	  this	  are	  desirable.	  
The	  targeting	  of	  Mφ	  	  scavenger	  receptors	  through	  peptide	  motifs	  is	  increasingly	  being	  
explored	   for	   imaging	  applications,	  particularly	   in	   the	   field	  of	  atherosclerosis	   research	  
(Cormode,	   Chandrasekar	   et	   al.	   2009;	   Segers,	   Yu	   et	   al.	   2012).	   Additionally,	   folate	  
receptor	   (FR)	   targeting	   is	   currently	   under	   clinical	   trials	   as	   a	   means	   of	   imaging	   and	  
therapeutic	  delivery	  of	  M1	  Mφ	  	   (Low,	  Henne	  et	  al.	  2008),	  and	  has	  seen	  successful	   in	  
visualising	   a	   variety	   of	   Mφ	   -­‐mediated	   disease	   settings,	   including	   arthritis	   (Xia,	  
Hilgenbrink	   et	   al.	   2009),	   atherosclerosis	   (Ayala-­‐Lopez,	   Xia	   et	   al.	   2010)	   and	   infection	  
(Henne,	   Rothenbuhler	   et	   al.	   2012).	   This	   promising	   tracer	   is	   also	   used	   for	   imaging	  
cancer	   as	   tumours	   have	   been	   shown	   to	   upregulate	   FR	   (see	   Chapter	   4),	   which	   does	  
confound	  its	  Mφ	  	  specificity,	  and	  also	  present	  imaging	  formulations	  are	  based	  on	  small	  






1.11 Rational	  for	  this	  study	  
Mφ	  are	  a	  critical	  cell	  type	  in	  a	  variety	  of	  homeostatic	  and	  pathological	  processes,	  such	  
that	   the	   ability	   to	   non-­‐invasively	   detect	   their	   presence	   or	   absence	   can	   inform	   upon	  
proper	  and	  improper	  host	  functioning.	  Furthermore,	  the	  ability	  to	  identify	  specific	  Mφ	  
subclasses	   is	  more	   informative	  as	  Mφ	  phenotype	   is	  often	  the	  determinant	  of	  disease	  
outcome.	  
The	   sialic	   acid	   receptor	   Sn	   is	   expressed	   on	  Mφ	   in	   disease	   settings	   and	   is	   conserved	  
between	  humans	  and	  preclinical	  models.	  We	  hypothesise	  that	  Sn	  represents	  a	  putative	  
candidate	   target	   for	   the	   imaging	   of	   a	   Mφ	   subpopulation	   in	   disease,	   and	   have	  




The	   aims	   of	   this	   project	   were	   to	   develop	   imaging	   systems	   that	   would	   allow	   the	  
detection	  of	  Sn-­‐expressing	  Mφ	  in	  disease	  conditions.	  	  
1. To	  produce	  and	  evaluate,	   in	   vitro,	   a	  mouse	  Sn	   specific	   imaging	  agent	   for	  SPECT	  
using	  the	  mAb	  SER-­‐4	  
2. To	  validate	  the	  use	  of	  the	  SPECT	  tracer	  in	  vivo	  and	  in	  an	  acute	  transplant	  rejection	  
model	  in	  the	  mouse	  
3. To	  produce	  and	  validate	  an	  anti-­‐Sn	  PET	   radio-­‐immunoconjugate	  using	  a	  murine	  
radioablation	  model	  
4. To	   evaluate	   the	   utility	   of	   two	   radiolabelled	   antibodies	   against	   CD163	   and	   Sn	   in	  
imaging	  endogenous	  Mφ	  	  in	  the	  rat	  
Radiotracers	  were	  evaluated	  in	  wild	  type	  animals	  and,	  with	  time	  permitting,	  in	  disease	  
models.	  The	  disease	  models	  included	  an	  acute	  transplant	  rejection	  model	  in	  which	  
macrophage	  recruitment	  was	  analysed	  following	  heterotopic	  transplantation	  of	  
matched	  and	  mis-­‐matched	  donor	  hearts	  using	  a	  SPECT	  tracer.	  Additionally,	  a	  model	  of	  
localised	  bone	  marrow	  radioablation	  was	  also	  selected	  where	  macrophage	  recruitment	  





2 	  	  	  	  	  	  Chapter	  2:	  	  Expression,	  Purification	  and	  in	  vitro	  Characterisation	  of	  99mTc-­‐SER-­‐4	  
2.1 Introduction	  
Monoclonal	  antibodies	  have	  revolutionised	  medical	  science	  by	  virtue	  of	  their	  exquisite	  
specificity	   in	   recognising	   molecular	   structures.	   Their	   ability	   to	   bind	   unique	   cellular	  
markers	  has	  long-­‐since	  been	  combined	  with	  radioactive	  nuclides	  to	  afford	  compounds	  
that	   demonstrate	   high	   binding	   selectively	   and	   which	   are	   detectable	   at	   minute	  
concentrations.	  Such	  technology	  has	  found	   increasing	  utility	   in	  the	  field	  of	  diagnostic	  
medicine,	  and	  in	  particular	  imaging.	  However	  of	  all	  the	  cellular	  targets	  chosen	  none	  so	  
far	   have	   been	   directed	   to	   Mφ,	   a	   critical	   cell	   type	   in	   a	   variety	   of	   homeostatic	   and	  
pathological	  processes.	  In	  this	  chapter	  we	  aim	  to	  produce	  a	  novel	  radiotracer	  based	  on	  




Antibodies	   are	   a	   class	   of	   protein	  which	   are	   secreted	   by	   a	   subset	   of	   immune	   cells	   in	  
order	   to	   recognise	  and	  remove/neutralise	  pathological	  processes	  or	  pathogens.	  They	  
are	  produced	  by	  the	  pairing	  of	  two	  different	  proteins	  (denoted	  heavy	  and	  light	  chains)	  
which	   in	   turn	   associate	   with	   other	   paired	   chains	   depending	   upon	   the	   isotype	   of	  
antibody	  (IgA,	  IgG,	  IgD,	  IgE,	  IgM	  represent	  the	  five	  known	  isotypes).	  In	  the	  circulation,	  
the	  most	  abundant	  antibody	   type	   is	  denoted	   IgG	   (or	   immunoglobulin-­‐gamma)	  which	  
accounts	   for	   approximately	   70%	   of	   circulating	   antibodies.	   IgG	   is	   a	  molecule	   formed	  
from	  the	  association	  of	  two	  heavy	  and	  light	  chain	  pairs.	  The	  heavy	  and	  light	  chains	  of	  
IgG	   are	   formed	   from	   4	   domains	   and	   2	   domains	   for	   the	   heavy	   and	   light	   chain,	  
respectively)	  of	  which	  the	  N	  terminal	  domain	  contains	  the	  sequence	  which	  determines	  
binding	  specificity	  of	  the	  antibody	  and	  is	  known	  as	  the	  variable	  region.	  The	  C	  terminal	  
domains	  define	  the	  effector	  functions	  of	  the	  antibody,	  such	  as	  recruitment	  of	  immune	  





Figure	  2.1	  Schematic	  domain	  structure	  of	   IgG.	   	  Intact	  IgG	  is	  a	  150kDa	  tetramer	  composed	  of	  
an	  identical	  light	  (purple)	  and	  heavy	  (blue)	  chain	  pair	  connected	  by	  disulfides	  (green	  bar).	  The	  
N	  terminal	  domain	  of	  both	  heavy	  and	  light	  chains	  defines	  antigen	  binding	  (including	  so-­‐called	  
variable	   region)	   whilst	   the	   C	   terminal	   domains	   of	   the	   heavy	   chain	   define	   the	   antibody’s	  
effector	  functions.	  
	  
2.1.2 Hybridoma	  Technology	  
Much	   early	   research	   involving	   antibodies	   relied	   upon	   the	   handling	   of	   sera	   from	  
immunised	   animals	   containing	   antibodies	   raised	   to	   different	   epitopes	   of	   the	   same	  
immunogen	   (termed	   polyclonal	   antibodies)	   as	   well	   as	   irrelevant	   antibodies	   already	  
present	  in	  the	  circulation	  (see	  Section	  2.1.3).	  The	  ability	  to	  fuse	  an	  antibody	  secreting	  B	  
cell	  with	  a	  myeloma	  cell	  to	  produce	  an	  immortal	  cell	  line	  secreting	  antibodies	  with	  the	  
same	  specificity	  (a	  monoclonal	  antibody	  or	  mAb)	  was	  introduced	  in	  the	  late	  1970’s	  and	  
is	  known	  as	  hybridoma	  technology	  (Kohler	  and	  Milstein	  1975).	  This	  technology	  marked	  
a	  revolution	  in	  the	  use	  of	  antibodies	  as	  they	  could	  now	  be	  generated	  in	  large	  quantities	  






Figure	  2.2	  Preparation	  of	  a	  hybridoma.	  	  B	  cells	  are	  extracted	  from	  a	  mouse	  immunised	  with	  an	  
antigen.	  Harvested	  B	  cells	  are	  then	  fused	  with	  a	  myeloma	  cell	  line	  and	  the	  successful	  partners	  
selected	   for	   in	   selective	  media.	   The	   clone	   expressing	   the	   desired	   antibody	   is	   identified	   and	  
expanded.	  Figure	  adapted	  from	  Molecular	  Biology	  of	  the	  Cell,	  p509,	  2008.	  
	  
2.1.3 Radiolabelled	  Antibodies	  
Antibodies	   have	   long	   been	   of	   interest	   as	   research	   tools	   to	   scientists.	   By	   combining	  
antibody	  specificity	  with	  the	  ability	   to	  sensitively	  detect	  radioactivity,	   the	   labelling	  of	  
antibodies	   with	   radioisotopes	   has	   been	   pursued	   since	   the	   1940’s	   (Pressman	   and	  
Keighley	   1948).	   The	   application	   of	   radiolabelled	   antibodies	   for	   non-­‐invasive	   imaging	  
was	   originally	   published	   separately	   by	   two	   groups	   in	   1974,	   both	   utilising	   polyclonal	  
radiolabelled	  antibodies	  to	   image	  tumour	  growth	   in	  mice	   (Goldenberg,	  Preston	  et	  al.	  
1974;	   Mach,	   Carrel	   et	   al.	   1974).	   However	   the	   contribution	   of	   polyclonal,	   or	   “inert	  




(Goldenberg,	   Preston	   et	   al.	   1974).	  Upon	   the	   advent	   of	  mAb	  production,	   researchers	  
were	  quick	  to	  realise	  their	  application	  to	  imaging.	  During	  the	  first	  such	  study,	  authors	  
noted	   that	   both	   greater	   specificity	   and	   greater	   reproducibility	   over	   anti-­‐sera	   led	   to	  
lower	  doses	  for	  administration	  (Ballou,	  Levine	  et	  al.	  1979).	  
Monoclonal	  antibodies	  are	  now	  routinely	  used	  therapeutically	  for	  the	  management	  of	  
a	   variety	   of	   diseases,	   and	   increasingly	   their	   radiolabelled	   forms	   (known	   as	  
radioimmunoconjugates)	   are	   becoming	   important	   in	   both	   diagnosis	   and	   therapy	  
(Boswell	  and	  Brechbiel	  2007)	  (see	  Table	  2.1).	  
Generic	  Name	   Trade	  Name	   Agent/target	  
Rituximab	   Rituxan	   Chimeric	  anti-­‐CD20	  IgG1	  
Trastuzumab	   Herceptin	   Humanized	  anti-­‐HER2	  IgG1	  
Alemtuzumab	   CamPath	   Humanized	  anti-­‐CD52	  
Cetuximab	   Erbitux	   Chimeric	  anti-­‐EGFR	  







[99mTc]	  Murine	  anti-­‐NCA-­‐90	  Fab	  
[99mTc]	  Murine	  anti-­‐CEA	  Fab	  
[111In]	  Murine	  anti-­‐PSMA	  
Tositumomab	  "anti-­‐
B1"	   Bexxar	  
[131I]	  Murine	  anti-­‐CD20	  IgG	  +	  	  
unlabeled	  tositumomab	  
Ibritumomab	  tiuxetan	   Zevalin	  
[90Y]	  Murine	  anti-­‐CD20	  IgG	  +	  
rituximab	  
Table	  2.1	  Selected	  list	  of	  commercial	  FDA-­‐approved	  antibodies	  for	  detection	  and	  treatment	  
of	  cancer.	  Taken	  from	  (Boswell	  and	  Brechbiel	  2007).	  
	  
2.1.4 Radiolabelling	  Approaches	  
The	  selection	  of	  a	  radionuclide	  depends	  upon	  the	  kinetics	  of	  the	  radiotracer	  and	  on	  its	  
intended	   application	   (i.e.	   diagnostic	   or	   therapeutic).	   In	   general,	   intact	   antibodies	  
display	  relatively	  long	  blood	  half-­‐lives	  (of	  the	  order	  of	  days	  to	  weeks)	  due	  to	  their	  size	  
exceeding	   renal	   cut	   off	   and	   also	   neonatal	   Fc	   receptor	   (FcRn)-­‐mediated	   recycling	   of	  
internalised	   antibodies	   (see	   Figure	   2.3).	   For	   this	   reason	   long-­‐lived	   isotopes	   are	  
favoured	  when	  imaging	  with	  IgG,	  such	  as	  89Zr	  for	  PET	  and	  111In	  for	  SPECT,	  as	  sufficient	  
time	  must	  be	  allowed	  after	  administering	  a	  radiolabelled	  antibody	  to	  allow	  it	  to	  clear	  





Figure	   2.3	   FcRn-­‐mediated	   recycling	   of	   IgG.	   	   The	   neonatal	   Fc	   receptor	   for	   IgG	   (FcRn)	   is	  
expressed	   on	   endothelial	   cells	   and	   circulating	  monocytes.	   These	   cells	   internalise	   serum	   IgG	  
which	  binds	  to	  FcRn	  under	  acidic	  endosomal	  conditions	  FcRn	  then	  recycles	   IgG	  back	   into	  the	  
circulation,	  extending	  its	  serum	  half-­‐life.	  Serum	  proteins	  without	  an	  Fc	  region	  are	  subjected	  to	  
lysosomal	  degradation.	  Figure	  adapted	  from	  (Roopenian	  and	  Akilesh	  2007).	  
	  
Another	  practical	   factor	   to	  consider	  when	  selecting	  a	   radioisotope	   is	  availability.	  The	  
majority	   of	   PET	   isotopes	   are	   cyclotron	   produced	   and,	   relative	   to	   SPECT	   isotopes,	  
possess	   short	   half-­‐lives.	   This	   limits	   their	   use	   to	   centres	   with	   access	   to	   cyclotron	  
production	   facilities.	   SPECT	   isotopes	   are	   more	   readily	   available	   in	   part	   due	   to	   their	  
longer	  half-­‐lives	  permitting	  transport	  between	  production	  sites	  and	  end	  users,	  but	  also	  
because	  of	  the	  availability	  of	   in-­‐house	  generators.	  This	   is	  particularly	  relevant	  for	  the	  
isotope	  99mTc,	  for	  which	  the	  presence	  of	  a	  generator	  coupled	  with	  its	  favourable	  half-­‐
life	  (6	  h)	  permits	  radiotracer	  preparation	  and	  SPECT	  scanning	  whilst	  minimising	  patient	  
exposure)	  and	  its	  ideal	  emission	  properties	  (143	  KeV	  γ-­‐photon,	  complementing	  clinical	  
γ	  detectors),	  has	   led	  to	   its	  use	  accounting	  for	  over	  70%	  of	  diagnostic	  scans	   in	  the	  US	  
during	  2007	  (Liu	  2008). 
Although	   the	   half-­‐life	   of	   6	   h	   prohibits	   longitudinal	   studies	  with	   99mTc	   it	   is	   frequently	  
used	   for	   in	   vivo	   imaging	   of	   intact	   antibodies.	   In	   this	   case	   it	   is	   not	   just	   the	  
aforementioned	  favourable	  imaging	  properties	  that	  make	  99mTc	  attractive	  but	  also	  the	  
simplicity	   with	   which	   antibodies	   can	   be	   radiolabelled	   with	   it.	   Traditionally	   when	  
preparing	   a	   radiopharmaceutical	   using	   a	   metallic	   radionuclide,	   the	   structure	   of	   the	  




bind	   to	   the	   radioisotope.	  Often	   this	   is	  achieved	  by	   the	   introduction	  of	  a	  bifunctional	  
chelator	  (BFC),	  a	  reagent	  that	  possesses	  a	  metal	  chelating	  site	  as	  well	  as	  a	  site	  capable	  
of	   covalently	   bonding	   to	   a	   targeting	   molecule.	   With	   a	   variety	   of	   BFC	   available	   the	  
ability	  to	  introduce	  radiometals	  into	  a	  host	  of	  different	  structures	  is	  possible.	  However	  
introduction	  of	  a	  BFC	  onto	  an	  antibody	  is	  a	  delicate	  process	  as	  antibody	  affinity	  must	  
be	  maintained	   by	   ensuring	   biologically	   relevant	   sites	   are	   not	  modified	  whilst	   at	   the	  
same	   time	   incorporating	   enough	   chelating	   sites	   to	   be	   able	   to	   prepare	   a	  
radiopharmaceutical	  with	  a	  high	  specific	  activity.	  This	  is	  known	  as	  indirect	  labelling.	  A	  
BFC-­‐independent	   strategy	  of	   radiolabelling	  antibodies	  with	   99mTc	   is	   also	  possible	  and	  
this	   is	   afforded	  by	   the	  exposing	  of	   internal	   cysteines	  by	  mildly	   reducing	   an	  antibody	  
and	  using	  these	  as	  intrinsic	  chelators	  for	  99mTc	  (see	  Figure	  2.4).	  This	  process	  is	  known	  
as	   direct	   labelling	   and	   its	   advantages	   over	   indirect	   labelling	   are	   that	  modification	   is	  
restricted	  largely	  to	  the	  hinge	  region	  of	  the	  antibody,	  thus	  removed	  from	  the	  binding	  
domains,	  and	  also	  it	  requires	  no	  BFC	  handling	  which	  reduces	  the	  overall	  complexity	  of	  
the	  labelling	  process.	  
	  
Figure	   2.4	   Direct	   labelling	   of	   IgG.	   	   Disulfides	   reduced	   by	   2-­‐mercaptoethanol	   followed	   by	  
pertechnetate	  in	  the	  presence	  of	  a	  reducing	  agent	  (SnCl2)	  and	  MDP.	  Free	  cysteines	  co-­‐ordinate	  
with	  reduced	  99mTc(V)	  and	  disulphides	  reform.	  
	  
2.1.5 Monoclonal	  Antibody	  SER-­‐4	  
The	  mAb	  SER-­‐4	  recognises	  the	  antigen	  sialoadhesin	   (Sn),	  a	  Mφ-­‐restricted	  cell	   surface	  
marker	  (Crocker	  and	  Gordon	  1989;	  Crocker,	  Kelm	  et	  al.	  1991).	  Sn	  is	  a	  member	  of	  the	  
sialic	   acid	   IgG-­‐like	   lectin	   family	   of	   proteins	   which	   are	   characterised	   by	   affinity	   for	  
specific	   sialic	   acid	   ligands	   (Kelm,	   Pelz	   et	   al.	   1994),	   and	   so	   far	   has	   been	   identified	   in	  
humans	   (Hartnell,	   Steel	   et	   al.	   2001),	  mice	   (Crocker	   and	  Gordon	  1989),	   rats	   (Dijkstra,	  




der	  Linden,	  Sjoberg	  et	  al.	  2000).	  Endogenously,	  the	  highest	  levels	  of	  Sn	  expression	  are	  
found	  in	  Mφ	  populations	   located	  in	  the	  LNs	  and	  spleen,	  typically	  bordering	   lymphoid	  
tissue	  and	   transiting	   fluid.	  Sn	   induction	   is	  broadly	   related	   to	   type	   I	  and	   II	   interferons	  
(vandenBerg,	  vanDie	  et	  al.	  1996;	  Hartnell,	  Steel	  et	  al.	  2001;	  Delputte,	  Van	  Breedam	  et	  
al.	  2007),	  and	  Sn	  positive	  Mφ	  exhibit	  immunoregulatory	  behaviour	  both	  in	  vivo	  and	  in	  
vitro	   (Oetke,	   Vinson	   et	   al.	   2006;	   Ip,	   Kroner	   et	   al.	   2007;	   Wu,	   Rauch	   et	   al.	   2009).	  
Targeting	  of	  antigens	  to	  Sn	  positive	  Mφ	  has	  been	  shown	  to	  be	  an	  efficient	  means	  of	  
evoking	  an	  immune	  response	  (Backer,	  Schwandt	  et	  al.	  2010;	  Poderoso,	  Martinez	  et	  al.	  
2011),	  whilst	  deletion	  of	  this	  subset	  can	  enhance	  autoimmunity	  (Miyake,	  Asano	  et	  al.	  
2007;	   McGaha,	   Chen	   et	   al.	   2011).	   However	   knock	   down	   of	   Sn	   has	   been	   shown	   to	  
reduce	  disease	  severity	  in	  various	  autoimmune	  models	  (Jiang,	  Hwenda	  et	  al.	  2006;	  Ip,	  
Kroner	   et	   al.	   2007;	   Wu,	   Rauch	   et	   al.	   2009),	   which	   altogether	   illustrates	   an	  
immunoregulatory	   role.	   Sn	   positive	   Mφ	   have	   been	   detected	   in	   various	   preclinical	  
disease	  models	  and	  in	  clinical	  settings	  including	  tumour	  infiltrates	  (Nath,	  Hartnell	  et	  al.	  
1999),	   glomerular	   nephritis	   (Ikezumi,	   Suzuki	   et	   al.	   2005)	   and	   rheumatoid	   arthritis	  
(Hartnell,	  Steel	  et	  al.	  2001).	  Hence	  non-­‐invasive	  imaging	  of	  Sn	  positive	  Mφ	  may	  inform	  
upon	  an	  important	  class	  of	  immunologically	  active	  cells.	  
2.2 Materials	  and	  Methods	  
2.2.1 SER-­‐4	  Hybridoma	  	  
Anti-­‐mouse	   Sn	   SER-­‐4	   antibody	  was	   isolated	   as	   previously	   described	   using	   the	   SER-­‐4	  
hybridoma	   (Crocker	   PR,	   1989)	   which	   was	   kindly	   provided	   by	   Dr.	   Paul	   Crocker	  
(University	   of	  Dundee,	  Dundee,	  UK)).	   Cells	  were	   grown	   in	   1640	  RPMI	   (Sigma,	   Poole,	  
UK)	   supplemented	   with	   pen/strep	   (Invitrogen)	   and	   IgG	   depleted	   FBS	   (Source	  
Bioscience	   UK	   Ltd,	   Nottingham,	   UK).	   8	   x	   106	   cells	   were	   suspended	   in	   5	   mL	   then	  
transferred	   to	   a	   Celline	   CL350	   flask	   (Figure	   2.4;	   Integra	   Biosciences	   AG).	   Cells	   were	  
pelleted	  every	  7	  days,	  and	  the	  supernatant	  harvested	  with	  the	  pellet	  resuspended	  1:4	  





Figure	  2.5	  Celline	  CL350	  design.	  	  Celline	  CL350	  permits	  high	  densities	  of	  hybridoma	  cells	  to	  be	  
cultured	  by	  continuous	  exchange	  of	   fresh	  nutrients	  and	  media	   from	  media	  chamber	  through	  
semipermeable	  membrane	  into	  the	  cell	  chamber	  by	  diffusion.	  10	  kDa	  molecular	  weight	  cut-­‐off	  
for	  semipermeable	  membrane	  results	   in	  retention	  of	  serum	  proteins	  and	  antibody	  in	  the	  cell	  
chamber,	  facilitating	  purification	  as	  well	  as	  decreasing	  FBS	  consumption	  as	  media	  chamber	  can	  
be	  used	  with	  unsupplemented	  media.	  	  
	  
2.2.2 SER-­‐4	  Purification	  
5	  mL	  of	  supernatant	  from	  SER-­‐4	  hybridoma	  (Crocker	  and	  Gordon	  1989)	  was	  diluted	  in	  
5	  mL	  binding	  buffer	  (20	  mM	  sodium	  phosphate,	  pH	  7.0)	  and	  passed	  through	  a	  0.22	  µm	  
filter.	  Filtrate	  was	   loaded	  on	  to	  a	  5	  mL	  HiTrap	  Protein	  G	  HP	  column	  (GE,	  Chalfont	  St.	  
Giles,	   UK)	   then	   washed	   with	   10	   column	   volumes	   of	   binding	   buffer.	   Antibody	   was	  
eluted	  with	   0.1	  M	   glycine-­‐HCl,	   pH	   2.7,	   collected	   in	   2.5	  mL	   fractions	   and	   neutralised	  
with	   200	   µL	   of	   1	   M	   Tris.HCl,	   pH	   9.0.	   Protein	   concentration	   was	   determined	   by	  
measuring	  OD280	  using	  a	  Biophotometer	  (Eppendorf,	  Cambridge,	  UK).	  Protein	  fractions	  
were	  transferred	  to	  dialysis	  cassettes	  (Thermofisher,	  Loughborough,	  UK)	  and	  dialysed	  
in	   phosphate	   buffered	   saline	   (PBS)	   with	   3	   buffer	   exchanges.	   Antibody	   was	   then	  
concentrated	   using	   Vivaspin	   columns	   (Sartorius	   Stedim,	   Epsom,	   UK)	   to	   10	   mg/mL.	  
Protein	   fractions	  were	  then	  analysed	  by	  reduced	  and	  non-­‐reduced	  SDS	  PAGE	  (200	  V,	  
120	  A,	  50	  min).	  Gels	  were	  then	  stained	  with	  SimplyBlue	  Safe	  Stain	  (Invitrogen,	  Paisley,	  
UK)	  for	  45	  minutes	  followed	  by	  3	  washes	  with	  deionised	  water.	  
	  
2.2.3 Immunohistochemistry	  
Spleens	   from	  8	  week	  old	  male	  C57BL/6	  mice	  were	  harvested,	  embedded	   in	  OCT	   (RA	  
Lamb	  Ltd,	  Eastbourne,	  UK)	  and	  snap	  frozen	  in	  liquid	  nitrogen.	  Tissues	  were	  then	  cut	  5	  




(Thermofisher,	   Loughborough,	  UK).	   Sections	  were	   air	   dried	   overnight,	   transferred	   to	  
50	  mL	  Falcon	  tubes	  (BD	  Biosciences)	  and	  then	  stored	  at	  -­‐80°C.	  
	  
For	  staining,	  sections	  were	  left	  at	  room	  temperature	  for	  10	  min	  before	  removing	  from	  
the	  falcon	  tube.	  Sections	  were	  immersed	  in	  chilled	  acetone	  for	  5	  min.	  and	  then	  left	  to	  
air	   dry	   for	   15	   min.	   Sections	   were	   incubated	   in	   0.3%	   H2O2	   in	   PBS	   (BDH)	   for	   30	   min	  
followed	   by	   avidin/biotin	   blocking	   (Vector	   Laboratories,	   Burlingame,	   USA).	   Sections	  
were	   incubated	   overnight	   with	   SER-­‐4	   (1	   µg/mL),	   followed	   by	   incubation	   with	  
biotinylated	   goat	   anti-­‐rat	   secondary	   (10	   µg/mL,	   BD),	   and	   finally	   streptavidin-­‐horse	  
radish	  peroxidase	   (undiluted,	   Pharmingen,	   San	  Diego,	  USA).	   Samples	  were	   visualised	  
using	   the	   Vector	   NovaRed	   Substrate	   kit	   (Vector	   Labs)	   and	   counter	   stained	   with	  
haematoxylin	   (RA	   Lamb	   Ltd,	   Eastbourne,	  UK),	   followed	  by	  washing,	   dehydration	   and	  
mounting	   in	   DPX	  mountant	   (BDH).	   Images	   were	   captured	   using	   a	   Leica	   Leitz	   DMRB	  
research	  microscope	  and	  Micro-­‐Publisher	  3.3	  RTV	  camera.	  Images	  were	  analysed	  with	  
Image-­‐Pro	  Plus	  7.0	  from	  Media	  Cybernetics	  software	  and	  Photoshop.	  
	  
2.2.4 Preparation	  of	  99mTc-­‐SER-­‐4	  
200	   µL	   of	   purified	   SER-­‐4	   (10	   mg/mL,	   PBS)	   was	   incubated	   with	   2	   µL	   of	   2-­‐
mercaptoethanol	   (14.3	  M,	  Sigma	  Aldrich,	  Poole,	  UK)	  for	  30	  min	  at	  21°C.	  The	  solution	  
was	  transferred	  to	  a	  PD	  MiniTrap	  G-­‐10	  column	  (GE	  Healthcare,	  Chalfont	  St.	  Giles,	  UK)	  
and	  eluted	  with	  degassed	  PBS.	  0.5	  mL	  fractions	  were	  collected	  and	  OD280	  determined	  
using	   a	   BioPhotometer	   (Eppendorf,	   Cambridge,	   UK).	   Fractions	   with	   an	   OD280	  
corresponding	  to	  antibody	  concentrations	  of	  >1	  mg/mL	  were	  pooled,	  aliquoted	  into	  20	  
µL	  fractions,	  snap-­‐frozen	  in	  liquid	  nitrogen	  and	  stored	  at	  -­‐80o	  C	  until	  further	  use.	  
To	   establish	   the	   influence	   of	   methylene	   diphosphonate	   (MDP)	   kit	   volume	   on	  
radiolabelling	  efficiency,	  radiolabelling	  was	  initially	  performed	  using	  X	  µL	  (X	  =	  0,	  5,	  7.5,	  
15,	  20)	  of	  a	  reconstituted	  MDP	  kit	  (Medronate	  Draximage,	  Draxis,	  USA)	  added	  to	  20	  µL	  
of	   freshly	   thawed	   reduced	  SER-­‐4,	   followed	  by	  200	  MBq	  of	   sodium	  pertechnetate	  Tc-­‐
99m	   in	   a	   volume	   of	   20	   to	   40	   µL	   saline	   (kindly	   provided	   by	   Department	   of	   Nuclear	  




Labelling	   efficiency	   measured	   using	   instant	   thin	   layer	   chromatography-­‐SA	   (ITLC-­‐SA)	  
strips	   (Varian	  Medical	   Systems	  UK,	   Ltd.,	  Crawley,	  UK)	  using	  a	  mobile	  phase	  of	  0.1	  M	  
citrate	  buffer,	  pH	  5,	  and	  analysed	  using	  a	  gamma	  ray	  thin	  layer	  chromatography	  (TLC)	  
scanner	   (Lablogic,	   UK).	   Labelling	   efficiency	   was	   assessed	   also	   by	   high	   performance	  
liquid	  chromatography-­‐size	  exclusion	  chromatography	  (HPLC-­‐SEC)	  using	  a	  BioSep	  SEC-­‐
300	  column	  (Phenomenex,	  Macclesfield,	  UK)	  with	  an	  isocratic	  mobile	  phase	  of	  100	  mM	  
phosphate	   buffer	   pH	   7.0	   at	   a	   flow	   rate	   of	   1	   mL/min	   and	   in-­‐line	   gamma	   detector	  
(Lablogic,	  UK).	  Mouse	  IgG2a	  isotype	  (AbD	  Serotec,	  Oxon,	  UK)	  control	  IgG	  was	  prepared	  
as	  described	  above.	  
	  
2.2.5 99mTc-­‐SER-­‐4	  Serum	  Stability	  
50	  MBq	  of	  99mTc	   labelled	  SER-­‐4	  or	   isotype	  control	   IgG	  were	  added	  to	  AB	  type	  human	  
serum	  (Sigma)	  or	  0.1	  M	  PBS	  (Gibco)	  at	  1:4	  v/v	  and	  incubated	  at	  37	  °C	  for	  20	  h.	  Samples	  
were	   analysed	   at	   0,	   4,	   6	   and	   20	   h	   by	   HPLC-­‐SEC	   using	   a	   BioSep	   SEC-­‐300	   column	  
(Phenomenex,	  Macclesfield,	  UK)	  with	  an	  isocratic	  mobile	  phase	  of	  100	  mM	  phosphate	  
buffer,	  pH	  7.0,	  at	  a	  flow	  rate	  of	  1	  mL/min.	  Serum	  stability	  was	  calculated	  as	  the	  area	  
under	   the	   99mTc-­‐SER-­‐4	   peak	   (retention	   time	   =	   8	   min	   25	   sec)	   as	   a	   fraction	   of	   total	  
activity.	  
	  
2.2.6 In	  vitro	  99mTc-­‐SER-­‐4	  Binding	  Assay	  
0.1	   µg	   of	   labelled	   antibody	   (0.1	   µg/µL)	   was	   added	   to	   0.2	   µg	   of	   recombinant	  
sialoadhesin-­‐Fc	   fusion	   protein	   (Sn-­‐Fc,	   6.7	   µg/mL)	   (Kelm,	   Pelz	   et	   al.	   1994)	   (kindly	  
provided	   by	   Dr.	   Paul	   Crocker	   (University	   of	   Dundee,	   UK)	   and	   incubated	   at	   37	   °C.	  
Binding	   to	   Sn-­‐Fc	   was	   measured	   by	   HPLC-­‐SEC	   using	   a	   BioSep	   SEC-­‐300	   column	  
(Phenomenex,	  Macclesfield,	  UK)	  with	  an	  isocratic	  mobile	  phase	  of	  100	  mM	  phosphate	  
buffer,	   pH	   7.0	   at	   a	   flow	   rate	   of	   1	   mL/min	   and	   compared	   to	   the	   99mTc-­‐IgG	   isotype	  
binding.	  Specificity	  was	  shown	  by	  comparison	  with	  the	  binding	  of	  isotype	  99mTc-­‐IgG	  and	  






2.3.1 SER-­‐4	  Purification	  
SER-­‐4	   antibody	  was	  purified	   from	   the	   supernatant	  of	   SER-­‐4	  hybridoma	  grown	   in	   IgG	  
depleted	   media	   using	   Protein	   G	   purification.	   Yields	   of	   between	   9	   –	   12	   mg/L	   of	  
unsupplemented	   media	   were	   recovered.	   Hybridoma	   supernatant	   displayed	   the	  
presence	  of	  SER-­‐4	  by	  protein	  band	  at	  approx.	  150	  kDa,	  which	  approximates	  to	  the	  size	  
of	   an	   intact	   IgG	   (lane	   1	   –	   see	   Figure	   2.6).	   The	   absence	   of	   this	   band	   in	   the	   loading	  
fraction	   indicates	   the	   successful	   extraction	   of	   SER-­‐4	   antibody	   from	   the	   hybridoma	  
supernatant	  (lane	  2).	  Similarly	  the	  wash	  fraction	  displayed	  no	  IgG	  contamination	  (lane	  
3).	  Protein	   collected	   from	   the	  elution	   fraction	   indicated	   the	  presence	  of	   IgG	   (lane	  4)	  
with	   reduction	   resulting	   in	   the	   disappearance	   of	   intact	   IgG	   band	   and	   emergence	   of	  
heavy	  and	  light	  chain	  protein	  bands	  at	  	  c.25	  and	  50kDa	  mass	  (lane	  5).	  	  
	  
	  
Figure	  2.6	  Protein	  G	  purification	  of	  SER-­‐4.	   	  SER-­‐4	  hybridoma	  supernatant	  (lane	  1)	  was	  loaded	  
on	  to	  a	  Protein	  G	  column	  (unbound	   loading	  fraction	  –	   lane	  2)	  which	  was	  then	  washed	  (wash	  
fraction	  -­‐	  lane	  3).	  SER-­‐4	  antibody	  was	  then	  eluted	  (lane	  4).	  A	  sample	  of	  SER-­‐4	  was	  then	  reduced	  






Frozen	  spleen	  sections	  were	  incubated	  overnight	  with	  SER-­‐4,	  followed	  by	  biotinylated	  
secondary	   and	   streptavidin-­‐HRP	   with	   VectorRed	   substrate	   for	   staining.	   Nuclei	   were	  
counter-­‐stained	   with	   haemotoxylin.	   In	   the	   absence	   of	   SER-­‐4,	   white	   pulp	   can	   be	  
observed	  as	  patches	  of	  heavy	  nuclear	  staining	  encapsulated	  by	  less	  nucleated	  red	  pulp	  
(see	   Figure	   2.7	   A).	   Incubation	   with	   SER-­‐4	   reveals	   elliptical	   rings	   of	   SER-­‐4	   staining	  
delineating	  the	  border	  between	  the	  white	  and	  red	  pulp	  regions	  of	  the	  spleen.	  Sporadic	  
staining	  is	  also	  observed	  in	  the	  red	  pulp	  region	  (see	  Figure	  2.7	  B).	  
	  
Figure	  2.7	  SER-­‐4	  staining	  of	  spleen.	   	  Mouse	  spleens	  were	  incubated	  with	  PBS	  (A	  +	  C)	  or	  SER-­‐4	  
(B	   +	   D)	   overnight,	   followed	   by	   appropriate	   secondary/substrate	   and	   counter	   stained	   with	  
haemotoxylin.	  Regions	  of	   increased	  nuclear	   staining	   identify	   the	  white	  pulp	  characterised	  by	  
abundant	   lymphocyte	   populations,	   whilst	   sparser	   nuclear	   stain	   corresponds	   to	   red	   pulp	  
composed	  of	  a	  loosely	  populated,	  sinusoidal	  structure.	  Perimeter	  between	  white	  and	  red	  pulp	  
containing	  MMMs	  stains	   strongly	   for	  SER-­‐4,	  with	   sporadic	   staining	  observed	   in	   the	   red	  pulp.	  





2.3.3 Preparation	  of	  99mTc-­‐SER-­‐4	  
SER-­‐4	  was	  partially	  reduced	  by	  incubation	  with	  2-­‐mercaptoethanol,	  purified	  and	  stored	  
in	   frozen	   aliquots	   then	   radiolabelling	   performed	   by	   addition	   of	   pertechnetate	   with	  
freshly	   reconstituted	  MDP	   kit.	   Radiochemical	   purity	   and	   yield	  were	   assessed	   by	   SEC	  
radioHPLC	  with	  PBS	  as	  eluent	  and	  ITLC	  using	  citrate	  buffer	  (pH	  5,	  0.1	  M),	  respectively.	  
SEC	   radioHPLC	   showed	   two	   peaks	   with	   >	   99%	   of	   activity	   eluted	   at	   8	   min	   25	   sec,	  
corresponding	  to	  antibody	  fraction,	  and	  a	  negligible	  proportion	  (<	  1%)	  eluted	  at	  17	  min	  
45	  sec,	  corresponding	  to	  free	  pertechnetate	  (see	  Figure	  2.8	  A).	  ITLC	  shows	  presence	  of	  
protein-­‐associated	  activity	  (Rf	  =	  0)	  with	  an	  absence	  of	  free	  Tc-­‐99m	  pertechnetate	  (Rf	  =	  
1)	  (see	  Figure	  2.8	  B).	  
	  
Figure	  2.8	  Direct	   labelling	  of	  SER-­‐4.	   	  Following	  disulphide	  reduction,	  SER-­‐4	  was	  labelled	  with	  
99mTc.	   (A)	   Samples	  were	   injected	  on	   SEC	   radioHPLC	   showing	  elution	  of	  majority	   activity	  with	  
the	  antibody	   (t	  =	  8	  min	  20	   sec,	  >	  99%)	  and	  a	  minor	  peak	   (t	  =	  17	  min	  45	   sec,	  <	  1%).	   (B)	   ITLC	  






Figure	  2.9	  %	  Radiolabelling	  with	  respect	  to	  MDP	  kit	  volume	  added.	   	  In	  the	  absence	  of	  MDP,	  
only	  small	  amounts	  of	  antibody	  are	   labelled	   (1%).	  Addition	  of	   intermediate	  amounts	  of	  MDP	  
kit	   (5	   and	   10	   µL)	   achieves	   97%	   radiolabelling,	   whilst	   further	   increases	   in	   MDP	   kit	   addition	  
diminish	  %	  radiolabelling.	  
	  
The	   influence	  of	  MDP	   kit	   volume	  on	  %	   radiolabelling	  was	   established	  by	   addition	  of	  
various	   amounts	   of	   kit	   to	   constant	   amounts	   of	   antibody	   and	   activity.	  With	   no	  MDP	  
present,	  radiolabelling	  is	  1%,	  whilst	  addition	  of	  both	  5	  and	  10	  µL	  of	  MDP	  kit	  achieved	  
97%	  labelling,	  which	  dropped	  with	  increasing	  amounts	  of	  kit	  (see	  Figure	  2.9)	  
	  
2.3.4 99mTc-­‐SER-­‐4	  and	  Isotype	  Serum	  Stability	  
99mTc-­‐SER-­‐4	  was	   incubated	   in	  the	  presence	  of	  serum	  or	  PBS	  and	  stability	  assessed	  by	  
SEC	   radioHPLC	   at	   the	   time	  points	   0,	   4,	   6	   and	   20	   h.	   In	   the	   presence	  of	   PBS	   alone,	  %	  
radiolabelling	  decreases	  over	  20	  h	  (see	  Table	  2.2)	  whilst	  in	  the	  presence	  of	  serum	  the	  
speciation	  of	  activity	  remains	  unchanged.	  In	  serum	  at	  20	  h,	  98%	  activity	  is	  associated	  
with	   antibody	   (elution	   time	   8	  min	   25	   sec)	   with	   2	   %	   released	   as	   free	   pertechnetate	  
(elution	  time	  17	  min	  45	  sec).	   In	  PBS	  the	  values	  change	  to	  92	  %	  and	  8	  %	  for	  antibody	  
bound	  and	  free	  pertechnetate	  peaks,	  respectively	  (see	  Figure	  2.8).	  Similarly	  the	  isotype	  
demonstrates	  greater	  stability	   in	  serum	  (97	  %	  antibody	  radiolabelled	  at	  20	  h)	  than	  in	  







	   Time	  (hr)	   0	   4	   8	   20	  
SER-­‐4	   Serum	  (%	  bound)	   98	   98	   98	   98	  
PBS	   99	   96	   94	   92	  
Isotype	   Serum	   100	   100	   98	   97	  
PBS	   100	   98	   95	   89	  
Table	   2.2	   Serum	   stability	   of	   99mTc	   labelled	   SER-­‐4	   and	   Isotype.	   Antibodies	   were	   labelled	  
according	  to	  2.3.3,	   incubated	   in	  either	  mouse	  serum	  or	  PBS	  and	  stability	  assessed	  by	  
SEC	   radioHPLC.	   Percentage	   bound	  was	   assessed	   by	   comparison	   of	   bound	   activity	   to	  
that	  of	  free	  activity	  peaks.	  
	  
Figure	   2.10	   SEC	   radioHPLC	   analysis	   of	   99mTc-­‐SER-­‐4	   stability	   at	   20	   hr.	   	   99mTc-­‐SER-­‐4	   was	  
incubated	   in	   the	   presence	   of	   PBS	   (A)	   or	   serum	   (B)	   for	   20	   hr	   at	   37°C	   then	   injected	   into	   SEC	  
radioHPLC	  system.	  Percentage	  bound	  was	  assessed	  by	  comparison	  of	  bound	  activity	  (integral	  
of	  8	  min	  25	  sec	  peak)	  to	  that	  of	  free	  activity	  (integral	  of	  17	  min	  45	  sec	  peak).	  
	  
2.3.5 In	  vitro	  99mTc-­‐SER-­‐4	  Binding	  Assay	  
Binding	  of	  99mTc-­‐SER-­‐4	  was	  semi-­‐quantitatively	  assessed	  by	  binding	  to	  recombinant	  Sn-­‐
Fc	   fusion	   protein	   using	   SEC	   radioHPLC.	   Binding	  was	   observed	   by	   a	   shift	   in	   retention	  
time	  of	  the	  gamma	  signal	  owing	  to	  increased	  mass	  of	  99mTc-­‐SER-­‐4+Sn-­‐Fc	  as	  compared	  
to	  free	  99mTc-­‐SER-­‐4.	  Free	  99mTc-­‐SER-­‐4	  eluted	  with	  a	  retention	  time	  of	  8	  min	  35	  sec	  (see	  
Figure	  2.11	  A)	  whereas	  99mTc-­‐SER-­‐4	  in	  the	  presence	  of	  Sn-­‐Fc	  eluted	  at	  7	  min	  20	  sec	  (see	  
Figure	  2.11	  B),	  with	  82%	  activity	  associated	  this	  peak.	  A	  proportion	  of	  unbound	  99mTc-­‐
SER-­‐4	  (2%	  of	  total	  activity)	  was	  also	  detected	  at	  12	  min	  45	  sec.	  The	  binding	  of	  99mTc-­‐
SER-­‐4	  to	  Sn-­‐Fc	  was	  completely	  abrogated	  by	  the	  presence	  of	  10	  fold	  excess	  unlabelled	  
SER-­‐4	  (see	  Figure	  2.11	  C).	   Isotype	  control	  99mTc-­‐IgG	  had	  a	  retention	  time	  of	  8	  min	  30	  





Figure	   2.11	   SEC	   radioHPLC	   analysis	   of	   99mTc-­‐SER-­‐4	   binding.	   	   Binding	   of	   99mTc-­‐SER-­‐4	   to	  
recombinant	  Sn-­‐Fc	  protein	  was	  assessed	  by	  SEC	  radioHPLC.	  Unbound	  99mTc-­‐SER-­‐4	  eluted	  with	  a	  
retention	  time	  of	  8	  min	  35	  sec	  (A)	  whilst	  99mTc-­‐SER-­‐4	  in	  the	  presence	  of	  Sn-­‐Fc	  showed	  a	  shift	  in	  
retention	  time	  to	  7	  min	  20	  sec	  corresponding	  to	  99mTc-­‐SER-­‐4+Sn-­‐Fc	  complex	  along	  with	  some	  
unbound	   99mTc-­‐SER-­‐4	   (B).	   Binding	   to	   Sn-­‐Fc	  was	   completely	   abrogated	   by	   incubation	  with	   10	  
fold	  excess	  of	  cold	  SER-­‐4	  (C)	  whilst	  99mTc-­‐IgG	  showed	  no	  binding	  to	  recombinant	  Sn-­‐Fc	  (D).	  
	  
2.4 Discussion	  
SER-­‐4	  hybridoma	  was	  grown	  using	  the	  Celline	  CL350	  system	  in	  order	  to	  minimise	  the	  
quantity	  of	  media	  supplements	  required	  as	  compared	  to	  using	  a	  traditional	  T75	  flask	  
procedure.	   This	   was	   especially	   relevant	   with	   regards	   to	   the	   consumption	   of	   IgG-­‐
depleted	   FBS,	   an	   expensive	  media	   supplement	   essential	   for	   the	   purification	   of	  mAb	  
free	   from	   contaminating	   IgG.	   In	   this	   system	   approximately	   4	   mL	   supernatant	   was	  
recovered	  per	  week,	  from	  which	  between	  3	  –	  4	  mg	  of	  SER	  antibody	  could	  be	  retrieved	  




litre	  was	  produced,	  making	  the	  Celline	  system	  an	  efficient	  means	  of	  producing	  SER-­‐4	  
antibody.	  
The	  purification	  of	  hybridoma	  supernatant	  using	  Protein	  G	  resulted	  in	  a	  protein	  band	  
corresponding	   to	   the	  expected	  mass	  of	  an	   intact	  mononclonal	   IgG	  antibody	   (approx.	  
150	  kDa).	  Reduction	  of	  the	  purified	  protein	  resulted	   in	  the	  characteristic	  bands	  at	  25	  
and	   50kDa	   corresponding	   to	   the	   light	   and	   heavy	   chain	   repsectively	   (see	   Figure	   2.4).	  
Confirmation	  of	  SER-­‐4	  binding	  to	  endogenous	  Sn	  was	  demonstrated	  by	  staining	  frozen	  
mouse	  spleen	  sections	  SER-­‐4.	  Incubation	  with	  SER-­‐4	  revealed	  elliptical	  staining	  pattern	  
characteristic	  of	  marginal	  metallophilic	  Mφ	  forming	  boundaries	  between	  the	  red	  and	  
white	  pulp	  regions	  of	  the	  spleen	  (see	  Figure	  2.5)	  (Crocker,	  Hill	  et	  al.	  1988).	  
SER-­‐4	  was	  was	  radiolabelled	  with	  99mTc	  using	  the	  direct	  labelling	  method	  described	  by	  
Mather	  and	  Ellison	   (Mather	  and	  Ellison	  1990).	   The	   selection	  of	   radioisotope	  and	   the	  
method	   employed	   were	   complementary:	   direct	   labelling	   is	   a	   fast	   and	   convenient	  
means	   of	   labelling	   antibodies,	   and	   is	   used	   clinically	   (hence	   reliable,	   robust	   and	  
reproducible).	   Direct	   radiolabelling	   involves	   partial	   reduction	   of	   disulphide	   bonds	  
concentrated	  in	  the	  hinge	  region	  of	  the	  intact	  antibody	  such	  that	  the	  overall	  structure	  
is	  preserved.	  Pertechnetate	  is	  then	  reduced	  by	  SnCl2	  and	  weakly	  chelated	  to	  the	  ligand	  
MDP	  in	  the	  presence	  of	  the	  partially	  reduced	  antibody.	  Weak	  chelation	  of	  Tc(V)	  results	  
in	   transfer	   of	   99mTc	   to	   only	   sites	   with	   higher	   affinity	   than	   MDP,	   thus	   decreasing	  
occupancy	  of	  low	  affinity	  sites	  from	  which	  99mTc	  could	  be	  stripped	  easily	  in	  vivo.	  Once	  
transferred	   to	   reduced	   disulphide	   it	   is	   speculated	   that	   the	   bridge	   is	   reformed	   with	  
99mTc	   linking	   the	   cysteines.	   Mather	   and	   Ellison	   also	   reported	   that	   the	   presence	   of	  
contaminating	   2-­‐mercaptoethanol	   from	   the	   reduction	   step	   in	   the	   radiolabelling	   step	  
was	   desirable	   for	   optimal	   radiolabelling.	   They	   reasoned	   that	   contamination	   possibly	  
prevents	  the	  rapid	  reoxidation	  of	  reduced	  disulphides	  as	  well	  as	  maybe	  participating	  in	  
chelation	  with	  99mTc	  (Mather	  and	  Ellison	  1990).	  
With	   the	   variables	   of	   MDP	   volume,	   amount	   of	   activity	   and	   antibody	   concentration	  
during	   radioabelling	   it	   was	   decided	   in	   order	   to	   conserve	   antibody	   stocks	   that	   the	  
amount	   of	   activity	   used	   would	   be	   based	   upon	   clinically	   administered	   activites.	  




(Gmeiner	  Stopar,	  Fettich	  et	  al.	  2008;	  Malviya,	  de	  Vries	  et	  al.	  2011)	  and	  so	  a	  value	  of	  2	  
MBq/µg	   of	   SER-­‐4	  was	   selected.	  MDP	   kit	   addition	  was	   then	   varied	   to	   establish	  what	  
volume	  would	  achieve	  the	  greatest	   labelling	  efficiency	  for	  200	  MBq	  99mTcO4	  added	  to	  
100	   µg	   SER-­‐4.	   Addition	   of	   5	   µL	   of	   reconstituted	  MDP	   kit	   (approx	   10%	   total	   volume)	  
achieved	  a	  maximum	  labelling	  efficiency,	  whereas	  addition	  of	  >10	  µL	  saw	  a	  decrease	  in	  
%	   radiolabelling.	   This	   was	   probably	   due	   to	   excess	   MDP	   competing	   with	   reduced	  
disulphides	   for	   binding	   to	   99mTc.	   Absence	   of	  MDP	   kit	   resulted	   in	   negligible	   labelling	  
(1%)	   as	   SnCl2	   reagent	   is	   required	   for	   reduction	   of	   Tc	   to	   permit	   bonding	   with	   free	  
cysteines.	  	  
SER-­‐4	  was	  reduced	  in	  batch,	  then	  aliquoted	  and	  snap	  frozen	  in	  order	  to	  provide	  a	  stock	  
of	  reduced	  antibody	  for	  labelling.	  This	  was	  done	  for	  convenience	  as	  well	  as	  to	  reduce	  
variation	   in	   radiolabelling.	   Aliquots	   were	   radiolabelled	   then	   quality	   control	   was	  
performed	   via	   radioTLC	   and	   SEC-­‐radioHPLC.	   These	   techniques	   are	   complimentary	   as	  
radioTLC	   is	   a	   reliable	   method	   of	   assaying	   total	   bound	   and	   unbound	   activity	  
(radiochemical	   yield)	   whilst	   radioHPLC	   is	   able	   to	   resolve	   labelled	   proteins	  
(radiochemical	   purity).	   By	   ITLC	   a	   high	   radiochemical	   yield	   was	   routinely	   achieved,	  
however	   the	   quantity	   of	   contaminating	   colloidal	   pertechnetate	   was	   not	   established	  
(see	   Figure	   2.6	   A).	   SEC	   radioHPLC	   showed	   a	   high	   radiochemical	   purity	   and	   gamma	  
counter	   detection	   of	   the	   guard	   column	   inidcated	   an	   absence	   of	   trapped	   colloidal	  
pertechnetate.	  Using	  these	  techniques,	  antibody	  radiolabelling	  >99%	  was	  consistently	  
achieved.	  
Serum	  stability	  of	  99mTc-­‐SER-­‐4	  was	  assayed	  by	  incubation	  of	  the	  radiotacer	  in	  serum	  or	  
PBS	  and	  sampling	  performed	  at	  0,	  4,	  6	  and	  20	  hr	  time	  points.	  Radiolabelled	  antibody	  in	  
the	   presence	   of	   PBS	   exhibited	   higher	   instability	   than	   in	   serum.	   The	   observed	  
degradation	   in	   the	   absence	   of	   serum	   could	   be	   the	   result	   of	   radiolysis,	   a	   process	   in	  
which	  it	  is	  thought	  free	  radicals	  generated	  during	  radioactive	  decay	  can	  lyse	  chemical	  
bonds	  and	  lead	  to	  loss	  of	  a	  radioisotope	  from	  its	  parent	  radiopharmaceutical.	  Thus	  it	  is	  
speculated	  that	  the	  presence	  of	  free	  radical	  scavengers,	  such	  as	  bovine	  serum	  albumin,	  




The	   immunoreactive	   fraction	   of	   99mTc-­‐SER-­‐4	   was	   determined	   by	   binding	   to	  
recombinant	  Sn-­‐Fc	  protein	  followed	  by	  analysis	  using	  radioHPLC	  in	  conjunction	  with	  a	  
SEC.	  Recombinant	  Sn-­‐Fc	  contains	  the	  first	  4	  N-­‐terminal	  domains	  of	  Sn	  fused	  to	  the	  Fc-­‐
portion	  of	  human	  IgG,	  resulting	  in	  a	  dimer	  with	  approximate	  mass	  of	  150kDa	  (Crocker,	  
Freeman	  et	  al.	  1995).	  Binding	  of	  99mTc-­‐SER-­‐4	  to	  at	  least	  one	  epitope	  per	  dimer	  would	  
result	   in	   a	   mass	   increase	   of	   approximately	   double	   the	   native	   antibody,	   significant	  
enough	  to	  alter	  the	  retention	  time	  of	  the	  antigen-­‐antibody	  complex	  relative	  to	  the	  free	  
antibody	  by	  size	  exclusion	  chromatography.	  	  
However,	   resolution	   of	   the	   antigen-­‐antibody	   and	   antibody	   peaks	   was	   incomplete,	  
which	  prevented	  affinity	  from	  being	  calculated	  reliably	  as	  peak	  integrals	  could	  only	  be	  
approximated.	   For	   this	   assay,	   the	   lowest	   detectable	   99mTc-­‐SER-­‐4	   concentration	   by	  
radioHPLC	  was	  determined	  and	   then	   incubated	  with	  an	  excess	  of	   recombinant	  Sn-­‐Fc	  
protein	   for	  30	  min.	  The	   resulting	  binding	   trace	  was	  used	   to	  determine	   the	  minimum	  
immunoreactive	   fraction,	   calculated	   at	   82%.	   Specificity	   of	   binding	   was	   shown	   by	  
blocking	   in	   the	   presence	   of	   10	   fold	   excess	   of	   cold	   SER-­‐4	   as	   well	   as	   by	   absence	   of	  
antigen-­‐antibody	  complex	  in	  the	  after	  incubation	  of	  Sn-­‐Fc	  with	  control	  99mTc-­‐IgG.	  
	  
2.5 Summary	  
A	   novel	   radiopharmaceutical	   for	   Mφ	   imaging,	   99mTc-­‐SER-­‐4,	   has	   been	   prepared	   and	  
evaluated	   in	  vitro.	   It	  binds	  to	  the	  cell	  membrane	  marker	  Sn	   in	  marginal	  metallophilic	  
Mφ	  found	  in	  splenic	  tissue	  section	  as	  well	  as	  to	  soluble	  antigen	  in	  solution.	  An	  efficient	  
Tc-­‐99m	  labelling	  procedure	  has	  been	  developed	  with	  specific	  activities	  that	  will	  allow	  
for	   in	  vivo	   imaging.	  The	  directly-­‐labelled	  antibody	  SER-­‐4	  displays	  both	  serum	  stability	  








3 Chapter	  3:	  	  
In	  vivo	  SPECT	  Imaging	  of	  99mTc-­‐SER-­‐4	  
	  
3.1 Introduction	  
Radiolabelled	   antibodies	   are	   increasingly	   important	   as	   a	   means	   of	   visualising	  
pathology,	   finding	   utility	   in	   the	   diagnosis	   of	   disease	   and	   following	   its	   response	   to	  
treatment.	  In	  the	  instance	  of	  chronic	  ailments,	  such	  as	  with	  maintenance	  of	  transplant	  
tolerance,	  patient	  treatment	  relies	  on	  the	  early	  identification	  of	  rejection	  events	  so	  as	  
to	   manage	   exposure	   to	   otherwise	   deleterious	   drug	   regimens	   whilst	   prolonging	  
transplant	  viability.	  Approaches	  to	  identifying	  pathological	  processes	  involve	  detecting	  
the	   cellular	   or	  molecular	   effectors	   of	   disease,	   or	   their	   by-­‐products,	   using	   a	   suitable	  
sensor.	  One	  such	  cellular	  effector	  is	  the	  Mφ,	  an	  important	  cell	  type	  in	  homeostasis	  but	  
also	   critical	   to	   pathogenesis	   in	   various	   disease	   settings.	   A	   notable	   feature	   of	  Mφ	   is	  
their	   considerable	   phenotypic	   variability,	  where	   often	   it	   is	   their	   activation	   state	   and	  
not	   just	  presence	  that	  determines	  the	  outcome	  of	  disease.	   In	  this	  chapter	  we	  aim	  to	  
evaluate	   the	   in	   vivo	   behaviour	   of	   the	   putative	   SPECT	   imaging	   agent	   99mTc-­‐SER4	   in	  
detecting	  endogenous	  Mφ	  populations	  as	  well	  as	  recruited	  inflammatory	  Mφs	  during	  
acute	  transplant	  rejection.	  
	  
3.1.1 Antibody	  Imaging	  
The	   clinical	   imaging	   of	   radiolabelled	   antibodies	   is	   now	   routinely	   performed	   for	   both	  
diagnostic	   and	  dosimetry	   purposes.	   The	  use	  of	   a	   radiolabelled	  mAb	   in	   diagnosis	   can	  
reveal	   the	   presence	   of	   pathology,	   the	   suitability	   of	   a	   given	   therapy	   (e.g.using	   the	  
unconjugated	   antibody)	   and	   also	   allow	   monitoring	   of	   a	   subjects	   response	   to	  
treatment.	   Alternatively	   dosimetry	   studies	   can	   be	   performed	   prior	   to	  
radioimmunotherapy	   with	   a	   conjugated	   mAb	   which	   allows	   the	   calculation	   of	   the	  
maximum	   administered	   dose	   whilst	   minimising	   undesirable	   effects,	   such	   as	  
myeloablation	  (Goldsmith	  and	  Signore	  2010).	  For	  these	  reasons	  numerous	  mAbs	  have	  
been	  radiolabelled	  and	  their	  in	  vivo	  properties	  assessed,	  of	  which	  the	  selected	  targets	  




unique	  to	  specific	  cell	  types,	  such	  as	  T	  and	  B	  cells	  (Malviya,	  Galli	  et	  al.	  2010),	  in	  order	  
to	  track	  the	  immune	  response	  during	  pathology;	  2)	  antibodies	  directed	  to	  cancer	  cell-­‐
associated	  antigens	  which	  permits	  the	  direct	   identification	  of	  malignant	  cell	   types;	  3)	  
antibodies	   which	   target	   secretory	   products/signalling	   molecules	   associated	   with	   a	  
pathological	  process	  (Glaudemans,	  Dierckx	  et	  al.	  2010).	  
 
3.1.2 Transplant	  Rejection	  	  	  
During	   transplant	   rejection,	   the	   donor	   organ	   promotes	   an	   immune	   response	   in	   the	  
recipient	   in	  which	  T	  cells	  play	  a	  central	  role.	  By	  recognising	  mismatches	   in	  the	  donor	  
MHC	   or	   other	   donor	   polymorphic	   cellular	   proteins,	   host	   T	   cells	  will	   either	   eliminate	  
donor	   cells	   directly,	   via	   CD8	   effector	   cells,	   or	   by	   driving	   the	   expansion	   of	   B	   cells	  
directing	   antibody	   to	   the	   grafted	   organ.	   Additionally,	   Treg	   cells	   are	   thought	   to	   be	  
important	   for	   the	   maintenance	   of	   tolerance	   to	   a	   transplanted	   organ.	   Aside	   from	   T	  
cells,	   components	   of	   innate	   immunity	   also	   play	   a	   variety	   of	   roles	   during	   transplant	  
rejection	  and	  tolerance.	  In	  this	  setting	  the	  presence	  of	  Mφ	  is	  generally	  associated	  with	  
graft	   rejection	  and/or	   resistance	   to	   tolerance	   induction	   (Li	   2010).	   The	   significance	  of	  
this	   cell	   type	   is	  underlined	  by	  depletion	  of	  Mφ	   in	  a	  murine	  cardiac	   transplant	  model	  
resulting	  in	  a	  70%	  decrease	  cardiac	  allograft	  vasculopathy	  (CAV),	  a	  hallmark	  of	  chronic	  
rejection	  (Kitchens,	  Chase	  et	  al.	  2007).	  
Despite	  advances	  in	  the	  median	  survival	  rate	  of	  cardiac	  transplant	  recipients	  (from	  8.3	  
years	  in	  the	  1980’s	  to	  10.4	  years	  in	  the	  1990’s),	  long	  term	  survival	  has	  not	  significantly	  
altered	  in	  the	  last	  20	  years	  (Stehlik,	  Edwards	  et	  al.	  2010)	  Post	  transplantation	  patients	  
receive	   immunosuppressive	   therapy	   to	   help	   maintain	   tolerance	   to	   the	   transplanted	  
organ	  with	  the	  complication	  that	  immune	  compromised	  individuals	  are	  more	  likely	  to	  
develop	  malignancy	  or	  infection.	  Hence	  transplant	  recipients	  receive	  on	  going	  immune	  
monitoring	   in	   order	   to	   predict	   acute	   events	   but	   also	   to	   determining	   an	   individual’s	  
immune	   response	   so	   as	   to	   minimise	   these	   toxic	   immunosuppression	   regimens	  





3.1.3 Imaging	  Transplant	  Rejection	  
Despite	  the	  development	  of	  non-­‐invasive	  techniques	  to	  identify	  acute	  cellular	  rejection	  
in	   cardiac	   transplants,	   none	   so	   far	   have	   replaced	   the	   surveillance	   biopsies	   due	   to	  
failure	   to	   validate	   the	   preliminary	   findings	   of	   these	   studies.	  With	   its	   invasive	   nature	  
and	  associated	  risk	  coupled	  with	  non-­‐representative	  sampling,	  there	  is	  a	  clinical	  need	  
to	   replace	   biopsy	   sampling	  with	   non-­‐invasive	  monitoring	   of	   rejection	   (Labarrere	   and	  
Jaeger	   2012).	   In	   the	   instance	   of	   cardiac	   transplant	   rejection,	   the	   requirement	   for	  
molecular	  imaging	  is	  outlined	  by	  morphological/functional	  imaging	  techniques	  such	  as	  
echocardiogram	   being	   insufficiently	   sensitive	   to	   detect	   early	   rejection	   events,	   and	  
leading	   to	   diagnosis	   only	   after	   irreparable	   damage	   to	   the	   transplanted	   organ	   has	  
occurred	   (Christen,	   Shimizu	   et	   al.	   2010).	   Despite	   this	   need,	   only	   preliminary	   studies	  
have	  been	  performed	  using	  molecular	  imaging	  to	  monitor	  transplant	  status.	  Thus	  far,	  
only	  radiolabelled	  annexin-­‐V	   (which	  targets	  exposed	  phosphatidylserine	  on	  apoptotic	  
cells)	   has	   been	   used	   clinically	   to	   study	   transplant	   rejection,	   and	   has	   shown	   a	  
correlation	  between	  rejection	  severity	  and	  tracer	  uptake	  (Narula,	  Acio	  et	  al.	  2001).	  
	  
Preclinically,	  Mφ-­‐targeting	  iron	  oxide	  nanoparticles	  (see	  Chapter	  1)	  have	  been	  shown	  
to	   image	   both	   renal	   and	   cardiac	   transplant	   rejection	   and	   to	   be	   able	   to	   detect	   the	  
response	  to	  immune	  suppressive	  therapy	  (Wu,	  Ye	  et	  al.	  2011).	  More	  recently,	  the	  19F	  
MRI	  has	  been	  examined	  to	  monitor	  acute	  transplant	  rejection,	  offering	  the	  advantage	  
over	  iron	  oxide	  nanoparticles	  as	  the	  signal	  detected	  is	  unique	  to	  the	  tracer	  rather	  than	  
emerging	  from	  the	  water.	  This	  makes	  detecting	  the	  tracer	  far	  less	  ambiguous,	  although	  
suffers	   from	   the	   drawback	   that	   is	   even	   less	   sensitive	   than	   1H	   nanoparticle	   MRI	  
(Hitchens,	  Ye	  et	  al.	  2011).	  The	  utility	  of	  Mφ	   imaging	  has	  been	  shown	  by	  recruitment	  
monitored	  during	  chronic	  renal	  rejection	  using	  USPIOs	  to	  show	  improved	  sensitivity	  of	  






3.2 Materials	  and	  Methods	  
3.2.1 Standard	  Biodistribution	  
Syringes	   (25G	  X	  16mm,	  Terumo)	  were	  weighed	  before	  and	  after	   injection,	  and	  serial	  
dilutions	   of	   1:4	   were	   performed	  with	   a	   starting	   50	   µL	   stock	   solution.	   Animals	   were	  
injected	  via	  tail	  vein	  with	  approximately	  20	  MBq	  of	  99mTc-­‐SER4	   in	  PBS	  (100	  µL	  at	  100	  
µg/ml).	   After	   culling	   according	   to	   schedule	   1,	   the	   animals	   were	   dissected	   and	   the	  
following	   organs	   collected:	   intestines,	   stomach,	   spleen,	   liver,	   kidney,	   heart,	   lungs,	  
blood	   (20	   µL),	   muscle,	   bone	   and	   tail.	   The	   tissue	   samples	   were	   weighed	   and	  
radioactivity	  counted	  using	  a	  gamma	  counter	  (LKB	  Wallac,	  Finland).	  Injected	  dose	  was	  
calculated	  from	  total	  activity	  in	  each	  injected	  syringe	  minus	  activity	  counted	  in	  tail,	  and	  
presented	  as	  the	  percentage	  of	  injected	  dose	  per	  gram	  (%ID/g)	  of	  each	  tissue	  sample.	  
	  
3.2.2 In	  vivo	  SPECT/CT	  Imaging	  	  
Imaging	   was	   performed	   using	   a	   nanoSPECT/CT	   small	   animal	   scanner	   (Bioscan	   Inc.,	  
Washington,	   USA)	   SPECT	   images	   were	   obtained	   using	   a	   4-­‐head	   scanner	   with	   1	  mm	  
pinhole	  collimators.	  Helical	  acquisitions	  were	  performed	  with	  24	  projections	  with	  the	  
time	   per	   projection	   adjusted	   so	   as	   to	  make	   overall	   scan	   time	   of	   30	  min.	   CT	   images	  
were	   obtained	   using	   45	   KVp	   X-­‐ray	   source,	   set	   with	   a	   500	  ms	   exposure	   time	   in	   180	  
projections	  lasting	  approximately	  10	  min.	  Images	  were	  reconstructed	  using	  proprietary	  
BioScan	  InVivoScope	  (IVS)	  software.	  	  
Adult	   male	   mice	   (C57BL/6,	   8	   –	   10	   weeks)	   were	   injected	   IV	   under	   anaesthesia	  
(isoflurane,	  VetOne,	  UK)	  with	  approximately	  20	  MBq	  99mTc-­‐SER4	  in	  100	  µL	  (100	  µg/ml;	  
n	   =	   9).	   After	   injection,	   one	   mouse	   was	   transferred	   to	   nanoSPECT/CT	   and	   imaged	  
continuously	  for	  6	  h.	  Non-­‐imaged	  mice	  were	  recovered	  and	  culled	  at	  1	  h,	  3	  h	  and	  6	  h	  
post	   injection	   (n	   =	   3	   per	   time	   point)	   after	   which	   standard	   biodistributions	   were	  
performed.	  	  
8	   week	   old	   	   C57BL/6	   and	   C57BL/6	   Sn-­‐/-­‐	   (Sn	   KO)	   male	   mice	   were	   injected	   IV	   under	  
anaesthesia	  (isoflurane,	  VetOne,	  UK)	  with	  approximately	  20	  MBq	  99mTc-­‐SER4	  or	  99mTc-­‐
IgG	  in	  100	  µL	  (100	  µg/ml;	  n	  =	  3).	  Mice	  were	  recovered,	  then	  anaesthetised	  and	  imaged	  





3.2.3 Heart	  Transplant	  Rejection	  Model	  
Transplants	   were	   performed	   by	   L	   Meader,	   K	   Brown	   and	   W	   Wong.	   8	   week	   old	  
allogeneic	  (BALB/c)	  and	  syngeneic	  (C57Bl/6)	  hearts	  were	  transplanted	  in	  to	  adult	  male	  
mice	  (C57Bl/6)	  (Corry	  RJ,	  Primarily	  vascularized	  allografts	  of	  hearts	  in	  mice.	  The	  role	  of	  
H-­‐2D,	   H-­‐2K,	   and	   non-­‐H-­‐2	   antigens	   in	   rejection,	   1973).	   Briefly,	   superior	   and	   inferior	  
vena	  cava	  and	  pulmonary	  veins	  of	  the	  donor	  heart	  were	  ligated.	  The	  donor	  aorta	  was	  
then	   anastomosed	   to	   the	   recipient	   aorta	   and	   the	   donor	   pulmonary	   artery	  
anastomosed	   to	   the	   inferior	   vena	   cava	   in	   the	   recipient	   abdomen.	   The	   transplanted	  
heart	   was	   perfused	   via	   the	   coronary	   arteries,	   resulting	   in	   a	   fully	   vascularised	  
heterotopic	  transplant	  (see	  Figure	  3.1).	  	  
	  
7	  days	  post	   transplantation	  mice	  were	   injected	   IV	  with	  approximately	  20	  MBq	  99mTc-­‐
SER4	  (1	  mg/mL;	  n	  =	  5	  and	  4	  for	  allogeneic	  and	  syngeneic,	  respectively)	  or	  99mTc-­‐IgG	  in	  
100	   µL	   (n	   =	   5).	   Mice	   were	   imaged	   at	   3	   h	   and	   culled	   4	   h	   post-­‐injection.	   Standard	  
biodistributions	   were	   performed	   and	   additionally	   the	   donor	   hearts	   were	   collected,	  
washed	  outside	  in	  PBS	  then	  divided	  in	  two	  approximately	  equal	  portions.	  One	  portion	  
was	  weighed	  and	  gamma	  counted	  with	  the	  other	  collected	  tissues.	  The	  second	  portion	  
was	   embedded	   in	   optimum	   cutting	   temperature	   (OCT)	   matrix	   (RA	   Lamb,	   Thermo	  







Figure	  3.1	  Schematic	  of	  Heart	  before	  and	  after	  	  transplantation.	  	  (A)	  The	  superior	  and	  inferior	  
vena	  cava	  as	  well	  as	  the	  pulmonary	  vein	  is	  ligated	  in	  the	  pretransplanted	  heart,	  while	  the	  aorta	  
and	  pulmonary	  artery	  are	  prepared	  for	  anastomosis.	  (B)	  The	  transplanted	  heart	  is	  placed	  in	  the	  
recipient’s	   abdominal	   cavity	   with	   donor	   aorta	   and	   pulmonary	   artery	   anastomosed	   to	  
abdominal	  aorta	  and	  inferior	  vena	  cava.	  Perfusion	  of	  the	  transplanted	  heart	  takes	  place	  via	  the	  
coronary	  arteries.	  
	  
3.2.4 Statistical	  Analysis	  
All	   of	   the	  data	   are	   given	   as	  means	   ±	   SD	  of	  n	   independent	  measurements.	   Statistical	  
analysis	   of	   experiments	  was	   performed	  with	   a	   Student	   T	   test	   using	  GraphPad	   Prism	  
(GraphPad	  Software).	  Statistical	  significance	  was	  assigned	  for	  P	  values	  <	  0.05.	  
	  
3.2.5 Immunohistochemistry	  
OCT	   embedded	   tissues	   were	   cut	   at	   5	   µm	   using	   a	   Brightwater	   Cryostat	   (Bright	  
Instruments,	   Huntingdon,	   UK)	   and	   mounted	   onto	   polylysine	   slides	   (Thermofisher,	  
Loughborough,	   UK).	   Sections	   were	   air	   dried	   overnight,	   transferred	   to	   50	   ml	   falcon	  
tubes	  (BD	  Biosciences)	  then	  stored	  at	  –	  80°C	  until	  staining.	  For	  staining,	  sections	  were	  
taken	   from	   freezer	   and	   left	   at	   room	   temperature	   for	   10	  min	   before	   removing	   from	  
falcon	  tube.	  Sections	  were	  immersed	  in	  chilled	  acetone	  for	  5	  min	  and	  then	  left	  to	  air	  




followed	   by	   avidin/biotin	   blocking	   (Vector	   Laboratories,	   Burlingame,	   USA).	   Sections	  
were	   incubated	   overnight	   with	   SER4	   (1	   µg/mL),	   followed	   by	   incubation	   with	  
biotinylated	   goat	   anti-­‐rat	   secondary	   (10	   µg/ml,	   BD),	   and	   finally	   streptavidin-­‐horse	  
radish	   peroxidase	   (Pharmingen,	   San	   Diego,	   USA).	   Samples	   were	   visualised	   using	   the	  
Vector	   NovaRed	   Substrate	   kie	   (Vector	   Labs)	   and	   counter	   stained	  with	   haematoxylin	  
(RA	   Lamb	   Ltd,	   Eastbourne,	   UK),	   followed	   by	   washing,	   dehydration	   and	  mounting	   in	  
DPX	   mountant	   (BDH).	   Images	   were	   captured	   using	   a	   Lecia	   Leitz	   DMRB	   research	  
microscope	  and	  Micro-­‐Publisher	  3.3	  RTV	   camera.	   Images	  were	  analysed	  with	   Image-­‐
Pro	  Plus	  7.0	  from	  Media	  Cybernetics	  software	  and	  Photoshop.	  
	  
3.3 Results	  
3.3.1 Biodistribution	  of	  99mTc-­‐SER4	  
Mice	  were	  injected	  with	  99mTc-­‐SER4	  and	  one	  mouse	  scanned	  continuously	  for	  6	  hr	  post	  
injection	   using	   nanoSPECT/CT	   (see	   Figure	   3.2).	   Whole	   body	   imaging	   showed	   rapid	  
accumulation	   of	   99mTc	   in	   the	   spleen,	   liver	   and	   bone	  marrow,	  with	   a	   gradual	   drop	   in	  
blood	  pool	  as	  seen	  in	  the	  observed	  heart	  signal	  along	  with	  a	  concomitant	  accumulation	  
in	   the	   bladder.	   Imaging	   also	   revealed	   the	   uptake	   of	   99mTc-­‐SER4	   in	   the	   intestines.	  
Superior	   to	   the	   heart,	   and	   within	   the	   thoracic	   cage	   a	   signal	   was	   detected	   in	   the	  







Figure	  3.2	  Static	  nanoSPECT/CT	  imaging	  of	  99mTc-­‐SER4	  in	  wild	  type	  mouse.	  	  Mouse	  injected	  IV	  
with	  ∼20	  MBq	  of	   99mTc-­‐SER4	  and	   imaged	  over	   time.	  A-­‐D:	  Static	  SPECT	  acquisitions	  at	  30,	  60,	  
180	  and	  360	  min	  post-­‐injection,	  respectively,	  overlayed	  on	  CT	  acquired	  10	  min	  post	  injection.	  
Arrows	  indicate	  liver	  (L),	  spleen	  (S)	  and	  bone	  marrow	  (BM).	  Images	  normalised	  by	  application	  
of	  same	  arbitrary	  threshold	  limits.	  
	  
Alongside	   scanning,	   biodistributions	   were	   performed	   by	   weighing	   and	   measuring	  
radioactivity	  of	  tissues	  removed	  from	  culled	  mice	  at	  1	  h,	  3	  h	  and	  6	  h	  post	  injection	  (n	  =	  
3	  per	   time	  point	   	   -­‐	   see	  Figure	  3.3).	  Rapid	  accumulation	  of	   99mTc-­‐SER4	  within	  an	  hour	  
post	  injection	  was	  observed	  in	  the	  spleen,	  liver	  and	  bone	  marrow	  with	  313,	  87	  and	  22	  
%ID/g	   values	   recorded	   an	   hour	   post	   injection,	   respectively.	   Blood	   levels	   drop	  
















Figure	   3.3	   Biodistribution	   of	   99mTc-­‐SER4	   in	   C57Bl/68	  week	   old	   	  mice	   (n=3	   per	   time	   point).	  	  
Mice	  were	   injected	   IV	   into	  the	  tail	  vein	  with	  ∼20MBq	  of	  99mTc-­‐SER4.	  After	  1	  h,	  3	  h	  and	  6	  h	  
mice	  were	  culled	  and	  organs	  harvested,	  weighed	  and	  gamma	  counted.	  Radioactive	  uptake	   in	  
organs	   is	   presented	   as	   the	   percentage-­‐injected	   dose	   per	   gram	   per	   organ.	   A:	   Full	  
biodistribution.	  B:	  Rescaled	  to	  a	  max	  of	  50	  %ID/g	  of	  A	  to	  see	  biodistribution	  of	   lower	  activity	  
organs	  (error	  represents	  a	  standard	  deviation	  of	  n	  =	  3)	  
	  
3.3.2 Comparison	  of	  99mTc-­‐SER4/IgG	  in	  Wild	  Type	  and	  Sn	  KO	  mice	  
C57BL/6	  Sn	  mice	  were	   injected	  with	  either	  99mTc-­‐SER4	  or	  99mTc-­‐IgG	  and	  C57BL/6	  Sn-­‐/-­‐	  
mice	  injected	  with	  99mTc-­‐SER4.	  Mice	  were	  imaged	  at	  3	  h	  post	  injection	  and	  culled	  at	  4	  
h.	  Whole	   body	   imaging	   showed	   absence	   of	   characteristic	   splenic	   and	   bone	  marrow	  
uptake	  of	  99mTc-­‐IgG	  in	  wild	  type	  mice	  (Figure	  3.4	  A)	  as	  well	  99mTc-­‐SER4	  in	  Sn	  KO	  mice	  







































groups	  demonstrated	  significant	  blood	  pool	   (as	  observed	  by	  heart	  and	  carotid	  artery	  
visualisation)	   as	   well	   as	   increased	   abdominal	   signal.	   In	   all	   three	   groups,	   bladder	  
accumulation	  was	  observed.	  
	  
Figure	  3.4	  nanoSPECT/CT	  imaging	  of	  99mTc-­‐SER4	  and	  99mTc-­‐IgG	  in	  wild	  type	  and	  Sn	  knockout	  
mice.	  	  Wild	  type	  mice	  were	  injected	  IV	  with	  ∼20	  MBq	  of	  either	  99mTc-­‐IgG	  	  (A)	  or	  99mTc-­‐SER4	  (B)	  
and	   Sn	   knockout	  mice	  with	   99mTc-­‐SER4	   (C)	   	   and	   imaged	  3	  hours	   later.	  Arrows	   indicate	   signal	  
arising	  from	  carotid	  arteries	  (CA),	  heart	  (H),	  aorta	  (A)	  and	  bladder	  (B).	  	  
	  
Biodistribution	  data	  records	  elevated	  splenic	  (207	  %ID/g)	  and	  bone	  marrow	  (40	  %ID/g)	  
uptake	  of	  99mTc-­‐SER4	  in	  wild	  type	  versus	  KO	  mice	  (8	  and	  4	  %ID/g	  for	  spleen	  and	  bone	  
marrow,	   respectively)	   as	  well	   as	   enhanced	   uptake	   compared	   to	   control	   99mTc-­‐IgG	   in	  
wild	   type	   mice	   (17	   and	   9	   %ID/g	   for	   spleen	   and	   bone	   marrow,	   respectively).	   Liver	  
uptake	  was	  also	  higher	  for	  99mTc-­‐SER4	  in	  wild	  type	  mice	  (38	  %ID/g)	  as	  compared	  to	  in	  
the	   KO	   (10	  %ID/g)	   and	   99mTc-­‐IgG	   in	  wild	   type	  mice	   (26	  %ID/g)	   (see	   Figure	   3.5).	   The	  
presence	  of	  contaminating	  blood	  pool	  signal	  is	  significant	  (especially	  when	  considering	  
highly	  vascularised	  organs	  such	  as	  the	  heart	  and	  liver).	  Tissue-­‐to-­‐blood	  ratios	  attempt	  
to	  correct	   for	   the	   influence	  of	  blood	  pool	  signal	   from	  specific	  uptake	  for	  each	  tissue,	  
with	   spleen,	   liver	   and	   bone	  marrow	   showing	   on	   average	   28,	   4	   and	   10	   times	   higher	  
tissue-­‐to-­‐blood	   ratio,	   respectively,	   in	   wild	   type	   mice	   injected	   with	   99mTc-­‐SER4	   as	  
compared	  to	  the	  control	  groups	  (99mTc-­‐IgG	  in	  wild	  type	  mice	  plus	  99mTc-­‐SER4	  in	  Sn	  KO	  








Figure	   3.5	   Biodistribution	   of	   99mTc-­‐SER4	   and	   99mTc-­‐IgG	   in	   wild	   type	   and	   Sn	   knockout	   mice	  
(n=3).	   	  Wild	   type	  mice	  were	   injected	   IV	  with	  ∼20	  MBq	  of	  either	  99mTc-­‐IgG	   	   (blue)	  or	   99mTc-­‐
SER4	  (red)	  and	  Sn	  knockout	  mice	  with	  99mTc-­‐SER4	  (green)	  	  and	  imaged	  3	  hours	  later.	  After	  3	  h	  
organs	  were	  harvested,	  weighed	  and	   then	  counted	   for	   radioactivity	  using	  a	  gamma	  counter.	  
Uptake	   into	   organs	   is	   presented	   as	   the	   percent-­‐injected	   dose	   per	   gram	   organ.	   A:	   Full	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Figure	   3.6	   Tissue-­‐to-­‐blood	   ratio	   of	   99mTc-­‐SER4	   and	   99mTc-­‐IgG	   in	  wild	   type	   and	   Sn	   knockout	  
mice	  (n=3).	  	  Representation	  of	  biodistribution	  data	  from	  figure	  4.7	  as	  tissue-­‐to-­‐blood	  ratio.	  
	  
3.3.3 Heart	  Transplant	  Rejection	  Model	  
Heterotopic	  cardiac	  transplants	  were	  performed	  using	  syngeneic	  (donor	  and	  recipient	  
from	   same	   background)	   and	   allogeneic	   (donor	   and	   recipient	   from	   different	  
backgrounds)	   donor	   hearts	   transplanted	   into	   the	   recipient	   abdominal	   cavity.	   Mice	  
were	   recovered	   and	   imaging	   performed	   7	   days	   post	   transplantation.	   Whole	   body	  
nanoSPECT/CT	   imaging	   revealed	   characteristic	   99mTc-­‐SER4	  uptake	   to	   the	   spleen,	   liver	  
and	  bone	  marrow	  in	  both	  transplant	  groups	  (Figure	  3.7	  A	  and	  B).	  Analysis	  orthogonal	  
slices	   taken	   from	  the	  abdominal	  cavity	   reveals	  emergence	  of	  signal	  corresponding	   to	  
soft	   tissue	   from	   the	   site	   of	   transplantation	   (and	   not	   a	   bowel	   loop)	   in	   the	   allogeneic	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Figure	   3.7	   nanoSPECT/CT	   imaging	   of	   99mTc-­‐SER4	   in	   heterotopic	   transplant	   model.	  
Representative	   nanoSPECT/CT	   images	   of	   recipients	  with	   either	   a)	   allogeneic	   or	   b)	   syngeneic	  
donor	  heart	  imaged	  3	  hrs	  post	  injection	  with	  99mTc-­‐SER4.	  	  CT,	  SPECT	  and	  fused	  images	  from	  
coronal	   (c,	   d,	   e,	   respectively)	   and	   transversal	   (f,	   g,	   h,	   respectively)	   planes	   of	   an	   allogeneic	  
recipient	  are	  shown.	  Arrows	  indicate	  site	  of	  abdominal	  cardiac	  transplant	  with	  uptake	  of	  tracer	  
in	  allogeneic	  donor	  heart	  absent	  in	  the	  syngeneic	  donor	  heart..	  	  
Biodistribution	  data	   shows	   99mTc-­‐SER4	  uptake	   in	  allogeneic	   transplants	   (8.40	  %ID/g	  ±	  
1.78	  %ID/g)	  to	  be	  significantly	  higher	  than	  99mTc-­‐SER4	  uptake	  in	  syngeneic	  transplants	  
(3.00	  %ID/g	   ±	   1.63	  %ID/g;	   p	   =	   0.0023)	   or	   99mTc-­‐IgG	   uptake	   in	   allogeneic	   transplants	  
(5.93	  %ID/g	  ±	  0.57	  %ID/g;	  p	  =	  0.0336)	  (see	  Figure	  3.10).	  Likewise,	  target-­‐to-­‐blood	  ratios	  
illustrate	   higher	   uptake	   in	   allogeneic	   99mTc-­‐SER4	   uptake	   versus	   99mTc-­‐IgG	   and	   99mTc-­‐
SER4	   in	   allogeneic	   and	   syngeneic	   transplants,	   respectively.	   Approximately	   an	   8-­‐fold	  
higher	   99mTc-­‐SER4	   uptake	   in	   allogeneic	   donor	   heart	   versus	   the	   99mTc-­‐SER4	   syngeneic	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Figure	  3.8	  Biodistribution	  of	  99mTc-­‐SER4	  in	  allogeneic	  and	  syngeneic	  heart	  grafts	  (n=	  4	  to	  5).	  
8	  week	  old	  C57Bl/6	  mice	   receiving	  either	   allogeneic	  BALB/c	   	   heart	   grafts	  were	   injected	  with	  ∼20	   MBq	   99mTc-­‐SER4	   (blue)	   or	   99mTc-­‐IgG	   (green)	   and	   syngeneic	   C57Bl/6	   heart	   grafts	   were	  
injected	  IV	  with	  99mTc-­‐SER4	  (red)	  7	  days	  post	  transplantation.	  After	  4	  h	  organs	  were	  harvested,	  
weighed	   and	   then	   counted	   for	   radioactivity	   using	   a	   gamma	   counter.	   Uptake	   into	   organs	   is	  
presented	  as	  the	  percent-­‐injected	  dose	  per	  gram	  organ.	  A:	  Full	  biodistribution.	  B:	  Donor	  heart,	  
























































Figure	   3.9	   Ratio	   of	  %	   injected	   dose	   per	   gram	   of	   syngeneic	   and	   allogeneic	   donor/recipient	  
hearts	  to	  blood.	   	  %ID/g	  data	  from	  recipient	  and	  donor	  hearts	  (allogeneic	  and	  syngeneic)	  were	  
expressed	  as	  a	  factor	  of	  blood	  %ID/g.	  
	  
3.3.4 Transplant	  Immunohistochemistry	  
Donor	   and	   recipient	   hearts	   from	   day	   7	   post	   transplantation	   were	   snap	   frozen	   and	  
stained	   for	  Sn	  expression.	  Allogeneic	  donor	   transplants	  exhibit	  high	  expression	  of	  Sn	  
(see	  Figure	  3.10	  A)	  as	  compared	  to	  syngeneic	  donor	  transplants	  (see	  Figure	  3.10	  B).	  Of	  
interest,	  recipient	  (i.e.	  native)	  hearts	  exhibit	  an	  endogenous	  population	  of	  Sn	  positive	  
cells	  (see	  Figures	  3.10	  C	  and	  D).	  
	  
Figure	   3.1010	   Recipient	   and	   donor	   hearts	   stained	   for	   Sn	   expression.	   	   5	   µm	   sections	   from	  
donor	  ((A)	  allogeneic,	  (B)	  syngeneic)	  and	  recipient	  ((C)	  allogeneic,	  (D)	  syngeneic)	  were	  stained	  
for	   Sn	   (brown)	   and	   counter-­‐stained	  with	  haematoxylin.	   For	  donor	   transplants,	   allogeneic	   (A)	  
heart	  shows	  substantially	  higher	  Sn	  expression	  as	  compared	  to	  syngeneic	  (B)	  heart.	  Recipients	  

















3.4 Discussion	  	  
Intact	  antibodies	  can	  display	  serum	  half-­‐lives	  of	  the	  order	  of	  days	  to	  weeks,	  which	  is	  a	  
function	  of	  their	  molecular	  mass	  exceeding	  the	  renal	  cut	  off	  (typically	  150	  kDa	  for	  full	  
length	  IgG	  versus	  50	  kDa	  cut	  off)	  and	  of	  neonatal	  FcR-­‐mediated	  recycling	  of	  IgG	  (Carter	  
2006).	   99mTc-­‐SER4	  exhibits	  uniquely	   rapid	  blood	  extravasation	  due	  to	  high	  expression	  
of	   endogenous	   antigen	   principally	   in	   the	   spleen.	   From	   one	   comparison	   of	   a	  
radiolabelled	   antibody	   and	   its	   engineered	   fragments,	   the	   blood	   clearance	   of	   99mTc-­‐
SER4	   resembles	   that	  of	  a	  diabody	   rather	   than	  an	   IgG	   (with	  half-­‐lives	  of	  170	  min	  and	  
330	  min,	  respectively)	  (Jain,	  Venkatraman	  et	  al.	  2007).	  Mφ	  populations	  expressing	  the	  
highest	  levels	  of	  Sn	  are	  typically	  found	  in	  border	  regions	  between	  flowing	  lymph/blood	  
and	   lymphoid	   tissue,	   implying	   a	   function	   as	   sentinel	   cell	   types	   (see	   Chapter	   1).	   This	  
property	  seems	  to	  be	  critical	  in	  the	  rapid	  extravasation	  of	  99mTc-­‐SER4	  from	  the	  blood,	  
uniquely	   offering	   imaging	   time	  points	   far	   earlier	   than	   for	   any	   known	   intact	   IgG.	   The	  
specificity	  of	  this	  effect	  was	  confirmed	  by	  the	  99mTc-­‐SER4’s	  distribution	  in	  Sn	  KO	  mice,	  
in	   which	   blood	   retention	   of	   99mTc-­‐SER4	   was	   similar	   to	   that	   of	   untargeted	   isotype	  
control	  in	  wild	  type	  mice.	  
The	  distribution	  characteristics	  of	  radiolabelled	  SER4	  are	   in	  accordance	  with	  the	  data	  
concerning	  Sn	  expression	  in	  mice,	  and	  in	  line	  with	  this	  %ID/g	  values	  reflect	  the	  relative	  
expression	   levels	   as	   determined	   by	   IHC	   between	   tissues.	   In	   descending	   levels	   of	  
expression,	   spleen,	   liver	   and	   bone	  marrow	   represent	   the	   set	   of	   vascularised	   tissues	  
expressing	  Sn	  (avascular	  LNs	  contain	  the	  highest	  expressing	  Sn	  cells	  in	  the	  body	  located	  
in	   the	   SCS)	   and	   thus	   the	   expected	   locations	   of	   99mTc-­‐SER4	   uptake.	   A	   complicating	  
matter	   for	   the	   determination	   of	   activity	   of	   a	   given	   tissue	   is	   the	   contribution	   that	  
residual	  blood	  makes	  to	  the	  overall	  gamma	  counts.	  This	   is	  particularly	  evident	   in	   the	  
liver	  (and	  to	  some	  extent	  the	  bone	  marrow),	  where	  only	  after	  representing	  the	  data	  as	  
tissue-­‐to-­‐blood	  ratio	   is	   it	  clear	   that	  enhanced	  uptake	   in	  the	   liver	   is	  a	  consequence	  of	  
targeting	   to	   Sn.	   This	   effect	   would	   be	   reduced	   by	   washing	   of	   removed	   organs	   with	  
saline	  (as	  was	  performed	  in	  transplanted	  hearts)	  or	  by	  culling	  by	  exsanguination.	  This	  




The	   differential	   uptake	   observed	   in	   the	   bone	   (highest	   in	   femur	   and	   vertebrae)	  may	  
represent	   enhanced	  uptake	   in	   regions	  with	   larger	   cavities	   (i.e.	   greater	   bone	  marrow	  
mass).	   Alternatively	   this	   may	   relate	   to	   heterogenous	   Sn	   expression	   across	   bone	  
marrow	   reservoirs,	   which	   could	   be	   examined	   by	   histological	   analysis.	   As	   Sn	   positive	  
Mφ	  are	   implicated	   in	  haematopoieitic	   stem	  cell	   (HSC)	   retention	   in	   the	  bone	  marrow	  
(Chow,	  Lucas	  et	  al.	  2011),	  heterogenous	  Sn	  expression	  may	  inform	  upon	  different	  HSC	  
niches	   localised	   in	   different	   bone	   marrow	   regions.	   Progressive	   accumulation	   in	   the	  
intestines	  observed	  by	  whole	  body	  imaging	  may	  represent	  specific	  uptake	  mediated	  by	  
Sn	   positive	   Mφ	   resident	   in	   the	   lamina	   propria	   and	   Peyer’s	   patches	   (Crocker	   and	  
Gordon	   1989),	   or	   possibly	   non-­‐specific	   metabolism.	   The	   absence	   of	   progressive	  
accumulation	   represented	   in	   the	   biodistribution	   data	   may	   represent	   any	   localised	  
specific	   uptake	   being	   masked	   by	   the	   considerable	   size	   of	   the	   intestines,	   in	   effect	  
normalising	   the	   intestinal	   %ID/g	   data.	   This	   may	   be	   avoided	   by	   assessing	   intestinal	  
activity	  on	  sections	  of	  intestine	  rather	  than	  counting	  the	  intact	  organ.	  
From	   the	   biodistribution	   there	   are	   still	   significant	   amounts	   of	   99mTc-­‐SER4	   in	   the	  
circulation	   at	   6	   hr.	   Imaging	   at	   a	   later	   time	   point	   would	   permit	   greater	   clearance	   of	  
antibody	   and	   thus	   drop	   the	   contribution	   blood	   pool	   would	   make	   to	   the	   collected	  
samples.	  However	  with	  the	  isotope	  99mTc,	  imaging	  at	  greater	  than	  24	  h	  would	  equate	  
to	  4	  half-­‐lives	  and	  thus	  drastically	  affect	  the	  quality	  of	  image.	  An	  alternative	  would	  be	  
to	  use	  a	   longer	   lived	   isotope,	   such	  as	   111In,	  which	  would	  allow	   imaging	  at	   later	   time	  
points	   without	   significant	   drop	   in	   the	   achieved	   image	   quality.	   The	   reason	   for	   using	  
99mTc	  in	  this	  study	  was	  its	  ready	  availability	  as	  compared	  to	  longer	  lived	  isotopes	  and	  
the	  ease	  with	  which	  the	  radiolabelled	  compound	  (99mTc-­‐SER4)	  could	  be	  prepared.	  The	  
selection	   of	   imaging	   at	   3	   h	   post-­‐injection	   was	   decided	   upon	   qualitatively	   using	   the	  
imaging	  data	  in	  which	  the	  blood	  pool	  significantly	  dropped	  over	  the	  first	  60	  min,	  whilst	  
between	   hours	   3	   and	   6	   substantial	   changes	   in	   blood	   pool	   visualisation	   weren’t	  
observed.	   Also	   imaging	   at	   earlier	   time	   points	   provides	   a	   more	   dynamic	   picture	   of	  
radiotracer	  uptake	  and	  hence	  disease	  processes.	  This	  is	  lost	  when	  imaging	  using	  slow	  
clearing	   agents,	   such	   as	   with	   USPIOs	   which	   are	   imaged	   approximately	   36	   h	   post	  




The	   progressive	   accumulation	   of	   activity	   in	   the	   bladder	   has	   been	   attributed	   to	  
transchelation	   of	   99mTc	   from	   the	   IgG	   disulphides	   to	   free	   sulfhydryls	   presented	   by	  
cysteine	  and	  glutathione	   (Hnatowich,	  Mardirossian	  et	   al.	   1993).	   This	  effect	  has	  been	  
considered	   favourable	   for	   earlier	   imaging	   as	  blood	  pool	   activity	   is	   significantly	   lower	  
than	   indirectly	   labelled	   antibodies.	   Some	   authors	   have	   speculated	   that	   in	   vivo,	   the	  
extracellular	   concentration	   of	   sulfhydryls	   isn’t	   sufficient	   for	   transchelation	   to	   take	  
place,	   and	   instead	   speculate	   elevated	   excretion	   of	   directly	   labelled	   antibodies	  
represents	   internalisation	   followed	   by	   transchelation	   in	   the	   lysozyme,	   after	   which	  
chelated	   99mTc	   is	   transported	   and	   excreted	   (Karacay,	   Ong	   et	   al.	   1998).	  Whether	   the	  
rapid	   accumulation	   of	   99mTc	   in	   urine	   following	   99mTc-­‐SER4	   administration	   can	   be	  
explained	  by	  an	  internalising	  process	  is	  debatable	  given	  the	  short	  time	  frame	  between	  
injection	  and	  imaging.	  
In	  vivo	  specificity	  of	  99mTc-­‐SER4	   in	  wild	  type	  mice	  was	  confirmed	  by	  comparison	  with	  
99mTc-­‐IgG	   and	   99mTc-­‐SER4	   in	   wild	   type	   and	   Sn	   KO	   mice,	   respectively.	   Whole	   body	  
imaging	  at	  3	  hr	  post	  injection	  showed	  high	  splenic	  uptake	  as	  well	  as	  distinct	  liver	  and	  
bone	  marrow	  uptake	   in	   the	   case	  of	   99mTc-­‐SER4	  administered	   to	  wild	   type	  mice.	   This	  
distribution	  was	  absent	   in	  both	  of	  the	  control	  groups,	  where	   instead	  high	  blood	  pool	  
was	   observed	   (indicated	   by	   visualisation	   of	   the	   heart	   and	   the	   carotid	   arteries).This	  
accords	   with	   endogenous	   Sn	   expression	   promoting	   extravasation	   of	   radiotracer	  
whereas	   the	   absence	   of	   this	   sink	   in	   the	   control	   groups	   leads	   to	  much	   higher	   blood	  
retention.	   A	   diffuse	   peritoneal	   signal	   was	   seen	   in	   the	   control	   mice	   that	   may	   be	  
attributed	  to	  the	  longer	  blood	  half	  live	  of	  radiotracer	  in	  these	  control	  groups	  affording	  
greater	   access	   to	   metabolic	   processing	   and	   excretion.	   Alternatively,	   although	   all	  
images	  were	  adjusted	  to	  the	  same	  threshold,	  the	  intense	  signal	  provided	  by	  the	  spleen	  
in	  the	  targeted	  group	  may	  obstruct	  detection	  of	  a	  weaker	  peritoneal	  signal.	  Across	  all	  
groups	   similar	   bladder	   uptake	   was	   observed,	   implicating	   the	   role	   of	   transchelation.	  
Also	   an	   absence	   of	   any	   thyroid	   or	   stomach	   signal	   indicates	   the	   stability	   of	   the	  
radiotracer	   regarding	  release	  of	   free	  pertechnetate	  which	  would	   target	  hNIS	  positive	  
tissues	  in	  these	  organs.	  
Biodistribution	   data	   corroborates	   with	   whole	   body	   imaging	   by	   showing	   greatly	  




control	  groups.	  Although	  this	  effect	  is	  observed	  in	  the	  liver	  it	  is	  to	  some	  extent	  masked	  
by	   the	   contaminating	   blood	   signal	   owing	   to	   perfusion	   effects.	   Thus	   higher	   blood	  
activity	  in	  control	  groups	  results	  in	  an	  increased	  non-­‐specific	  liver	  uptake	  (due	  to	  blood	  
perfusion)	   as	   compared	   to	   the	   non-­‐specific	   uptake	   in	   the	   targeted	   group.	   This	   non-­‐
specific	  effect	  offsets	  the	  specific	  uptake	  of	  99mTc-­‐SER4	  to	  Sn	  positive	  Mφ	  in	  the	   liver	  
and	   so	   to	   account	   for	   this	   data	   was	   represented	   as	   a	   tissue-­‐to-­‐blood	   ratio.	   This	  
representation	   shows	  enhanced	  uptake	   in	   spleen,	  bone	  marrow	  and	   liver	  and	  hence	  
indicates	  the	  specificity	  of	  the	  99mTc-­‐SER4	  tracer.	  The	  increased	  uptake	  observed	  in	  the	  
intestine	   of	   99mTC-­‐SER4	   treated	   WT	   mice	   (as	   compared	   to	   control	   groups)	   may	  
correspond	   to	   specific	   uptake	   by	   Sn	   positive	   Mφ	   populations	   found	   in	   the	   lamina	  
propria	  and	  Peyer’s	  patches	  (Crocker	  and	  Gordon	  1989).	  
Targeting	   of	   Sn	   positive	   Mφ	   during	   disease	   was	   performed	   using	   allogeneic	   and	  
syngeneic	  cardiac	  heterotopic	  heart	   transplants	  at	  day	  7	  post	   transplantation.	  Whole	  
body	   imaging	   at	   3	   hr	   post	   radiotracer	   injection	   revealed	   characteristic	   uptake	   to	  
spleen,	  bone	  marrow	  and	   liver.	  Additionally,	   99mTc-­‐SER4	   showed	   increased	  uptake	   in	  
the	   abdominal	   cavity	   for	   the	   allogeneic	   compared	   to	   syngeneic	   transplant.	   This	   is	  
expected	  as	  the	  allogeneic	  response	  is	  far	  more	  aggressive	  compared	  to	  syngeneic	  and	  
in	  turn	  leads	  to	  greater	  Mφ	  recruitment	  (Mannon	  2012).	  
Biodistributions	   were	   performed	   at	   4	   hr	   post	   injection	   and	   reproduce	   the	   imaging	  
data,	  with	   	   specificity	   indicated	   by	   elevated	   99mTc-­‐SER4	   uptake	   compared	   to	   control	  
99mTc-­‐IgG	  for	  both	  spleen	  and	  bone	  marrow.	  Blood	  pool	  activity	  was	  recorded	  highest	  
in	  the	  isotype	  control	  group	  followed	  by	  the	  SER4	  syngeneic	  then	  allogeneic	  groups.	  In	  
the	   SER4	   groups,	   blood	   activity	   corresponded	   to	   splenic	   uptake,	  with	   the	   allogeneic	  
transplanted	  mice	  showing	  the	  least	  uptake.This	  may	  be	  a	  result	  of	  increased	  uptake	  in	  
the	  allogeneic	  donor	  heart	  compared	  to	  the	  syngeneic	  reducing	  the	  overall	  blood	  load.	  	  
The	  presence	  of	  Sn	  positive	  Mφ	  was	  confirmed	  by	  immunohistochemistry.	  Comparison	  
of	   staining	   from	   allogeneic	   and	   syngeneic	   donor	   hearts	   confirmed	   increased	   Sn	  
expression	  along	  with	  the	  allogeneic	  response.	  Interestingly,	  staining	  of	  recipient	  heart	  
revealed	  the	  presence	  of	  Sn	  positive	  Mφ	  which	  represents	  the	  presence	  of	  an	  as	  yet	  





In	  this	  chapter,	  the	  in	  vivo	  functioning	  of	  the	  novel	  Mφ	  imaging	  agent	  99mTc-­‐SER4	  was	  
assessed.	   99mTc-­‐SER4	  exhibited	  unique	  clearance	  kinetics	   for	  an	   intact	  antibody,	  with	  
endogenous	   Sn	   expression	   (principally	   in	   the	   spleen)	   permitting	   earlier	   imaging	   as	  
compared	   to	   control	   antibodies.	   Specificity	   of	   99mTc-­‐SER4	   was	   confirmed	   by	  
comparison	  with	  untargeted	  isotype	  antibody	  as	  well	  use	  of	  99mTc-­‐SER4	  in	  Sn	  KO	  mice.	  
A	   proof-­‐of-­‐principle	   imaging	   experiment	   was	   performed	   using	   a	   cardiac	   model	   of	  
transplant	   rejection	   to	   elicit	  Mφ	   recruitment.	   99mTc-­‐SER4	  displayed	   increased	  uptake	  
corresponding	   to	   increased	   Sn	   positive	   Mφ	   burden	   as	   compared	   to	   non-­‐specific	  
control	  antibody,	  illustrating	  99mTc-­‐SER4	  suitability	  as	  a	  Mφ	  targeting	  imaging	  agent.	  
	  




4 Chapter	  4	  	  
In	  vivo	  PET	  	  Imaging	  of	  64Cu-­‐SER464Cu-­‐SER4	  
4.1 Introduction	  	  
Mφs	  are	  a	  highly	  adaptable	  cell	  type	  able	  to	  alter	  their	  behaviour	  drastically	  in	  order	  to	  
manipulate	   their	   environment.	   For	   this	   reason	   endogenous	   tissue	   residing	   Mφ	  
populations	   are	   invaluable	   for	   their	   ability	   to	   display	   varied	   responses	   in	   order	   to	  
maintain	  homeostasis.	  One	   such	   little	  understood	  population	  are	  bone	  marrow	  Mφs	  
which	   play	   an	   important	   role	   in	   the	   regulation	   of	   the	   haematopoietic	   environment,	  
and	  may	  have	  important	  implications	  for	  transplantation.	  Similarly,	  tumour	  associated	  
Mφs	  (TAMs)	  are	  critical	  to	  the	  regulation	  of	  the	  tumoural	  environment	  and	  are	  shown	  
to	   assist	   in	   tumour	   progression	   and	   present	   as	   potential	   therapeutic	   targets.	   In	   this	  
chapter	  we	  aim	  to	  produce	  a	  novel	  PET	   radiotracer	  using	   the	  anti-­‐Sn	  antibody	  SER-­‐4	  
and	   perform	   preliminary	   imaging	   studies	   to	   examine	   its	  Mφ	   targeting	   properties	   of	  
resident	   bone	   marrow	   subpopulation	   response	   to	   irradiation	   as	   well	   as	   Sn	   Mφ	  
recruitment	  to	  tumours.	  In	  particular,	  we	  examine	  the	  influence	  of	  the	  cytokine	  colony	  
stimulating	   factor	   1	   (CSF-­‐1)	   upon	   Mφ	   recruitment	   and	   the	   relationship	   of	   Sn	  
expression	  to	  the	  heterogenous	  cell	  population	  known	  as	  myeloid-­‐derived	  suppressor	  
cells	   (MDSC).	   The	  data	   presented	  here	   is	   collected	   from	  a	   3	  month	   residence	   in	   the	  
laboratories	   of	   Prof	   Anna	  Wu,	   Department	   of	   Molecular	   Imaging,	   Crumps	   Institute,	  
UCLA	  and	  supported	  by	  the	  MEC	  Luminary	  Fund.	  
	  
4.1.1 	  Bone	  Marrow	  Mφ	  and	  Radioablation	  
In	  the	  carefully	  regulated	  environment	  of	  the	  bone	  marrow,	  HSCs	  -­‐	  the	  source	  of	  all	  the	  
blood	   cell	   types	   including	   lymphoid,	   myeloid	   and	   erythroid	   lines	   -­‐	   are	   found	   in	  
specialized	  niches	  which	  support	   their	   renewal	  and	  maturation	  down	  committed	  cell	  
lineages	   	   Within	   this	   specialised	   environment	   it	   is	   speculated	   that	   Mφ	   maintain	  
homeostasis	  via	  classical	  phagocyte	  activity	  alongside	  performance	  of	  trophic	  functions	  
such	   as	   participation	   in	   erythrocyte	   development	   (so-­‐called	   erythroblast	   islands)	  




Due	   to	   the	   presence	   of	   highly	   proliferating	   immature	   cells,	   the	   bone	   marrow	   is	  
considered	  one	  of	  the	  most	  radiosensitive	  organs,	  which	  permits	  its	  selective	  ablation	  
using	   levels	  of	   irradiation	   that	   leave	  other	   cell	   populations	  unharmed	   (Dainiak	  2002;	  
Fliedner,	   Graessle	   et	   al.	   2002).	   This	   phenomenon	   is	   used	   to	   replace	   a	   host’s	   bone	  
marrow	  with	  that	  of	  a	  donor,	  and	  has	  found	  extensive	  use	  preclinically	  for	  the	  study	  of	  
cell	   behaviour	   (Aparicio-­‐Vergara,	   Shiri-­‐Sverdlov	   et	   al.	   2010)	   and	   clinically	   for	   the	  
treatment	   of	   haematological	   disease	   (Copelan	   2006).	   The	   effects	   of	   acute	   localised	  
irradiation	   to	   the	   regenerative	   capacity	   of	   the	   bone	   marrow	   have	   long	   been	  
investigated,	  with	   exposure	   causing	   rapid	   depletion	   in	   cellularity	  which	   then	   fails	   to	  
regain	  haematopoietic	  function	  (Knospe,	  Blom	  et	  al.	  1966).	  In	  the	  case	  of	  whole	  body	  
irradiation	  and	  HSC	  transfer,	  HSC	  homing	  to	  the	  depleted	  bone	  marrow	  results	  in	  the	  
restoration	  of	  haematopoiesis	  (Srour,	  Jetmore	  et	  al.	  2001).	  	  
Following	  localised	  irradiation,	  bone	  marrow	  cellularity	  is	  observed	  to	  decrease,	  while	  
erythrocytes	   extravasate,	   sinusoids	   dilate/collapse,	   blood	   flow	   and	   vascular	  
permeability	  increase,	  and	  progenitor	  and	  inflammatory	  cells	  infiltrate	  (Higashi,	  Fisher	  
et	  al.	  2000).	  MRI	  has	  been	  used	  to	  track	  the	  processes	  of	  oedema	  formation	  and	  the	  
emergence	  of	  adipose	  tissue	  which	  gradually	  reforms	  into	  marrow	  following	  irradiation	  
(Daldrup-­‐Link,	   Henning	   et	   al.	   2007).	   However	   there	   is	   a	   striking	   lack	   of	  
immunohistochemical	  data	  regarding	  this	  process	   (Lerouxel,	  Moreau	  et	  al.	  2009)	  and	  
so	   the	   involvement	   of	   cellular	   subsets	   and	   their	   spatial	   interplay	   during	   recovery	   to	  
irradiation	  is	  under	  represented.	  	  
	  
4.1.2 Tumour	  Associated	  Mφ,	  MDSC	  and	  CSF-­‐1	  
Cancer	   is	   a	   systemic	   disease,	   altering	   the	   immune	   response	   to	   evade	   eradication	   as	  
well	   as	   promoting	   trophic	   activities	   that	   enable	  metastasis.	   Tumours	  modulate	   their	  
local	   environment	   as	  well	   as	   the	   regional	   environment	   in	   order	   to	   achieve	   this.	   For	  
instance,	  both	  infiltrating	  and	  sentinel	  LN	  lymphocytes	  which	  directly	  drain	  a	  primary	  
tumour	   show	   immune	   supressed	   activity.	   In	   this	   way	   tumours	   can	   be	   considered	  




interplay	  to	  sustain	  and	  promote	  tumour	  growth	  (Cochran,	  Huang	  et	  al.	  2006;	  Pollard	  
2009;	  Laoui,	  Van	  Overmeire	  et	  al.	  2011).	  
Mφ	  are	  key	  components	  of	  the	  tumoural	  environment	  and	  are	  considered	  important	  
for	  initiation	  through	  to	  metastasis.	  Clinically,	  the	  increased	  presence	  of	  Mφ	  (or	  TAMs)	  
is	   correlated	   with	   poorer	   prognosis	   (Bingle,	   Brown	   et	   al.	   2002)	   and	   thought	   to	   be	  
attributed	   to	   their	   immunoregulatory	   and	   trophic	   functions.	   For	   instance,	   TAM	  
accumulation	  is	  associated	  with	  the	  angiogenic	  switch,	  causing	  tumour	  vascularisation	  
and	   increasing	   malignancy,	   whilst	   release	   of	   cytokines	   such	   as	   TGF-­‐β	   and	   IL-­‐10	  
suppress	   the	   immune	   response	   (Pollard	   2009).	   It	   has	   been	   speculated	   that	   this	  
immune	  suppressive	  activity	  can	  be	  regarded	  as	  normal	  trophic	  behaviour	  whereby	  in	  
response	  to	  tissue	  damage	  (caused	  by	  tumour	  development)	  TAMs	  propagate	  an	  anti-­‐
inflammatory	   environment	   in	   order	   to	   not	   stimulate	   autoimmunity	   to	   self-­‐antigens	  
(Qualls	  and	  Murray	  2010).	  	  
Another	   population	   of	   cells	   recognised	   for	   their	   pro-­‐tumoural	   effects	   are	   MDSC,	   a	  
heterogeneous	   population	   of	   immature	   myeloid	   cells	   noted	   for	   their	  
immunosuppressive	  effects	  and	  first	  identified	  in	  the	  circulation	  of	  cancer	  patients	  and	  
tumour-­‐bearing	   mice	   (Gabrilovich	   and	   Nagaraj	   2009).	   They	   are	   acknowledged	   to	  
participate	  in	  disease	  settings	  by	  impairing	  cytotoxic	  T	  cell	  and	  NK	  cell	  activity,	  as	  well	  
promoting	   Treg	   cells,	   leading	   to	   their	   therapeutic	   targeting.	   Inhibition/elimination	   of	  
MDSC	   so	   as	   to	   ablate	   their	   pro-­‐tumour	   activity	   is	   currently	   being	   explored,	   whilst	  
stimulation	   of	   MDSC	   is	   being	   examined	   for	   promoting	   tolerance	   in	   transplant	  
recipients	   (Ochando	   and	   Chen	   2012).	   However,	   MDSC	   also	   display	   a	   functional	  
plasticity	  commonly	  associated	  with	  Mφ,	  where	  a	  recent	  evaluation	  has	  shown	  them	  
to	  possess	  both	  immuno-­‐suppressive	  and	  immuno-­‐stimulating	  properties	  (Pastula	  and	  
Marcinkiewicz	  2011).	  
An	   important	   mediator	   of	   Mφ	   behaviour	   is	   CSF-­‐1	   (also	   known	   as	   Mφ	   colony	  
stimulating	  factor),	  a	  cytokine	  that	  promotes	  myeloid	  differentiation	  and	  Mφ	  function,	  
survival	   and	   migration	   (Hamilton	   2011;	   Hume	   and	   MacDonald	   2012).	   In	   vivo,	  
administration	  of	  CSF1	  and	  soluble	  CSF1	  receptor	  (CSF1R)	  has	  been	  shown	  to	  elevate	  




Inhibition	   of	   CSF1R	   has	   variously	   been	   shown	   to	   downregulate	   Mφ	   recruitment	   to	  
tumours	   (MacDonald,	   Palmer	   et	   al.	   2010;	   Coniglio,	   Eugenin	   et	   al.	   2012)	   and	  
experimentally-­‐induced	  inflammation	  (Lenzo,	  Turner	  et	  al.	  2012).	  	  
	  
4.1.3 Tumour	  Imaging	  with	  PET/CT	  
A	  discussion	  of	  nuclear	   imaging	   is	  presented	   in	  Chapter	  1.	  The	  clinical	  use	  of	  PET/CT	  
has	   resulted	   in	   significant	   advances	   in	   the	   diagnosis,	   as	   well	   as	   the	   staging	   and	  
management,	  of	  cancer.	  In	  the	  field	  of	  oncology	  there	  is	  an	  array	  of	  tracers	  that	  have	  
been	   employed	   to	   identify	   tumours	   and	   to	   define	   their	   functional	   status.	   18F-­‐
Fluorodeoxyglucose	  is	  at	  present	  one	  of	  the	  most	  widely	  used	  tracers,	  and	  functions	  as	  
a	   glucose	   analogue	   resulting	   in	   accumulation	   in	   highly	   metabolic	   cells	   that	   often	  
characterises	  cancerous	  tissues.	  18F-­‐Fluorodeixy-­‐L-­‐thymidine	  is	  another	  small	  molecule	  
tracer,	  and	  behaving	  as	  an	  analogue	  of	  thymidine	   it	   is	   incorporated	   into	  proliferating	  
cells,	   which	   can	   often	   correlate	   with	   the	   response	   to	   treatment	   characteristics	   of	   a	  
tumour.	   In	   addition,	   tracers	   based	   upon	   integrin	   binding	   (the	   RGD	   peptides)	   which	  
identify	   neovascularisation,	   somatostatin	   receptors	   that	   characterise	   certain	  
neuroendocrine	   tumours	   and	   bone	   scintigraphy	   agents	   (such	   as	   NaF)	   are	   all	   used	  
routinely	   for	   oncological	   imaging	   (Histed,	   Lindenberg	   et	   al.	   2012).	   The	   use	   of	  
radiolabelled	   antibodies	   against	   antigens	   over-­‐expressed	   on	   tumour	   cells	   is	   also	  
steadily	   rising	   as	   a	   specific	   way	   of	   identifying	   tumours	   and	   their	  metastasis,	   and	   to	  
predict	   response	   to	   therapeutic	   antibodies	   as	   well	   as	   perform	   dosimetry	  
measurements	  (Kaur,	  Venktaraman	  et	  al.	  2012).	  
Preclinically,	   various	   strategies	   are	  being	  examined	   for	   targeting	  of	  Mφs	   in	   tumours.	  
The	   use	   of	  USPIOs	   that	   exploit	  Mφ	  phagocytosis	   (Daldrup-­‐Link,	  Golovko	   et	   al.	   2011;	  
Shih,	  Hsu	  et	  al.	  2011)	   is	  being	  explored	  due	   to	   the	  clinical	  availability	  of	  USPIOs	   (see	  
Chapter	  1).	  Additionally,	  targeting	  of	  the	  FR	  which	  is	  expressed	  by	  some	  Mφ	  subsets	  is	  
being	  examined,	  however	  as	  the	  FR	  is	  not	  restricted	  to	  Mφs	  and	  is	  also	  expressed	  by	  
certain	  tumours,	  this	  is	  not	  a	  cell	  specific	  approach	  (Mueller	  and	  Schibli	  2011;	  Fischer,	  




in	   pathogenesis	   of	   tumours,	   there	   is	   clearly	   a	   clinical	   imperative	   in	   being	   able	   to	  
identify	  specific	  Mφ	  populations	  via	  imaging.	  
	  
4.2 Materials	  and	  Methods	  
4.2.1 Cell	  Culture	  	  
Ras+myc-­‐transformed	   RM-­‐1	   prostate	   tumour	   cells	   (kind	   gifts	   from	   Dr.	   Timothy	   C.	  
Thompson,	   Baylor	   College	   of	   Medicine)	   were	   cultured	   in	   Dulbecco	   modified	   Eagle	  
medium	   (DMEM)	   containing	   10%	   fetal	   bovine	   serum	   (FBS),	   100	  U/mL	  penicillin,	   and	  
15mM	  HEPES	  at	  37°C	  with	  5%	  CO2.	  
	  
4.2.2 Tumour	  Models	  
Tumor	   implantation	   was	   performed	   by	   Dr	   Jingying	   Xu,	   UCLA.	   RM-­‐1	   (2.5	   x	   105	   cells)	  
were	   implanted	   subcutaneously	   in	   the	   thigh	   of	   C57BL6	  male	  mice	   (6-­‐10	   weeks	   old,	  
Jackson	  Laboratory,	  Bar	  Habor),	  and	  treatment	  started	  when	  the	  tumours	  reach	  4	  mm	  
in	   diameter.	   All	   animal	   experiments	   were	   approved	   by	   the	   Animal	   Research	  
Committee	  of	  the	  University	  of	  California	  Los	  Angeles.	  Tumour	  size	  was	  measured	  by	  
digital	  callipers	  daily	  or	  every	  two	  days	  depending	  on	  the	  model.	  Mice	  were	  sacrificed	  
and	  tissues	  were	  excised	  at	  the	  ethical	  tumour	  size	  limit	  of	  1.5	  cm	  in	  diameter.	  
	  
4.2.3 Localised	  Irradiation	  
Localised	  irradiation	  was	  performed	  by	  Dr	  Jingying	  Xu,	  UCLA.	  Localised	  irradiation	  was	  
performed	   from	  a	   linear	   accelerator	   (DMCO	  X-­‐irradiator,	   Precision	  X	  Ray,	   CT)	  with	   a	  
dose	   rate	   of	   1.84	   Gy/min	   and	   a	   1.5	   cm	   bolus	   on	   the	   surface	   (300kV,	   10mA).	  When	  
tumours	   reached	   4-­‐5	  mm	   in	   diameter,	  mice	  were	   anesthetized	   (30	   µL,	   4:1	   xylazine)	  
and	   radiated	  with	   a	   single	   dose	   of	   10	  Gy	   to	   the	   tumour	   area	  with	   the	   rest	   of	   body	  
shielded.	  Non-­‐tumour	  bearing	  and	  tumour	  bearing	  mice	  were	  both	   irradiated	  on	   the	  
right	  femur.	  Following	  irradiation,	  mice	  were	  divided	  into	  6	  groups	  receiving	  either	  no	  
treatment	   (NT	  group)	  or	   soluble	  CSF1R	   inhibitor	  PLX3397	   (CSF1R	  group)	   in	   their	  diet	  
(Plexxikon,	  CA),	  and	  recovering	   from	   localised	   irradiation	  by	  2	  days,	  7	  days	  or	  7	  days	  




prepared,	   however	   most	   groups	   experienced	  mortality	   during	   irradiation	   procedure	  




Figure	  4.1	  Schematic	  of	  Localised	  Irradiation	  and	  Tumour	  Model.	   	  Non-­‐tumour	  bearing	  mice	  
(A)	   were	   partially	   shielded	   and	   exposed	   to	   localised	   radiation	   on	   the	   right	   flank.	  Mice	   then	  
received	   either	   no	   treatment	   or	   CSF1R	   inhibitor	   treatment.	   Both	   groups	   were	   allowed	   to	  
recover	   for	   2	   or	   7	   days,	   whereupon	   they	   were	   imaged	   with	   64Cu-­‐SER4.	   (B)	   Tumours	   were	  
initiated	   and	   left	   for	   5-­‐7	   days	   before	  mice	   received	   partial	   irradiation.	  Mice	   received	   either	  
CSF1R	  treatment	  or	  no	  treatment	  and	  at	  day	  7	  post-­‐irradiation	  were	  imaged	  with	  64Cu-­‐SER4.	  3	  
mice	  per	  group	  were	  prepared,	  however	  most	  groups	  experienced	  mortality	  during	  irradiation	  
procedure	  resulting	  in	  group	  sizes	  of	  n	  =	  2	  and	  n	  =	  3.	  
	  
4.2.4 Preparation	  of	  SER4-­‐NOTA	  
2.8	   µL	   of	   S-­‐2-­‐(4-­‐Isothiocyanatobenzyl)-­‐1,4,7-­‐triazacyclononane-­‐1,4,7-­‐triacetic	   acid	  
(pSCN-­‐Bn-­‐NOTA,	   Macrocyclics,	   TX)	   in	   ethanol	   (2	   mg	   /	   100	   µL)	   was	   added	   to	   SER4	  
antibody	   (200	   µL,	   10	  mg/mL)	   in	   PBS	   (approx.	   40:1	   excess	   chelator)	   and	   adjusted	   to	  
pH	  8.0	   using	   concentrated	   sodium	   hydroxide.	   The	   reaction	   proceeded	   at	   room	  
temperature	   and	   after	   2	   hr	  was	   transferred	   to	   a	   PD10	   column	  pre-­‐equilibrated	  with	  
PBS.	   Eluted	   fractions	   were	   assayed	   for	   protein	   content	   using	   NanoDrop	   2000	  
(ThermoFisher)	   and	   protein	   fractions	   pooled	   (total	   volume	   1	   mL).	   Final	   solution	  





4.2.5 Radiolabelling	  of	  SER4-­‐NOTA	  
64CuCl2	  in	  0.1M	  HCl	  (Mallinckrodt	  Institute,	  Washington	  School	  of	  Medicine,	  MO)	  was	  
added	   to	   SER4-­‐NOTA	   and	   incubated	   at	   43	   °C	   for	   40	   min.	   Weakly	   bound	   Cu	   was	  
challenged	  by	  addition	  of	  10	  mM	  EDTA	   in	  ammonium	  acetate	   (100	  mM,	  pH	  6.0)	  and	  
incubated	   at	   room	   temperature	   for	   5	   min.	   The	   reaction	   was	   then	   transferred	   to	   a	  
Micro	  BioRad	  Spin	  Column	  6	  (BioRad,	  CA)	  pre-­‐equilibrated	  in	  ammonium	  acetate	  (100	  
mM,	  pH	  6)	  and	  eluted	  (1000	  RCF,	  2	  min).	  Radiolabelling	  was	  assayed	  using	  Monoclonal	  
Antibody	  ITLC	  Strips	  Kit	  (Biodex	  Medical	  Systems,	  NY)	  with	  PBS	  as	  eluent,	  the	  strips	  cut	  
in	   half	   and	   activity	   measured	   using	   a	   Wallac	   WIZARD	   automatic	   gamma	   counter	  
(PerkinElmer,	   MA).	   Serum	   stability	   and	   recombinant	   antigen	   binding	   were	   not	  
performed	  due	  to	  time	  constraints	  of	  the	  project.	  
	  
4.2.6 Standard	  Biodistribution	  
Syringes	   (25	  G	  X	  16	  mm,	  Terumo)	  containing	  approximately	  3.5	  MBq	  of	   64Cu-­‐SER4	   in	  
200	  µL	   saline	   (50	  µg/mL)	  were	  gamma	  counted	   (Capintec,	  NJ)	  before	   injection.	  Mice	  
were	  injected	  via	  the	  tail	  vain	  under	  isoflurane	  (Anaquest,	  WI)	  and	  after	  imaging	  were	  
culled	   immediately	   by	   exsanguination.	   The	   animals	   were	   then	   dissected	   and	   the	  
following	  organs	  collected:	  intestines,	  stomach,	  spleen,	  liver,	  kidney,	  heart,	  lungs,	  left	  
femur,	  right	  femur,	  blood	  (c.	  1	  mL),	  muscle	  and	  tail.	  The	  tissue	  samples	  were	  weighed	  
and	   radioactivity	   counted	   using	   a	   Wallac	   WIZARD	   automatic	   gamma	   counter	  
(PerkinElmer,	  MA).	   Injected	   dose	  was	   calculated	   from	   total	   activity	   in	   each	   injected	  
syringe	  as	  determined	  by	  a	  1%	  standard	  minus	  activity	  counted	  in	  tail,	  and	  presented	  
as	   the	  percentage	  of	   injected	  dose	  per	   gram	   (%ID/g)	  of	   each	   tissue	   sample.	  Relative	  
uptake	  values	  for	  the	  irradiated	  to	  non-­‐irradiated	  femur	  were	  determined	  as	  the	  ratio	  
of	  their	  respective	  tracer	  uptake	  (%ID/g)	  
	  
4.2.7 In	  vivo	  PET	  and	  CT	  Imaging	  	  
Dynamic	   imaging	   was	   performed	   using	   a	   Genisys4	   scanner	   (Sofiebiosciences,	   CA),	  




performed	  using	  Inveon	  PET	  (Siemens,	  WA),	  with	  10	  min	  acquisition	  and	  reconstructed	  
using	   filtered	   back	   projection.	   CT	   imaging	  was	   performed	   using	  MicroCat	   II	   Scanner	  
(Concorde	  Microsystems,	  TN)	  using	  45	  KVp	  X-­‐ray	  source,	  set	  with	  a	  500	  ms	  exposure	  
time	  in	  180	  projections	  lasting	  approximately	  10	  min.	  Images	  were	  reconstructed	  and	  
displayed	   using	   AMIDE	   (Loening	   and	   Gambhir	   2003).	   Percentage	   injected	   dose	   per	  
gram	   (%	   ID	   /	   g)	   values	   during	   dynamic	   imaging	   study	   were	   calculated	   using	   mean	  
activity	   per	   unit	   volume	   data	   from	   regions	   of	   interests	   (ROIs)	   defining	   target	  
organs/tissues.	  Mean	  activity	  per	  volume	  values	  were	  translated	  into	  activity	  per	  mass	  
by	   assuming	   the	   average	   density	   of	   tissue	   to	   be	   1	   g	   per	   cm3,	   and	   these	   values	  
compared	   to	   total	   activity	   defined	   by	   the	   scanner	   field	   of	   view	   to	   produce	   %ID/g	  
values.	   ROIs	   defining	   the	   irradiated	   and	   non-­‐irradiated	   femur	   cavities	   were	   used	   to	  
define	  relative	  uptake	  between	  irradiated	  and	  non-­‐irradiated	  femurs.	  The	  ratio	  of	  their	  
mean	   activity	   per	   volume	   of	   the	   irradiated	   to	   non-­‐irradiated	   femur	   determined	   the	  
relative	  uptake	  value.	  
Adult	   male	   mice	   (C57BL6,	   6	   –	   10	   weeks)	   were	   injected	   IV	   under	   anaesthesia	  
(isoflurane,	  VetOne,	  UK)	  with	  approximately	  3.5	  MBq	  64Cu-­‐SER4	  in	  200	  µL	  (50	  µg/mL).	  
For	   dynamic	   imaging,	   1	   cannulated	   mouse	   was	   injected	   whilst	   in	   the	   scanner	   and	  
image	   acquisition	   begun	   immediately.	   For	   static	   imaging,	   mice	   were	   allowed	   to	  
recover,	   then	   anaesthetised	   and	   imaged	   at	   4	   hr	   post	   injection.	   Mice	   were	   culled	  
immediately	  after	  static	  imaging	  and	  biodistributions	  performed.	  
	  
4.2.8 Flow	  Cytometry	  Analysis	  
Flow	  cytometry	  was	  performed	  by	  Dr	  Jingying	  Xu,	  UCLA.	  For	  bone	  marrow	  collection,	  
femurs	  were	  excised	  and	  flushed	  with	  PBS	  and	  cell	  numbers	  counted.	  Tumours	  were	  
dissected	   into	   approximately	   1-­‐	   to	   3-­‐mm3	   fragments	   and	   digested	   with	   80	   U/mL	  
collagenase	   (Invitrogen)	   in	   DMEM	   containing	   10%	   FBS	   for	   1.5	   hours	   at	   37°C	   while	  
shaking.	  Single-­‐cell	  suspensions	  were	  filtered	  and	  incubated	  for	  30	  min	  on	  ice	  with	  the	  
following:	  APC,	  PerCP-­‐Cy5.5,	  APC-­‐e780-­‐conjugated	  antibodies	  (CD11b,	  Gr-­‐1	  and	  F4/80,	  
respectively)	  were	  purchased	  from	  eBioscience	  (1:200).	  SER4-­‐FITC	  was	  prepared	  using	  




Cells	   were	   washed	   twice	   before	   analysis	   by	   flow	   cytometry	   (BD	   LSR-­‐II,	   Beckman	  
Coulter,	  CA).	  Data	  was	  analysed	  with	  FlowJo	  software	  (TreeStar).	  	  
	  
4.3 Results	  
The	   following	   results	   are	   representative	   of	   a	   pilot	   study.	   As	   such	   the	   data	   is	   from	  
limited	   group	   sizes	   (six	   groups	   n	   =	   2	   or	   n	   =	   3),	  which	   has	   restricted	   the	  majority	   of	  
analysis	   to	   descriptive	   rather	   than	   statistical.	  When	   sufficient	   group	   size	   permits,	   2-­‐
way	  unpaired	  Student’s	  T	  test	  is	  used,	  with	  significance	  ascribed	  to	  p	  values	  <	  0.05.	  
	  
4.3.1 Preparation	  of	  64Cu-­‐SER4	  
The	  recorded	  recovery	  of	  SER4-­‐NOTA	  from	  A280	  measurements	  was	  70%	  (1.4	  mg	  from	  
2.0	   mg	   starting	   material).	   Radiolabelling	   followed	   by	   EDTA	   challenge	   resulted	   in	  
radiolabelling	  purity	   >	   99%	  as	   assessed	  by	   ITLC,	   and	   specific	   activities	   of	   approx.	   3.5	  
MBq	  /	  10	  µg	  were	  recorded.	  	  
	  
4.3.2 Dynamic	  Scanning	  of	  64Cu-­‐SER4	  
A	  naïve	  mouse	  was	  injected	  via	  a	  tail	  vein	  cannula	  with	  64Cu-­‐SER4	  and	  a	  dynamic	  scan	  
was	   performed.	   The	   scan	   was	   initiated	   immediately	   prior	   to	   injection	   and	   recorded	  
automatically	  once	  activity	  was	  detected	  in	  the	  field	  of	  view.	  At	  T	  =	  0	  min	  (see	  Figure	  
4.2	  A),	  64Cu-­‐SER4	  was	  observed	  in	  the	  vasculature,	  as	  indicated	  by	  the	  detection	  of	  the	  
inferior	   vena	   cava	  which	   received	   the	   injected	   dose.	   The	   signal	   from	   the	   heart	   was	  
highest	  in	  this	  image	  relative	  to	  the	  later	  time	  points	  which	  also	  points	  to	  the	  presence	  
of	   probe	   throughout	   the	   vasculature.	   At	   T	   =	   5	   min	   (see	   Figure	   4.2	   B),	   the	   carotid	  
arteries	  and	  heart	  are	  delineated,	  as	  is	  the	  liver.	  By	  T	  =	  5	  min,	  both	  the	  femur	  and	  the	  
pelvis	  can	  also	  start	  to	  be	  visualised,	  which	  progressively	  become	  more	  defined	  (C	  to	  
F).	   The	   spleen	   is	   observed	   as	   a	   lower	   right	   hand	   lobe	   associated	   with	   the	   liver	  
(corresponding	   to	   the	   left	   hand	   side	   of	   the	   mouse)	   which	   gradually	   increases	   in	  
intensity	  throughout	  the	  study.	  From	  T	  =	  0	  min	  to	  T	  =	  60	  min	  (A	  to	  E),	  changes	  in	  the	  
redistribution	  of	  radionuclide	  are	  observed,	  however	  between	  60	  min	  and	  120	  min	  (E	  





Figure	  4.2	  Genesys4	  dynamic	  imaging	  of	  64Cu-­‐SER4.	  	  
Mouse	  injected	  IV	  via	  a	  tail	  vein	  cannula	  with	  ∼3.5	  MBq	  64Cu-­‐SER4	  and	  imaged	  continuously	  
over	  2	  hr.	  Images	  represent	  whole	  body	  acquisitions	  at	  (A)	  0	  min,	  (B)	  5	  min,	  (C)	  10	  min,	  (D)	  
30	  min,	  I	  60	  min	  and	  (F)	  120	  min	  post	  injection.	  Arrows	  indicate	  carotid	  arteries	  (Ca),	  heart	  
(H),	  liver	  (L),	  spleen	  (S),	  pelvis	  (P)	  and	  femur	  (Fm).	  	  
	  
ROIs	   were	   drawn	   over	   the	   spleen,	   right	   femur	   and	   heart	   and	   radiotracer	   uptake	  
(measured	   in	  %ID/g)	  analysed	  over	   time	   (see	  Figure	  4.3).	  A	   rapid	  drop	   in	  blood	  pool	  
was	  detected	  by	  heart	  uptake	  falling	  from	  51.2	  %ID/g	  at	  0	  min	  to	  19.1	  %ID/g	  at	  65	  min,	  
at	   which	   point	   activity	   decreased	  more	   steadily	   to	   18.2	  %ID/g	   at	   115	  min.	   Similarly	  
both	   the	   spleen	   and	   femur	   exhibited	   rapid	   uptake	   from	   0	   min	   to	   65	   min	   (8.8	   to	  
61.9	  %ID/g	  for	  spleen,	  1.8	  to	  36.1	  %ID/g	  for	  right	  femur)	  which	  increased	  less	  rapidly	  






Figure	   4.3	   Region	   of	   interest	   (ROI)	   analysis	   of	   64Cu-­‐SER4	   Genesys4	   dynamic	   scan	   (n	   =	   1).	  	  
Mouse	   injected	   IV	  via	  a	   tail	  vein	  cannula	  with	  ∼3.5	  MBq	  64Cu-­‐SER4	  and	   imaged	  continuously	  
over	  2	  hr.	  ROI	  were	  drawn	  over	  the	  spleen	  (blue	  diamond),	  right	  femur	  (red	  square)	  and	  heart	  
(green	  triangle).	  Activity	  was	  expressed	  as	  %	  injected	  dose	  per	  gram	  (%ID/g).	  
	  
4.3.3 Localised	  Irradiation	  
Mice	  were	   irradiated	   on	   the	   right	   hind	   leg	   and	   allowed	   to	   recover	   for	   either	   2	   or	   7	  
days,	   imaged	   with	   64Cu-­‐SER4	   then	   culled	   and	   biodistributions	   performed.	   Irradiated	  
mice	  were	   additionally	   split	   in	   to	   two	   groups,	   either	   treated	  with	   or	  without	   CSF1R	  
inhibitor	  for	  the	  period	  between	  irradiation	  and	  imaging.	  	  
Biodistributions	   for	  non-­‐tumour	  bearing	  mice	  were	  performed	  at	  4	  hr	  post	   injection,	  
whereas	   for	   tumour	  bearing	  mice	   they	  were	  performed	  at	  20	  hr	  post	   injection.	  Data	  
was	  presented	  as	  %	   injected	  dose	  per	  gram	  (%ID/g)	  of	   the	  tissue	  collected.	  As	  group	  
sizes	  were	  limited	  to	  n	  =	  2	  or	  n	  =	  3,	  only	  a	  descriptive	  analysis	  is	  performed.	  
Flow	  cytometry	  was	  performed	  on	  samples	  taken	  from	  one	  mouse	  per	  group,	  and	  as	  
such	  data	  is	  not	  analysed	  statistically.	  	  
	  
4.3.3.1 Day	  2	  Post	  Irradiation	  
At	  day	  2	  post	  irradiation,	  whole	  body	  imaging	  of	  non-­‐treated	  (NT)	  mice	  showed	  probe	  
distribution	  comparable	  to	  normal	  mice	  (see	  Figure	  4.4	  A)	  with	  uptake	   in	  the	  spleen,	  






















similar	   uptake	   pattern	   (see	   Figure	   4.4	   B),	   although	   slightly	   higher	   blood	   pool	   was	  
observed	  as	  visualised	  by	  greater	  detection	  of	  the	  heart.	  	  
	  
Figure	  4.4	  Inveon	  and	  microCT	  imaging	  of	  64Cu-­‐SER4	  in	  mice	  after	  2	  days	  recovery	  following	  
localised	   irradiation	   and	   CSF1R	   treatment.	  Mice	   were	   shielded	   on	   the	   left	   side	   (LHS)	   and	  	  
irradiated	   on	   right	   femur	   (RHS)	   with	   10Gy	   and	   received	   either	   no	   treatment	   (NT)	   or	   CSF1	  
inhibitor	   treatment	   (CSF1R)	   until	   the	   date	   of	   imaging(A	   and	   B,	   respectively).	   Mice	   were	  
injected	  with	  ∼3.5	  MBq	  64Cu-­‐SER4	  and	  images	  were	  acquired	  at	  4	  hours	  post	  injection.	  Arrows	  
indicate	  heart	  (H),	  liver	  (L),	  spleen	  (S),	  femur	  (Fm)	  and	  tumour	  (T).	  LHS	  =	  Left	  hand	  side;	  RHS	  =	  
Right	  hand	  side.	  
	  
For	   the	   NT	   group	   biodistributions	   (see	   Figure	   4.5),	   the	   spleen	   exhibited	   the	   highest	  
uptake	   (>	   155	  %ID/g),	   followed	   by	   the	   liver	   and	   femurs,	   with	   the	   irradiated	   femurs	  
recording	   at	   least	   10	  %ID/g	   greater	   uptake	   than	   the	   non-­‐irradiated.	   The	   spleen	   and	  
liver	   uptake	   values	   after	   treatment	   (CSF1R)	   were	   all	   less	   than	   the	   NT	   group,	   with	  
>	  10	  %ID/g	  difference	  in	  splenic	  uptake.	  Similar	  uptake	  was	  observed	  in	  irradiated	  and	  













Figure	   4.5Biodistribution	   of	   64Cu-­‐SER4	   in	   C57BL6	   mice	   after	   2	   days	   recovery	   following	  
localised	   irradiation	  with	   and	  without	   CSF1R	   treatment	   (n	   =	   2	   to	   3	   per	   group).	  Mice	  were	  
irradiated	   locally	   with	   10Gy	   then	   received	   either	   no	   treatment	   (NT	   –	   blue	   dash)	   or	   CSF1	  
inhibitor	  (CSF1R	  –	  red	  dash)	  for	  2	  days	  post	  irradiation.	  Mice	  were	  injected	  IV	  into	  the	  tail	  vein	  
with	  ∼3.5	   MBq	   64Cu-­‐SER4	   and	   culled	   at	   4	   hr,	   then	   organs	   harvested,	   weighed	   and	   gamma	  
counted.	   Each	   dash	   represents	   data	   from	   one	   mouse.	   Radioactive	   uptake	   in	   organs	   is	  
presented	  as	   the	  percentage-­‐injected	  dose	  per	  gram	  organ	   (%ID/g).	  A:	   full	  biodistribution,	  B:	  
zoom	  of	  biodistribution	  to	  view	  low	  activity	  organs.	  
Femurs	   were	   excised	   and	   bone	  marrow	   flushed	   using	   PBS,	   filtered	   then	   stained	   for	  




































(SSC)	   to	  eliminate	   small,	   granulous	  cells	   (see	  Figure	  4.6	  A	   to	  C).	   Live	  cell	  populations	  
were	  then	  assessed	  for	  %	  Sn	  expression	  using	  a	  threshold	  set	  at	  <	  1%	  expression	  for	  
unstained	   cells	   (see	   Figure	   4.7	   and	   Table	   4.1).	   Comparison	   of	   irradiated	   to	   non-­‐
irradiated	  femur	  %	  Sn	  expression	  of	  whole	  cell	  and	  MDSC	  subpopulations	  (identified	  by	  
CD11b	  and	  Gr-­‐1	   expression	  –	   see	   Figure	  4.6	  D)	   shows	   in	  both	  NT	   and	  CSF1R	   groups	  
expression	   is	   relatively	   less	   in	   the	   irradiated	   femur	   than	   the	  non	   irradiated,	  with	   the	  
CSF1R	  group	  exhibiting	  the	  least	  expression	  (see	  Figure	  4.7	  and	  Table	  4.1).	  
	  
Figure	  4.6	  Gating	  of	  live	  and	  myeloid	  derived	  suppressor	  cell	  (MDSC)	  populations	  from	  bone	  
marrow	   (n	   =	   1).	  Filtered	  bone	  marrow	  aspirates	  were	  analysed	  by	   flow	  cytometry	   (A)	  
and	  live	  cells	  identified	  by	  gating	  on	  forward	  scatter	  (FSC)	  and	  side	  scatter	  (A	  to	  C)	  to	  
identify	   live	   cells.	   MDSC	   sub-­‐population	   (D)	   was	   identified	   by	   expression	   of	   Gr-­‐1	  





Figure	   4.7	   Day	   2	   post	   irradiation	   bone	   marrow	   Sn	   expression	   of	   whole	   cell	   and	   MDSC	  
subpopulations	   (n	   =	   1).	   	   Live	   cells	   and	   MDSC	   from	   day	   2	   post	   irradiation	   femurs,	   without	  
treatment	  (NT)	  or	  with	  CSF1R	  treatment	  (CSF1R)	  were	  analysed	  for	  Sn	  expression	  (FITC).	  Blue	  =	  
non-­‐irradiated	  femur;	  Orange	  =	  irradiated	  femur;	  Red	  =	  unstained.	  
	  
	   Irradiated	  to	  Non-­‐irradiated	  Ratio	  
Whole	  cell	  
Irradiated	  to	  Non-­‐irradiated	  
Ratio	  
MDSC	  
Day	  2	  NT	   0.68	   0.92	  
Day	  2	  CSF1R	   0.13	   0.68	  
Table	   4.1	   Day	   2	   irradiated	   to	   non-­‐irradiated	   Sn	   expression	   ratio	   of	  whole	   cells	   and	  MDSC	  
subpopulations	   from	   bone	   marrow	   aspirates.	   Ratio	   between	   irradiated	   and	   non-­‐irradiated	  
femur	  Sn	  expression	  levels	  of	  whole	  cell	  and	  MDSC	  subpopulations	  from	  Figure	  4.10.	  Values	  <	  
1	  correspond	  to	  less	  Sn	  expression	  in	  irradiated	  bone	  marrow	  compared	  to	  non-­‐irradiated.	  
	  
4.3.3.2 Day	  7	  Post	  Irradiation	  
Mice	   were	   locally	   irradiated	   and	   allowed	   to	   recover	   for	   7	   days,	   the	   imaged.	   From	  
whole	  body	   imaging,	   the	  NT	  group	  (see	  Figure	  4.8	  A)	  demonstrated	  expected	  splenic	  
and	  liver	  uptake.	  However	  asymmetric	  uptake	  was	  observed	  in	  the	  hind	  legs,	  with	  the	  
irradiated	   limb	   exhibiting	   higher	   signal	   than	   the	   non-­‐irradiated	   limb.	   The	   CSF1R	   set	  




symmetrical	   hind	   limb	   uptake	   as	   well	   as	   increased	   blood	   pool,	   as	   visualised	   by	   the	  
heart,	  compared	  to	  NT	  mice.	  	  
	  
Figure	  4.8	  Inveon	  and	  microCT	  imaging	  of	  64Cu-­‐SER4	  in	  mice	  after	  7	  days	  recovery	  following	  
localised	   irradiation	   and	   CSF1R	   treatment.	   Mice	   were	   shielded	   on	   the	   left	   side	   (LHS)	   and	  	  
irradiated	   on	   right	   femur	   (RHS)	   with	   10Gy	   and	   received	   either	   no	   treatment	   (NT)	   or	   CSF1	  
inhibitor	   treatment	   (CSF1R)	   until	   the	   date	   of	   imaging	   (A	   and	   B,	   respectively).	   Mice	   were	  
injected	  with	  ∼3.5	  MBq	  64Cu-­‐SER4	  and	  images	  were	  acquired	  at	  4	  hours	  post	  injection.	  Arrows	  
indicate	  heart	  (H),	  liver	  (L),	  spleen	  (S),	  femur	  (Fm)	  and	  tumour	  (T).	  LHS	  =	  Left	  hand	  side;	  RHS	  =	  
Right	  hand	  side.	  
	  
In	  the	  biodistribution	  studies,	  NT	  mice	  showed	  highest	  uptake	   in	  the	  spleen	  followed	  
by	  liver	  and	  femurs	  (see	  Figure	  4.9).	  No	  uptake	  bias	  was	  observed	  between	  irradiated	  
and	  non-­‐irradiated	  NT	  femurs,	  with	  a	  wide	  range	  of	  uptake	  values	  recorded	  between	  
mice	   (almost	  20	  %ID/g	  difference	   in	  non-­‐irradiated	   femur	  uptake	  between	  NT	  mice).	  
The	  CSF1R	  group	  displayed	  reduced	  splenic	  (greater	  than	  20	  %ID/g	  between	  the	  lowest	  
NT	  and	  highest	  CSF1R	  values)	  and	   liver	  uptake,	  whilst	  more	  blood	   (>	  5	  %ID/g),	  heart	  
and	   lung	   uptake	  was	   observed	   as	   compared	   to	   the	   NT	   group.	   The	   CSF1R	   irradiated	  
femurs	  all	  showed	  lower	  uptake	  than	  the	  non-­‐irradiated	  femurs	  (>	  5	  %ID/g)	  and	  CSF1R	  












Figure	   4.9	   Biodistribution	   of	   64Cu-­‐SER4	   in	   C57Bl6	   mice	   after	   7	   days	   recovery	   following	  
localised	   irradiation	  with	   and	  without	   CSF1R	   treatment	   (n	   =	   2	   to	   3	   per	   group).	  Mice	  were	  
irradiated	   locally	   with	   10Gy	   then	   received	   either	   no	   treatment	   (NT	   –	   blue	   dash)	   or	   CSF1	  
inhibitor	  (CSF1R	  –	  red	  dash)	  for	  2	  days	  post	  irradiation.	  Mice	  were	  injected	  IV	  into	  the	  tail	  vein	  
with	  ∼3.5	   MBq	   64Cu-­‐SER4	   and	   culled	   at	   4	   hr,	   then	   organs	   harvested,	   weighed	   and	   gamma	  
counted.	   Each	   dash	   represents	   data	   from	   one	   mouse.	   Radioactive	   uptake	   in	   organs	   is	  
presented	  as	   the	  percentage-­‐injected	  dose	  per	  gram	  organ	   (%ID/g).	  A:	   full	  biodistribution,	  B:	  








































Flow	   cytometry	   shows	   the	   CSF1R	   irradiated	   limb	   to	   display	   approximately	   50	   %	   Sn	  
expression	   of	   the	   non-­‐irradiated	   limb	   (see	   Figure	   4.10	   and	   Table	   4.2).	   However	   this	  
relationship	  is	  reversed	  in	  the	  NT	  group	  where	  the	  irradiated	  femur	  expresses	  >	  5	  fold	  
increase	   in	   Sn	   to	   that	   of	   the	   non-­‐irradiated	   as	   measured	   by	   whole	   cell	   and	   MDSC	  
subset	  expression	  (see	  Table	  4.2).	  
	  
Figure	   4.10	   Day	   7	   post	   irradiation	   bone	   marrow	   Sn	   expression	   of	   whole	   cell	   and	   MDSC	  
subpopulations	   (n	   =	   1).	   Live	   cells	   and	   MDSC	   from	   day	   7	   post	   irradiation	   femurs,	   without	  
treatment	  (NT)	  or	  with	  CSF1R	  treatment	  (CSF1R)	  were	  analysed	  for	  Sn	  expression	  (FITC).	  Blue	  =	  
non-­‐irradiated	  femur;	  Orange	  =	  irradiated	  femur;	  Red	  =	  unstained.	  
	   Irradiated	  to	  Non-­‐irradiated	  Ratio	  
Whole	  cell	  
Irradiated	  to	  Non-­‐irradiated	  
Ratio	  
MDSC	  
Day	  7	  NT	   5.30	   7.54	  
Day	  7	  CSF1R	   0.54	   0.56	  
Table	   4.2	   Day	   7	   irradiated	   to	   non-­‐irradiated	   Sn	   expression	   ratio	   of	  whole	   cells	   and	  MDSC	  
subpopulations	   from	   bone	   marrow	   aspirates.	   Ratio	   between	   irradiated	   and	   non-­‐irradiated	  
femur	  Sn	  expression	  levels	  of	  	  whole	  cell	  and	  MDSC	  subpopulations	  from	  Figure	  4.10.	  Values	  <	  
1	   correspond	   to	   less	   Sn	   expression	   in	   irradiated	   bone	  marrow	   compared	   to	   non-­‐irradiated,	  





4.3.3.3 Tumour	  Bearing	  Mice	  	  
A	   further	   set	   of	   mice	   were	   given	   bilateral	   tumour	   implants	   in	   their	   thighs	   then	  
irradiated	  at	  7	  days	  post	  implantation	  on	  the	  right	  hind	  limb.	  The	  mice	  were	  allowed	  to	  
recover	  for	  7	  days	  with	  or	  without	  CSF1R	  treatment	  then	  imaged	  with	  64Cu-­‐SER4	  (see	  
Figure	  4.11).	  Both	  sets	  of	  mice	  (NT	  and	  CSF1R)	  exhibited	  splenic	  and	  liver	  targeting,	  but	  
once	  again	  only	  the	  NT	  group	  showed	  asymmetric	  right	  hind	  limb	  uptake.	  Additionally,	  
the	   CSF1R	   group	   showed	   increased	   blood	   pool	   as	   well	   visualisation	   of	   the	   non-­‐
irradiated	  tumour.	  
	  
Figure	   4.11	   Inveon	   and	  microCT	   imaging	   of	   64Cu-­‐SER4	   in	   tumour-­‐bearing	  mice	   after	   7	   days	  
recovery	  following	  localised	  irradiation	  and	  CSF1R	  treatment.	  Mice	  bearing	  bilateral	  tumours	  
were	   shielded	   on	   the	   left	   side	   (LHS)	   and	   	   irradiated	   on	   right	   femur	   (RHS)	   with	   10Gy	   and	  
received	   either	   no	   treatment	   (NT)	   or	   CSF1	   inhibitor	   treatment	   (CSF1R)	   until	   the	   date	   of	  
imaging(A	  and	  B,	  respectively).	  Mice	  were	  injected	  with	  ∼3.5	  MBq	  64Cu-­‐SER4	  and	  images	  were	  
acquired	  at	  4	  hours	  post	  injection.	  Arrows	  indicate	  heart	  (H),	  liver	  (L),	  spleen	  (S),	  bladder	  (Bl),	  
femur	  (Fm)	  and	  tumour	  (T).	  LHS	  =	  Left	  hand	  side;	  RHS	  =	  Right	  hand	  side.	  
	  
The	  tumour	  bearing	  NT	  and	  CSF1R	  group	  exhibited	  highest	  uptake	  in	  the	  spleen	  (22	  to	  
31	  %ID/g)	   and	   liver	   (19	   to	   28	  %ID/g)	   (see	   Figure	   4.12).	   The	  NT	   irradiated	   femurs	   all	  
displayed	   greater	   uptake	   than	   the	   non-­‐irradiated,	   as	   did	   the	   irradiated	   versus	   non-­‐
irradiated	   tumours.	   The	   CSF1R	   group	   showed	   higher	   blood,	   heart	   and	   lung	   uptake	  
values	  as	  compared	  to	  the	  NT	  group.	  CSF1R	  femurs	  showed	  greater	  uptake	  than	  their	  
respective	   NT	   counterparts,	   however	   neither	   irradiated	   nor	   non-­‐irradiated	   CSF1R	  




uptake	  than	  NT	  tumours	  but	  no	  such	  pattern	  was	  observed	  between	  CSF1R	  irradiated	  





Figure	  4.12	  Biodistribution	  of	  64Cu-­‐SER4	  in	  tumour	  bearing	  C57BL6	  mice	  after	  7	  days	  recovery	  
following	   localised	   irradiation	   with	   and	   without	   CSF1R	   treatment	   (n	   =	   2	   to	   3	   per	   group).	  
Bilateral	   tumour	   bearing	   mice	   were	   irradiated	   locally	   with	   10Gy	   then	   received	   either	   no	  
treatment	   (NT	  –	  blue	  dash)	   or	   CSF1	   inhibitor	   (CSF1R	  –	   red	  dash)	   for	   2	  days	  post	   irradiation.	  
Mice	  were	   injected	   IV	   into	   the	   tail	   vein	  with	  ∼3.5	  MBq	   64Cu-­‐SER4	   and	   culled	   at	   20	   hr,	   then	  
organs	  harvested,	  weighed	  and	  gamma	  counted.	  Each	  dash	  represents	  data	  from	  one	  mouse.	  
Radioactive	   uptake	   in	   organs	   is	   presented	   as	   the	   percentage-­‐injected	   dose	   per	   gram	   organ	  



































Tumours	  were	  excised	  and	  digested	  in	  collagenase,	  filtered	  then	  stained	  for	  CD11b,	  Gr-­‐
1,	  F4/80	  and	  Sn.	  Live	  cells	  were	  gated	  by	  forward	  scatter	  (FSC)	  and	  side	  scatter	  (SSC)	  to	  
eliminate	   small,	   granulous	   cells	   (see	   Figure	  4.13	  A	   to	  D).	  Whole	   live	   cell	   populations	  
were	  then	  assessed	  for	  %	  Sn	  expression	  using	  a	  threshold	  set	  at	  <	  1%	  expression	  for	  
unstained	   cells	   (see	   Figure	   4.14	   and	   Table	   4.3).	   Comparison	   of	   expression	   from	  
irradiated	   and	   non-­‐irradiated	   tumours	   in	   the	   NT	   group	   shows	   an	   increase	   following	  
irradiation	  of	  greater	  than	  2	  fold.	  	  
	  
Figure	   4.13	   Gating	   of	   live	   cell	   population	   from	   tumours.	   Filtered,	   de-­‐collagenised	   tumours	  
were	   analysed	   by	   flow	   cytometry	   (A)	   and	   live	   cells	   identified	   by	   gating	   on	   forward	   scatter	  





Figure	  4.14	  Sn	  expression	  of	  live	  cell	  population.	  Live	  cells	  from	  day	  7	  post	  tumours,	  without	  
treatment	  were	  analysed	  for	  Sn	  expression	  (FITC).	  Blue	  =	  left	  femur;	  Orange	  =	  right	  femur;	  Red	  
=	  unstained.	  
	  











0.194	   4.44	   11.6	   2.61	  
Table	   4.3	   Percentage	   Sn	   expression	   of	   whole	   live	   cells	   tumours.	   Data	   presented	   from	  
Figure	  4.18	  with	  Sn	  expression	  gate	  set	  using	  unstained	  control.	  
	  
The	   TAM	   subset	  was	   identified	   by	   expression	   of	   F4/80	   and	   CD11b.	   TAM	   and	  MDSC	  
subsets	  were	  analysed	  for	  Sn	  expression	  (see	  Figure	  4.15	  A	  and	  C).	  TAM	  expressing	  Sn	  
increased	  by	  74%	  following	   irradiation	  whilst	  Sn	  expression	   levels	   increased	   in	  MSDC	  
following	  irradiation,	  with	  15.7%	  of	  the	  irradiated	  tumour	  population	  exhibiting	  Sn	  as	  





Figure	  4.15	  Sn	  expression	  of	  tumour	  associated	  Mφ	  (TAM)	  and	  myeloid	  derived	  suppressor	  
cell	   (MSDC)	   populations.	   Live	   cells	   from	   tumours	   (Figure	   4.13	   D)	   were	   stained	   for	   TAM	  
subpopulations	  (A)–	  F4/80	  and	  CD11b	  –	  and	  MDSC	  subpopulations	  (C)	  -­‐	  Gr-­‐1	  and	  CD11b.	  Gated	  
cells	  were	  then	  analysed	  for	  Sn	  expression	  (B	  and	  D	   for	  TAM	  and	  MDSC,	  respectively).	  Red	  =	  
left	  femur;	  Blue	  =	  right	  femur;	  Red	  =	  unstained	  control.	  
	  




Tumour	  NT	   1.74	   15.7	  
Table	  4.4	  Sn	  expression	  of	  of	  tumour	  associated	  Mφ	  (TAM)	  and	  myeloid	  derived	  suppressor	  
cell	  (MSDC)	  populations.	  Data	  from	  figure	  4.15	  expressed	  as	  irradiated	  to	  non-­‐irradiated	  ratio	  
(TAM)	  or	  as	  %	  expression	  (MDSC).	  Gated	  cells	  were	  then	  analysed	  for	  Sn	  expression	  with	  Sn	  
expression	  gate	  set	  using	  unstained	  control.	  
	  
4.3.3.4 Relative	  Uptake	  Values	  
Relative	   uptake	   values	   were	   determined	   between	   the	   irradiated	   and	   non-­‐irradiated	  
bones	   (see	   Figure	   4.16),	   such	   that	   a	   value	   >	   1	   indicates	   increased	   uptake	   in	   the	  
irradiated	  limb	  as	  compared	  to	  the	  non-­‐irradiated.	  Relative	  uptake	  values	  calculated	  by	  
biodistribution	   showed	   all	   NT	  mice	   to	   have	   increased	   uptake	   in	   the	   irradiated	   limb,	  




For	   day	   7	   and	   tumour-­‐bearing	   groups,	   NT	  mice	   displayed	   greater	   uptake	   than	   their	  
respective	   CSF1R	   counterparts.	   No	   uptake	   bias	   was	   observed	   between	   day	   2	   CSF1R	  
and	  NT	  mice.	  
	  
Figure	  4.16	  Irradiated	  and	  non-­‐irradiated	  femur	  relative	  uptake	  values	  from	  biodistribution	  
(n	  =	  2	   to	  3	  per	  group).	  Tumour	  bearing	  and	  non-­‐tumour	  bearing	  mice	  (n	  =	  2	  to	  3	  per	  group)	  
receiving	   localised	   irradiation	  with	  treatment	  (NT	  –	  blue	  dash)	  or	  CSF1	   inhibitor	  (CSF1R	  –	  red	  
dash)	  were	  injected	  with	  ∼3.5	  MBq	  64Cu-­‐SER4.	  Non-­‐tumour	  bearing	  mice	  were	  culled	  at	  2	  days	  
and	  7	  days	  post	   irradiation,	   and	   tumour	  bearing	  mice	   culled	  at	  7	  days	  post	   irradiation.	   Each	  
dash	   represents	   data	   from	   one	   mouse.	   Relative	   uptake	   is	   presented	   as	   a	   ratio	   between	  
percentage	  injected	  dose	  per	  gram	  (%ID/g)	  of	  the	  irradiated	  (right)	  femur	  to	  that	  of	  the	  non-­‐
irradiated	  (left)	  femur.	  Values	  >	  1	  indicate	  an	  increase	  in	  uptake	  to	  the	  irradiated	  limb	  versus	  
the	   non-­‐irradiated,	   whilst	   <	   1	   indicate	   decrease	   in	   irradiated	   limb	   uptake	   relative	   to	   non-­‐
irradiated.	  
Comparison	  of	  the	  activity	  between	  the	  irradiated	  and	  non-­‐irradiated	  femurs	  was	  also	  
performed	  by	  ROI	  analysis	   (see	  Figure	  4.17).	  ROI	  defined	  by	   the	  bone	  marrow	  cavity	  
was	  compared	  to	  produce	  relative	  uptake	  values.	  The	  NT	  groups	  of	  day	  7	  and	  tumour-­‐
bearing	  mice	  all	  showed	  greater	  uptake	  in	  the	  irradiated	  limb	  than	  the	  CSF1R	  groups.	  
Additionally,	  tumour	  mice	  recorded	  higher	  relative	  uptake	  values	  than	  day	  7	  mice	  for	  
both	  NT	  and	  CSF1R	  groups	   respectively,	  with	  NT	   tumour	  bearing	  mice	  exhibiting	   the	  
highest	  relative	  uptake	  values	  of	  all	  groups.	  No	  uptake	  pattern	  was	  observed	  between	  

























Figure	  4.17	  13	   Irradiated	   to	  non-­‐irradiated	  bone	  marrow	   relative	  uptake	   values	   from	   64Cu-­‐
SER4	   imaging	   in	  tumour	  and	  non-­‐tumour	  bearing	  mice	  post	   localised	   irradiation	  and	  CSF1R	  
treatment	  (n	  =	  2	  to	  3	  per	  group).	  Mice	  received	  localised	  irradiation	  either	  no	  treatment	  (NT	  –	  
blue	   dash)	   or	   CSF1	   inhibitor	   treatment	   (CSF1R	   –	   red	   dash)	   until	   the	   date	   of	   imaging.	   Non-­‐
tumour	  bearing	  mice	  were	  imaged	  at	  2	  days	  and	  7	  days	  post	  irradiation.	  Mice	  bearing	  bilateral	  
tumours	  were	  imaged	  at	  7	  days	  post	  irradiation.	  Mice	  were	  injected	  with	  ∼3.5	  MBq	  64Cu-­‐SER4	  
and	  images	  were	  acquired	  at	  4	  hours	  post	  injection.	  Regions	  of	  interest	  (ROI)	  of	  bone	  marrow	  
were	   defined	   by	   the	   internal	   cavity	   of	   bone	   using	   CT.	   Comparison	   of	   the	   signal	   from	   the	  
irradiated	   to	   the	  non-­‐irradiated	  ROI	  was	  used	   to	   generate	   relative	  uptake	   values.	   Each	  dash	  
represents	  data	   from	  one	  mouse.	  Values	  >	  1	   indicate	  an	   increase	   in	  uptake	  to	   the	   irradiated	  




4.3.3.5 Comparison	  of	  Selected	  Organ	  Uptake	  	  
For	  day	  2	  and	  day	  7	  groups	  (see	  Figure	  4.18),	  blood	  activity	  varied	  with	  a	  range	  >	  10	  
%ID/g.	  In	  day	  7	  group,	  CSF1R	  mice	  had	  higher	  blood	  uptake	  values	  than	  NT	  mice,	  whilst	  
spleen	  and	  liver	  for	  all	  mice	  showed	  lower	  uptake	  values	  in	  the	  CSF1R	  group	  compared	  
to	  its	  respective	  NT	  group.	  No	  bias	  was	  observed	  between	  blood	  uptake	  for	  day	  2	  NT	  
and	  CSF1R	  groups,	  however	  as	  with	  day	  7,	  liver	  and	  spleen	  all	  recorded	  lower	  uptake	  
values	  in	  the	  day	  2	  CSF1R	  group	  versus	  NT	  group.	  	  
Day	   2	   and	   Day	   7	   CSF1R	   groups	   contained	   n	   =	   3	   data,	   permitting	   statistical	   analysis.	  
CSF1R	  mice	  from	  showed	  significantly	  lower	  splenic	  (p	  =	  0.033,	  decreasing	  by	  77.2%	  by	  
























percentage	   injected	   dose	   per	   gram)	   uptake	   in	   day	   7	   compared	   to	   day	   2	   groups,	   as	  
shown	  by	  Student’s	  T	   test.	  Additionally,	   significantly	  higher	  blood	  activity	   (p	  =	  0.033,	  
increasing	   by	   44.0%	   by	   percentage	   injected	   dose	   per	   gram)	   was	   recorded	   in	   CSF1R	  





Figure	  4.18	  Selected	  organ	  uptake	  	  of	  64Cu-­‐SER4	  in	  C57BL6	  mice	  after	  2	  and	  7	  days	  recovery	  
following	  localised	  irradiation	  with	  and	  without	  CSF1R	  treatment	  (n	  =	  2	  to	  3	  per	  group).	  Non-­‐
tumour	  bearing	  mice	  receiving	  localised	  irradiation	  with	  no	  treatment	  (NT	  )and	  CSF1	  inhibition	  
(CSF1R)	   were	   injected	  with	  ∼3.5	  MBq	   64Cu-­‐SER4	   at	   2	   days	   (yellow	   dash)	   and	   7	   days	   (green	  
dash)	  post	  irradiation,	  culled	  at	  4	  hr	  post	  injection	  then	  organs	  harvested,	  weighed	  and	  gamma	  
counted.	  Each	  dash	  represents	  data	  from	  one	  mouse.	  Radioactive	  uptake	  in	  blood,	  spleen	  and	  
liver	  is	  represented	  as	  percentage	  injected	  dose	  per	  gram	  (%ID/g).	  ).	  A:	  full	  biodistribution,	  B:	  

























Day	  2	  	  























Day	  2	  	  






The	   preparation	   and	   radiolabelling	   of	   NOTA-­‐conjugates	   for	   labelling	   with	   64Cu	   is	   a	  
routine	  procedure,	   affording	   immunoconjugates	  with	   fast	   labelling	   speed	   in	   ambient	  
conditions	  with	  a	  high	  degree	  of	  in	  vivo	  stability	  (Cooper,	  Sabbah	  et	  al.	  2006;	  Cooper,	  
Ma	   et	   al.	   2012).	   SER4-­‐NOTA	   exemplified	   this	   process	   and	   provided	   consistent	  
radiolabelling	  that	  was	  resistant	  to	  EDTA	  challenge,	  indicating	  incorporation	  of	  copper	  
into	  the	  chelator.	  Due	  to	  time	  constraints	  of	  project	  in	  UCLA,	   in	  vitro	  characterisation	  
of	  the	  64Cu-­‐SER4	  such	  as	  serum	  stability,	  number	  of	  chelators	  per	  antibody	  and	  binding	  
to	  recombinant	  Sn	  was	  not	  carried	  out	  (see	  chapter	  3	  for	  recombinant	  Sn	  binding	  and	  
serum	   stability	   assays	   performed	   with	   99mTc-­‐SER4).	   As	   stability	   of	   copper-­‐labelled	  
NOTA	  conjugates	  is	  well	  established,	  the	  binding	  of	  64Cu-­‐SER4	  to	  recombinant	  Sn	  was	  a	  
desirable	   assay	   to	   determine	   whether	   specificity	   of	   the	   parent	   antibody	   had	   been	  
retained	  for	  the	  immunoconjugate	  (for	  a	  description	  of	  this	  assay	  see	  chapter	  2).	  Given	  
time	  constraints	  an	  effective	   in	  vivo	  binding	  assay	  was	  decided	  upon	  using	  uptake	   in	  
endogenous	   Sn	   expressing	   tissues	   (such	   as	   the	   spleen)	   as	   indication	   of	   binding.	  
Unfortunately	  this	  technique	  doesn’t	  permit	  quantification	  of	  binding,	  and	  so	  it	  will	  be	  
necessary	   to	   conduct	   in	   vitro	   binding	   assays	   to	  determine	   immunoreactivity	   of	   64Cu-­‐
SER4.	  
Dynamic	  scanning	  was	  performed	  on	  one	  mouse	  and	  hence	  is	  not	  statistically	  analysed	  
or	  significant;	  however	   it	   indicated	  rapid	  accumulation	  of	  64Cu-­‐SER4	  to	  target	  organs.	  
As	  observed	  with	   the	   tracer	   99mTc-­‐SER4,	   the	  highest	  uptake	  of	   the	  antibody	   is	   in	   the	  
spleen,	   followed	   by	   the	   liver	   and	   bone	   marrow.	   Once	   again,	   the	   rate	   at	   which	   the	  
tracer	  accumulates	  is	  unique	  amongst	  intact	  IgG,	  which	  traditionally	  have	  much	  longer	  
residence	  times	   (see	  chapter	  3).	   	  Where	  targeting	   to	   the	  spleen	  results	   from	  antigen	  
expression,	  liver	  uptake	  is	  a	  combination	  of	  antigen	  targeting	  and	  non-­‐specific	  copper	  
uptake.	  Macrocyclic	  structures	  such	  as	  DOTA	  conjugated	  to	  peptides	  and	  proteins	  have	  
been	  noted	  for	  their	  high	  liver	  uptake	  (Smith	  2004).	  Although	  the	  mechanism	  has	  yet	  
be	   elucidated,	   in	   vivo	   transchelation	   of	   copper-­‐64	   to	   copper	   binding	   proteins	   is	  
thought	  to	  participate	  in	  this	  uptake.	  Further	  on,	  the	  selection	  of	  BFC	  has	  been	  shown	  




commercially	   available	   conjugate	   that	   affords	   the	   least	   non-­‐specific	   liver	   uptake	  
(Dearling,	   Voss	   et	   al.	   2011;	   Cooper,	   Ma	   et	   al.	   2012).	   The	   selection	   of	   NOTA-­‐SCN	  
reflected	  this	  favourable	  in	  vivo	  property,	  as	  well	  as	  its	  fast	  labelling	  kinetics.	  
From	  the	  kinetic	  data	  presented	  in	  the	  dynamic	  study,	  the	  rate	  of	  blood	  clearance	  and	  
tissue	  uptake	  appears	   to	  undergo	  two	  phases:	  an	   initial	   rapid	  change	   in	  which	  blood	  
activity	  is	  seen	  to	  half	  in	  approximately	  20	  min	  post	  injection,	  which	  adjusts	  to	  a	  slower	  
rate	   of	   change	   from	   approximately	   1	   hr	   post	   injection	   onwards,	   suggesting	   two	  
processes	  are	  taking	  place.	  A	  possible	  explanation	  is	  that	  in	  the	  first	  period	  the	  antigen	  
sink	  is	  in	  excess,	  as	  such	  the	  rate	  of	  tissue	  accumulation/blood	  clearance	  is	  determined	  
by	  antigen	  access	  and	  hence	  is	  rapid	  in	  the	  highly	  perfused	  organs	  where	  the	  antigen	  
resides	  at	  the	  point	  of	  contact	  with	  the	  blood.	  The	  transition	  to	  a	  slower	  rate	  of	  blood	  
clearance	   may	   result	   from	   antigen	   saturation,	   thus	   the	   probe	   is	   in	   approximate	  
equilibrium	   and	   further	   blood	   clearance	   results	   from	   antigen	   internalisation	   and/or	  
radiotracer	  metabolism.	  Whether	   or	   not	   antigen	   sink	   is	   the	   determinant	   of	   the	   first	  
phase	  could	  be	   investigated	  by	  kinetic	  studies	  of	  the	  radiotracer	   in	  combination	  with	  
excess	  cold	  antibody	  to	  block	  antigen	  sink.	  In	  the	  instance	  that	  antigen	  sink	  is	  in	  excess	  
but	   becomes	   saturated	  with	   time,	   addition	   of	   excess	   cold	   SER4	  would	   reduce	   organ	  
uptake/blood	  clearance.	  Such	  a	  methodology	  has	  been	  applied	  to	  the	  imaging	  of	  non-­‐
Hodgkin	  lymphoma	  using	  anti-­‐CD20	  IgG,	  in	  which	  unlabelled	  antibody	  is	  administered	  
before	   radiotracer	   to	  block	  endogenous	  antigen	  and	  thereby	  extend	  blood	  residence	  
of	   the	   tracer	   (Sharkey,	   Karacay	   et	   al.	   2009).	   Alternatively,	   the	   transition	   from	   rapid	  
uptake	   to	   slow	   uptake/plateau	   may	   represent	   the	   complete	   uptake	   of	   targeting	  
antibody	   and	   remaining	   non-­‐targeting	   immune-­‐conjugate	   (which	   has	   lost	   binding	  
through	  the	  process	  of	  radiotracer	  development)	  presenting	  as	  non-­‐specific	  signal.	  The	  
amount	  of	  non-­‐binding	  tracer	  could	  be	  ascertained	  by	  an	  immunoreactivity	  assay	  using	  
recombinant	  antigen	  (see	  Chapter	  2).	  
As	  the	  data	  is	  limited	  to	  one	  mouse,	  determining	  whether	  tissue	  uptake	  is	  occurring	  or	  
a	   plateau	   has	   been	   reached	   is	   not	   possible.	   However	   there	   is	   the	   suggestion	   that	  
splenic	   uptake	   is	   slowly	   increasing,	   possibly	   representing	   antigen	   internalising	   and	  
residualising	  of	   the	  tracer.	  This	  effect	  could	  be	  probed	  by	  comparison	  of	  kinetic	  data	  




internalising.	  This	  is	  based	  upon	  Cu	  presenting	  as	  a	  residualising	  radioisotope	  that	  after	  
internalisation	   is	   trapped	   intracellularly,	   whereas	   iodine	   is	   readily	   cleaved	   from	   the	  
radiotracer	  in	  the	  acidic	  environment	  of	  the	  phagolysosome	  and	  then	  exported	  out	  of	  
the	  cell	  (Olafsen	  and	  Wu	  2010).	  Establishing	  whether	  or	  not	  an	  antigen	  is	  internalising	  
has	  implications	  for	  both	  imaging	  and	  therapy	  (Nielsen	  and	  Marks	  2000).	  	  	  
The	  localised	  irradiation	  model	  was	  performed	  on	  groups	  of	  n	  =	  2	  or	  n	  =	  3,	  hence	  the	  
discussion	   does	   not	   include	   statistically	   significant	   conclusions	   unless	   specifically	  
mentioned.	   At	   day	   2	   post	   irradiation,	   correlation	   between	   Sn	   expression	   and	   tracer	  
uptake	  was	  not	  observed.	  For	  the	  NT	  group,	  decreased	  Sn	  expression	  was	  seen	  by	  flow	  
cytometry	   in	   the	   irradiated	   limb	   as	   compared	   to	   the	   non-­‐irradiated,	   whereas	  
biodistribution	   and	   ROI	   analysis	   all	   indicated	   higher	   uptake.	   This	   disparity	  may	   arise	  
from	   subject	   variability	   and	   be	   addressed	   by	   greater	   sample	   numbers.	   Alternatively,	  
lower	   Sn	   expression	  may	   result	   from	   radioablation	   of	   Sn	   expressing	   cells,	  whilst	   the	  
increased	   uptake	   could	   be	   accounted	   for	   by	   non-­‐specific	   uptake	   of	   the	   tracer.	  
Administered	   to	   the	   whole	   body,	   10	   Gy	   is	   lethal	   however	   localised	   irradiation	   of	   a	  
femur	   results	   in	   the	   collapse	   of	   the	   resident	   cell	   population	   which	   is	   then	   steadily	  
repopulated	   (Werts,	  Gibson	  et	   al.	   1980).	   Radiation	   induced	  break	  down	  of	   the	  bone	  
marrow	  sinusoidal	  structure	  can	  cause	  blood	  pooling	  (Higashi,	  Fisher	  et	  al.	  2000)	  which	  
may	   lead	   to	   enhanced	   non-­‐specific	   retention	   of	   the	   tracer.	   Flow	   data	   indicates	   that	  
CSF1R	   mice	   exhibit	   less	   Sn	   expression	   between	   irradiated	   and	   non-­‐irradiated	   limbs	  
than	   NT	   mice,	   so	   larger	   group	   sizes	   would	   allow	   for	   the	   statistical	   comparison	   of	  
whether	  Sn	  expression	  influences	  the	  uptake	  at	  day	  2	  post	  irradiation.	  
A	  striking	  asymmetrical	  tracer	  uptake	  was	  seen	  on	  Day	  7	  mice	  between	  irradiated	  and	  
non-­‐irradiated	  limbs	  of	  the	  NT	  group.	  Whole	  body	  imaging	  showed	  more	  uptake	  in	  the	  
irradiated	   femur,	   which	   was	   confirmed	   by	   relative	   uptake	   values	   determined	   from	  
both	   biodistribution	   and	   ROI	   analysis.	   Asymmetrical	   uptake	  was	   not	   seen	   directly	   in	  
the	  biodistribution	  data,	  as	  irradiated	  femurs	  did	  not	  display	  uniformly	  greater	  uptake	  
than	   non-­‐irradiated	   femurs.	   However	   the	   femurs	   showed	   a	   wide	   range	   of	   values	  
between	  mice,	  which	  may	   in	   part	   be	   due	   to	   recording	   the	  mass	   and	   activity	   of	   the	  
entire	  bone	  rather	  than	  the	  bone	  marrow.	  Additionally,	  it	  has	  been	  previously	  reported	  




considerable	   intersubject	   variation	   of	   bone	   marrow	   cellularity	   can	   comparison	   of	  
variations	  in	  absolute	  cell	  numbers	  during	  the	  response	  (Elnaggar,	  Hanna	  et	  al.	  1980).	  
As	  such,	  comparison	  of	   relative	  activity	  of	   the	  non-­‐irradiated	   femur	   to	   the	   irradiated	  
more	   accurately	   reflects	   the	   response	   to	   localised	   irradiation	   between	   subjects,	   and	  
confirmed	  the	  increased	  uptake	  observed	  by	  imaging.	  A	  possible	  explanation	  regarding	  
the	   increased	  Mφ	  burden	   is	   that	   following	   irradiation,	  a	  rapid	   influx	  of	  neutrophils	   is	  
observed	   (Higashi,	   Fisher	   et	   al.	   2000)	   which	   would	   require	   clearance	   during	   the	  
resolution	   of	   inflammation,	   a	   process	   that	   is	   conducted	   by	   tissue	   Mφ.	   Another	  
explanation	   is	   based	   on	   the	   recently	   finding	   that	   bone	   marrow	   Mφ	   are	   directly	  
implicated	   in	   the	   retention	   of	   HSCs	   (Winkler,	   Sims	   et	   al.	   2010),	   in	   which	   specific	  
ablation	  of	  Sn	  positive	  Mφ	  results	  in	  increased	  levels	  of	  circulating	  HSCs	  (Chow,	  Lucas	  
et	  al.	  2011).	  This	  raises	  the	  possibility	  that	  alongside	  a	  scavenging	  role,	  the	  presence	  of	  
increased	  numbers	  of	  Sn	  positive	  Mφ	  may	  be	  part	  of	  the	  host	  response	  in	  restoring	  the	  
haematopoietic	  environment	  through	  increased	  restriction	  of	  HSC	  efflux.	  	  
Furthermore,	  relative	  uptake	  values	  from	  ROI	  indicated	  higher	  uptake	  following	  7	  day	  
recovery	   to	   irradiation	   in	   the	  presence	  of	  a	   tumour.	  This	   suggests	   that	   the	   tumoural	  
environment,	  or	  its	  response	  to	  irradiation,	  has	  a	  local	  effect	  upon	  the	  bone	  marrow.	  
Flow	  cytometry	  of	  day	  7	  mice	   showed	   that	  Sn	  expression	  was	   relatively	   increased	   in	  
the	   irradiated	  bone	  marrow,	   and	   in	  particular	  on	  a	   subset	  of	   cells	   expressing	  CD11b	  
and	  Gr-­‐1,	  which	   are	   sometimes	   characterised	   as	  MDSC	   (Ribechini,	  Greifenberg	   et	   al.	  
2010).	   This	   result	   indicates	   Sn	   expression	   is	   present	   upon	   an	   immature	  myeloid	   cell	  
type	  resident	  in	  the	  bone	  marrow,	  which	  poses	  questions	  as	  to	  the	  identity	  of	  this	  cell	  
type	   (are	   they	   MDSC)	   and	   the	   purpose/function	   of	   Sn	   expression	   upon	   them.	   The	  
possibility	   arises	   that	   following	   irradiation	   tumours	  may	   enrich	  MDSC	   bone	  marrow	  
populations	   expressing	   Sn,	   which	  may	   then	   traffic	   to	   the	   tumour	   and	   contribute	   to	  
increased	  MDSC	   recruitment.	   To	   further	   investigate	   this,	   Sn	   expression	   in	   irradiated	  
bone	  marrow	  from	  tumour	  bearing	  mice	  should	  be	  compared	  to	  non-­‐tumour	  bearing	  
mice.	  
For	   tumour	  and	  non-­‐tumour	  bearing	  mice	  at	  day	  7	  post	   irradiation,	  CSF1R	  groups	  all	  
showed	   lower	   relative	   uptake	   values	   than	   their	   NT	   counterparts.	   In	   this	   instance,	  




tissue,	   a	   strategy	   which	   has	   been	   used	   for	   blocking	   Mφ	   recruitment	   to	   tumours	  
(MacDonald,	  Palmer	  et	  al.	  2010;	  Coniglio,	  Eugenin	  et	  al.	  2012).	  Alternatively,	  disruption	  
of	   CSF-­‐1	   may	   be	   inhibiting	   maturation	   signals	   that	   allow	   for	   Sn	   expression.	   It	   is	  
tempting	  to	  speculate	  that	  as	  the	  degree	  of	  structural	  damage	  arising	  from	  irradiation	  
is	  likely	  to	  be	  independent	  of	  Mφ	  recruitment,	  and	  thus	  non-­‐specific	  uptake	  to	  be	  the	  
same	  in	  both	  NT	  and	  CSF1R	  groups,	  that	  the	  increased	  relative	  uptake	  between	  NT	  and	  
CSF1R	  represents	  specific	  uptake.	  This	  may	  be	  probed	  by	  comparison	  of	  uptake	  using	  a	  
labelled	  isotype	  control	  or	  by	  using	  Sn	  KO	  mice	  (see	  Chapter	  3).	  
In	   the	  tumour-­‐bearing	  group,	  whole	  body	   imaging	  also	  delineated	  the	  non-­‐irradiated	  
tumour	   more	   clearly	   than	   the	   irradiated.	   On	   inspection	   the	   irradiated	   tumour	   was	  
significantly	   smaller	   than	   the	   non-­‐irradiated	   (approximately	   10	   times	   less	   mass	  
recorded	   during	   biodistribution).	   Additionally	   the	   non-­‐irradiated	   contained	   a	  
substantial	   necrotic	   core,	   and	   as	   such	   produced	   far	  more	   non-­‐specific	   tracer	   uptake	  
due	   to	   enhanced	   permeabilisation	   which	   contributed	   to	   better	   visualisation	   of	   the	  
non-­‐irradiate	  tumour.	   Irradiation	  of	  solid	  tumours	   frequently	  results	   in	  the	  enhanced	  
recruitment	   of	   myeloid	   cells	   which	   can	   enhance	   tumour	   growth	   (Ahn,	   Tseng	   et	   al.	  
2010;	   Kozin,	   Kamoun	   et	   al.	   2010)	   and	   the	   flow	   cytometry	   data	   from	   the	   tumours	  
revealed	   the	   upregulation	   of	   Sn	   following	   irradiation,	   agreeing	   with	   biodistribution	  
data.	  When	  cellular	  subsets	  were	  analysed,	  it	  could	  also	  be	  seen	  that	  Sn	  expression	  by	  
TAM	   increased	   following	   irradiation,	   and	   that	   the	   cell	   population	   defined	   as	   MDSC	  
showed	  upregulation	  of	  Sn.	  Though	   inconclusive,	   this	  data	  may	  reveal	   the	   target	  cell	  
type	  to	  be	  not	  exclusively	  mature	  Mφ	  but	  to	  include	  other	  cells	  of	  the	  myeloid	  lineage.	  
The	  subject	  of	  MDSC	  in	  tumour	  proliferation	  is	  an	  active	  area	  of	  research	  as	  this	  class	  
of	  cell	  are	   thought	   to	  contribute	   to	   the	   immunosuppressive	  environment	   that	  allows	  
permits	  tumour	  growth	  (Ochando	  and	  Chen	  2012).	  The	  data	  shows	  that	  Sn	  expressing	  
myeloid	  cells	  are	  part	  of	  the	  tumoural	   infiltrate	   in	  response	  to	   irradiation,	  and	  hence	  
may	   be	   an	   important	   cellular	   subset	   during	   this	   process.	   The	   preliminary	  
biodistribution	   data	   also	   indicates	   that	   higher	   uptake	   of	   tracer	   was	   observed	   in	  
tumours	  with	  higher	  target	  expression.	  Future	  studies	  may	  be	  performed	  with	  tumour	  




to	  be	  able	  to	  image	  tumours	  that	  are	  approximately	  of	  equivalent	  size	  and	  thus	  reduce	  
the	  impact	  of	  necrosis.	  	  
Day	  7	  CSF1R	  mice	   showed	  higher	  blood	  uptake	   than	  day	  7	  NT	  mice	  and	  significantly	  
higher	  blood	  uptake	  than	  day	  2	  CSF1R	  mice,	  suggesting	  CSF1R	  treatment	  and	  duration	  
influenced	  blood	  kinetics.	  All	  CSF1R	   treated	  mice	  also	   recorded	   lower	   splenic	  uptake	  
than	   their	   NT	   counterpart,	   suggesting	   that	   uptake	   decreases	   with	   CSF1R	   exposure.	  
Additionally,	  Day	  7	  CSF1R	  mice	  show	  significantly	  less	  splenic	  uptake	  than	  day	  2	  CSF1R	  
mice	  suggesting	  that	  uptake	  decreases	  with	  CSF1R	  treatment	  duration.	  This	  apparent	  
inverse	   relationship	   between	   splenic	   uptake	   and	   blood	   pool	   may	   be	   connected,	  
whereby	  reduced	  Sn	  levels	  in	  the	  spleen	  serve	  to	  decrease	  the	  antigen	  sink	  and	  hence	  
increase	  the	  amount	  of	  circulating	  64Cu-­‐SER4.	  This	  direct	  relationship	  between	  CSF1R	  
and	   Sn	   expression	   is	   in	   agreement	  with	   the	   recent	   finding	   that	   treatment	  with	   anti-­‐
CSF1R	  mAb	  results	  in	  down	  regulation	  of	  Sn	  expression	  in	  the	  MZM	  (Hashimoto,	  Chow	  
et	  al.	  2011).	  However	  the	  day	  2	  NT	  mice	  also	  exhibit	  higher	  splenic	  uptake	  values	  than	  
day	   7	  NT	  mice	   so	   it	   can’t	   be	   ruled	   out	   that	   this	   drop	   the	   CSF1R	   treated	   group	  may	  
reflect	  some	  overall	  change	  in	  Sn	  expression	  following	  irradiation.	  Radiation	  exposure	  
results	   in	   the	   release	  of	   cytokines,	   in	  particular	   IL-­‐6	   (Haveman,	  Geerdink	  et	  al.	  1998;	  
Van	   der	   Meeren,	   Monti	   et	   al.	   2001)	   which	   can	   induce	   systemic	   effects,	   such	   as	  
increased	  haematopoiesis	  (Mouthon,	  Vandamme	  et	  al.	  2001).	  In	  this	  way	  the	  influence	  
of	   irradiation	  may	  be	  realised	  by	   the	   release	  of	   soluble	   factors	   that	   influence	  splenic	  
populations	   of	   Mφ,	   upregulating	   Sn.	   However,	   the	   day	   2	   mice	   were	   on	   average	   2	  
weeks	  younger	  than	  the	  day	  7	  and	  tumour	  groups,	  hence	  it	  cannot	  be	  eliminated	  that	  
this	   observed	   change	   in	   splenic	   uptake	   between	   day	   2	   and	   day	   7	   groups	   may	   be	  
attributable	   to	  developmental	   regulation	  of	   Sn.	   To	  address	   this,	   the	   selection	  of	   age	  
matched	  mice	  could	  establish	  whether	  Sn	  upregulation	  is	  an	  early,	  systemic	  response	  








In	  this	  chapter	  the	  preparation	  and	  preliminary	  data	  concerning	  the	  in	  vivo	  functioning	  
of	   the	   novel	   Mφ-­‐specific	   PET	   imaging	   agent	   64Cu-­‐SER4	   was	   described.	   64Cu-­‐SER4	  
demonstrated	  rapid	  binding	  to	  endogenous	  populations	  of	  Sn	  positive	  Mφ.	  In	  a	  model	  
of	   localised	   bone	   marrow	   irradiation,	   64Cu-­‐SER4	   indicated	   increased	   Sn	   expression	  
during	  recovery	  which	  was	  increased	  further	  in	  the	  presence	  of	  an	  irradiated	  tumour.	  
Inhibition	   of	   CSF1	   signalling	   blocked	   increased	   uptake	   following	   irradiation,	   and	   also	  
diminished	   endogenous	   Sn	   expression.	   64Cu-­‐SER4	   may	   also	   have	   revealed	   transient	  
elevation	   in	   splenic	   Sn	   expression	   resulting	   from	   localised	   irradiation.	   Future	   studies	  
require	  greater	  subject	  numbers	  to	  establish	  significance,	  however	  at	  present	  the	  data	  
reports	   the	   first	   specific	  myeloid	   response	   to	   radiation	   recovery	  which	  may	   provide	  
insights	  for	  bone	  marrow	  transplantation.	  Furthermore,	  identification	  of	  Sn	  expressing	  
myeloid	   infiltrates	   in	   tumour	  confirms	   indicates	   the	  potential	  of	   imaging	   this	  class	  of	  
cell	  type	  following	  irradiation	  induced	  recruitment,	  however	  preliminary	  data	  indicates	  





5 Chapter	  5:	  	  Dual	  Isotope	  Imaging	  of	  	  ED2-­‐DTPA-­‐111In	  and	  99mTc-­‐ED3	  
5.1 Introduction	  
Mφs	  display	  considerable	  plasticity	  of	  phenotype	  and	  often	  it	  is	  considered	  the	  balance	  
between	  phenotypes	   that	  determines	   the	  outcome	  of	  disease	  processes.	   In	   this	  way	  
tumour	   progression	   is	   often	   considered	   the	   transition	   of	   an	   inflammatory	   M1	  
phenotype	   to	   an	   immuno-­‐suppressive	   M2	   phenotype	   (see	   Chapter	   1).	   Therefore	  
detecting	  the	  relative	  levels	  of	  these	  populations	  in	  vivo	  has	  important	  implications	  for	  
predicting	  disease	  progression	  and	   treatment.	  Given	   the	  promising	   results	  of	   anti-­‐Sn	  
imaging	  in	  mice	  as	  an	  M1	  marker	  (see	  Chapter	  3)	  we	  sought	  to	  compare	  the	  behaviour	  
of	  such	  an	  M1	  probe	  with	  an	  M2	  probe	  in	  the	  rat.	  SPECT	  imaging	  technology	  is	  able	  to	  
detect	   gamma	   emissions	   at	   different	   energies	   and	   consequently	   allows	   for	   the	  
simultaneous	   imaging	   of	   different	   tracers.	   In	   this	   chapter	   we	   aim	   to	   produce	   two	  
radiotracers	  using	  anti-­‐Mφ	  antibodies	  ED2	  and	  ED3	  with	  orthogonal	  radioisotopes	  and	  
evaluate	   their	   feasibility	   for	   imaging	   of	   different	   endogenous	  Mφ	   populations	   using	  
SPECT/CT.	  
	  
5.1.1 ED2	  and	  ED3	  
The	  ED	  hybridoma	  series	  were	  originally	  prepared	  by	  immunising	  mice	  with	  rat	  spleen	  
cells,	   then	   selecting	   clones	   on	   the	   basis	   of	   splenic	   tissue	   staining.	   ED2	   and	   ED3	  
emerged	   as	   antibodies	   identifying	   different	   Mφ	   subpopulations	   which	   exhibited	  
distinct	   localisation	  patterns	   in	   the	   lymphoid	   tissue	   (Dijkstra,	  Dopp	  et	   al.	   1985).	   ED3	  
was	   shown	   to	   have	   binding	   properties	   and	   tissue	   distribution	   similar	   to	   antibodies	  
recognising	  murine	  Sn	  leading	  to	  its	  assignment	  as	  an	  anti-­‐Sn	  antibody	  	  (Damoiseaux,	  
Huitinga	   et	   al.	   1992)	   and	   often	   cited	   as	   a	   marker	   of	   inflammatory/M1	   Mφs	   (see	  
Chapter	   1).	   ED2	   was	   more	   recently	   shown	   to	   recognise	   the	   antigen	   CD163,	   the	   so	  




to	  characterise	  mature	  tissue	  Mφ	  (Polfliet,	  Fabriek	  et	  al.	  2006)	  and	  is	  a	  putative	  marker	  
for	  M2	  Mφs	  (see	  below).	  
	  
5.1.2 Scavenger	  Receptor	  CD163	  
The	   SR	   family	   is	   a	   class	   of	   proteins	   defined	   by	   their	   ability	   to	   recognise	   polyanionic	  
structures,	   and	   originally	   identified	   by	   their	   mediation	   of	   modified	   low-­‐density	  
lipoprotein	   uptake	   by	   Mφ	   (Fabriek,	   van	   Bruggen	   et	   al.	   2009).	   CD163	   is	   a	   myeloid-­‐
restricted	   antigen	   belonging	   to	   the	   SR	   family	   which	   exhibits	   scavenging	   as	   well	   as	  
immunomodulatory	  behaviour	  (Van	  Gorp,	  Delputte	  et	  al.	  2010).	  
CD163	   is	   composed	   of	   nine	   extracellular	   scavenger	   receptor	   cysteine	   rich	   (SRCR)	  
domains,	  a	  transmembrane	  domain,	  and	  a	  cytoplasmic	  domain	  containing	  a	  variety	  of	  
phosphorylation	  sites	  as	  well	  as	  an	  internalising	  motif	  (Van	  Gorp,	  Delputte	  et	  al.	  2010).	  
Low	  levels	  of	  expression	  are	  found	  on	  circulating	  monocytes	  (in	  humans),	  with	   levels	  
significantly	  increased	  on	  tissue	  resident	  Mφs	  (such	  as	  Kupffer	  cells	  and	  red	  pulp	  Mφs)	  
suggesting	   its	   use	   as	   a	   maturation	  marker.	   Additionally,	   significant	   levels	   of	   soluble	  
CD163	   are	   found	   in	   serum	   (approximately	   2	   mg/L)	   which	   can	   be	   further	   elevated	  
during	  diseased	  states	  (Moller,	  Peterslund	  et	  al.	  2002).	  Expression	  of	  CD163	  in	  human	  
monocytes	   can	   be	   increased	   by	   exposure	   to	   glucocorticoids	   and	   anti-­‐inflammatory	  
cytokines	   IL-­‐6	  and	  IL-­‐10,	  whilst	   inflammatory	  cytokines	  such	  as	   IFN-­‐γ	  and	  TNF-­‐α	  have	  
been	  shown	  to	  decrease	  expression.	  However,	  ligation	  of	  toll-­‐like	  receptors	  (TLRs)	  has	  
been	  shown	  to	  increase	  expression	  whilst	  no	  modulation	  occurs	  in	  the	  presence	  of	  the	  
anti-­‐inflammatory	   cytokines	   IL-­‐4	   and	   IL-­‐13,	   qualifying	   expression	   as	   broadly	   anti-­‐
inflammatory	  (Van	  Gorp,	  Delputte	  et	  al.	  2010).	  Similarly,	  expression	  in	  rodent	  Mφs	  has	  
been	  shown	  to	  be	  induced	  by	  glucocorticoid	  exposure	  and	  enhanced	  by	  co-­‐incubation	  
with	  IL-­‐4,	  whilst	  a	  range	  of	  other	  cytokines	  have	  failed	  to	  exhibit	  regulation	  properties	  
(Polfliet,	  Fabriek	  et	  al.	  2006).	  
The	   most	   characterised	   function	   for	   CD163	   is	   as	   the	   haemoglobin	   SR,	   in	   which	   it	  
removes	   haemoglobin-­‐haptoglobin	   (Hb-­‐Hp)	   complexes	   from	   the	   circulation	   via	  
endocytosis	  (Kristiansen,	  Graversen	  et	  al.	  2001).	  Additionally	  CD163	  has	  been	  shown	  to	  




bacterial	  sensor	  (Fabriek,	  van	  Bruggen	  et	  al.	  2009)	  which	  has	  been	  exploited	  by	  some	  
pathogens	   for	   entry	   into	  Mφs	   (Van	  Gorp,	   Delputte	   et	   al.	   2010).	   Down	   regulation	   of	  
CD163	  by	  exposure	  to	  IFN-­‐γ	  and	  TNF-­‐α	  and	  induction	  from	  glucocorticoids,	  IL-­‐6	  and	  IL-­‐
10	  implies	  its	  expression	  relates	  to	  Mφ	  subsets	  known	  as	  “alternatively	  activated”	  (or	  
M2)	  (Van	  Gorp,	  Delputte	  et	  al.	  2010)	  rather	  than	  “classically	  activated”	  (M1)	  Mφs	  (see	  
Chapter	   1).	   In	   accordance	   with	   this,	   IL-­‐10	   secretion	   resulting	   from	   CD163-­‐mediated	  
internalisation	   of	   Hb-­‐Hp	   indicates	   an	   anti-­‐inflammatory	   role	   for	   CD163	   (Philippidis,	  
Mason	   et	   al.	   2004).	   However,	   antibody-­‐mediated	   cross-­‐linking	   of	   CD163	   as	   well	   as	  
bacterial	  ligation	  have	  been	  shown	  to	  induce	  secretion	  of	  pro-­‐inflammatory	  cytokines	  
(Polfliet,	   Fabriek	   et	   al.	   2006;	   Fabriek,	   van	   Bruggen	   et	   al.	   2009).	   These	   data	   point	   to	  
CD163	  exerting	  both	  pro-­‐	  and	  anti-­‐inflammatory	  functions	  in	  vivo.	  	  
With	  constitutive	  expression	  on	  monocytes	  making	  CD163	  not	  a	  strictly	  Mφ-­‐restricted	  
antigen,	   it	   can	   be	   argued	   that	   its	   targeting	   permits	   the	   tracking	   of	   myeloid	   cells.	  
However,	  the	  significant	  upregulation	  of	   it	   in	  mature	  Mφs	  as	  compared	  to	  circulating	  
monocytes	  may	  not	  preclude	  it	  from	  functioning	  as	  essentially	  a	  Mφ-­‐specific	  antigen.	  
Where	  clinically	  CD163	  Mφs	  have	  been	  identified	  in	  a	  variety	  of	  pathologies,	  including	  
atherosclerotic	  plaques	   (Johnson	  and	  Newby	  2009),	  multiple	  sclerotic	   lesions	   (Zhang,	  
Zhang	  et	  al.	  2011)	  as	  well	  as	  present	  on	  TAMs	  (Pettersen,	  Fuentes-­‐Duculan	  et	  al.	  2011),	  
there	  is	  clearly	  an	  imperative	  for	  assessing	  Mφ	  presence	  using	  this	  marker.	  
	  
5.2 Materials	  and	  Methods	  
5.2.1 ED2	  Hybridoma	  	  
Anti-­‐rat	  Sn	  ED2	  antibody	  was	  isolated	  as	  previously	  described	  using	  the	  ED2	  hybridoma	  
(Dijkstra,	  Dopp	  et	  al.	  1985)	  which	  was	  acquired	  from	  HPACC	  (UK).	  Cells	  were	  grown	  in	  
1640	   RPMI	   (Sigma,	   Poole,	   UK)	   supplemented	   with	   pen/strep	   (Invitrogen)	   and	   IgG	  
depleted	   FBS	   (Source	   Bioscience	   UK	   Ltd,	   Nottingham,	   UK).	   8	   x	   106	   cells	   were	  
suspended	  in	  5	  then	  transferred	  to	  a	  Celline	  CL350	  flask	  (Integra	  Biosciences	  AG).	  Cells	  
were	  pelleted	  every	  7	  days,	  the	  supernatant	  harvested	  with	  the	  pellet	  resuspended	  1:4	  





5.2.2 ED2	  and	  ED3	  Purification	  
ED3	  ascites	  was	  a	  gift	   from	  C.D.	  Dijkstra	   (VU	  University	  Medical	  Centre,	  Amsterdam,	  
Netherlands).	   Excess	   lipoprotein	   was	   removed	   from	   ascites	   by	   dextran	   sulphate	  
precipitation	   in	   the	   presence	   Ca2+	   ions	   to	   prevent	   column	   degradation	   (Amersham	  
Handbook	  of	  Protein	  Purification).	  0.32	  mL	  of	  10%	  dextran	   sulphate	   solution	   (Sigma,	  
Gillingham,	  UK)	  and	  8	  mL	  of	  1	  M	  CaCl2	  (Sigma,	  Gillingham,	  UK)	  were	  added	  to	  8	  mL	  of	  
ED3	  ascites	  and	  left	  for	  15	  min.	  The	  mixture	  was	  centrifuged	  at	  10,000	  x	  g	  for	  10	  min	  
and	  the	  supernatant	  collected.	  
	  5	   mL	   of	   supernatant	   from	   ED2	   hybridoma	   or	   lipoprotein-­‐depleted	   ED3	   ascites	   was	  
diluted	  in	  5	  mL	  binding	  buffer	  (20	  mM	  sodium	  phosphate,	  pH	  7.0)	  and	  passed	  through	  
a	   0.22	  µm	   filter.	   Filtrate	  was	   loaded	  on	   to	   a	   5	  mL	  HiTrap	   Protein	  G	  HP	   column	   (GE,	  
Amersham,	  UK)	  then	  washed	  with	  10	  column	  volumes	  of	  binding	  buffer.	  Antibody	  was	  
eluted	  with	   0.1	  M	   glycine-­‐HCl,	   pH	   2.7,	   collected	   in	   2.5	  mL	   fractions	   and	   neutralised	  
with	   200	   µL	   of	   1	   M	   Tris.HCl,	   pH	   9.0.	   Protein	   concentration	   was	   determined	   by	  
measuring	  OD280	  using	  a	  Biophotometer	  (Eppendorf,	  Cambridge,	  UK).	  Protein	  fractions	  
were	  transferred	  to	  dialysis	  cassettes	  (Thermofisher,	  Loughborough,	  UK)	  and	  dialysed	  
in	   PBS	   with	   3	   buffer	   exchanges.	   Antibody	   was	   then	   concentrated	   using	   Vivaspin	  
columns	   (Sartorius	   Stedim,	   Epsom,	   UK)	   to	   10	   mg/mL.	   Protein	   fractions	   were	   then	  
analysed	  by	  reduced	  and	  non-­‐reduced	  SDS	  PAGE	  gel	  (200	  V,	  120	  A,	  50	  min)	  Gels	  were	  
then	   stained	   with	   SimplyBlue	   Safe	   Stain	   (Invitrogen,	   Paisley,	   UK)	   for	   45	   minutes	  
followed	  by	  3	  washes	  with	  deionised	  water.	  
	  
5.2.3 Immunohistochemistry	  
Spleens	  from	  8	  week	  old	  male	  Wistar	  rats	  were	  harvested,	  embedded	  in	  OCT	  (RA	  Lamb	  
Ltd,	  Eastbourne,	  UK)	  and	  snap	  frozen	   in	   liquid	  nitrogen.	  Tissue	  was	  then	  cut	  at	  5	  µm	  
using	  a	  Brightwater	  Cryostat	  (Bright	  Instruments,	  Huntingdon,	  UK)	  and	  mounted	  onto	  
polylysine	  slides	  (Thermofisher,	  Loughborough,	  UK).	  Sections	  were	  air	  dried	  overnight,	  
transferred	  to	  50	  mL	  falcon	  tubes	  (BD	  Biosciences)	  then	  stored	  at	  –	  80°C	  until	  staining.	  
For	  staining,	  sections	  were	  taken	  from	  freezer	  and	  left	  at	  room	  temperature	  for	  10	  min	  
before	   removing	   from	   falcon	   tube.	   Sections	  were	   immersed	   in	   chilled	   acetone	   for	   5	  




incubated	   overnight	   with	   either	   ED2	   or	   ED3	   (1	   µg/mL),	   followed	   by	   anti-­‐mouse	   Fc	  
AlexaFluor-­‐480	  (1:200,	  1	  h,	  AbD	  Serotec,	  Oxon,	  UK).	  Slides	  were	  washed	  then	  mounted	  
in	  VectaShield	  with	  DAPI	  (Vector	  Labs).	  Images	  were	  captured	  using	  a	  Leica	  Leitz	  DMRB	  
research	  microscope	  and	  ExiBlue	  camera.	   Images	  were	  analysed	  with	   Image-­‐Pro	  Plus	  
7.0	  software	  from	  Media	  Cybernetics	  and	  Photoshop.	  
	  
5.2.4 Preparation	  of	  ED2-­‐CHX-­‐A’’-­‐DTPA	  
Ethylenediaminetetraacetic	  acid	  (EDTA,	  50	  mM,	  25	  µL)	  was	  added	  to	  ED2	  antibody	  (3	  
mg)	  in	  PBS	  (250	  µL)	  and	  incubated	  at	  room	  temperature	  for	  30	  min.	  The	  solution	  was	  
transferred	  to	  an	  ultracentrifugation	  tube	  (Vivaspin	  2,	  30,000	  MWCO,	  PES	  membrane)	  
and	  the	  buffer	  exchanged	  to	  0.1	  M	  HEPES	  buffer,	  pH	  8.9	  by	  washing	  three	  times	  with	  
HEPES	  buffer.	  	  
N-­‐[(R)-­‐2-­‐Amino-­‐3-­‐(p-­‐isothiocyanato-­‐phenyl)	   propyl]-­‐trans-­‐(S,S)-­‐	   cyclohexane-­‐1,2-­‐
diamine-­‐N,N,N’,N”,N”-­‐pentaacetic	   acid	   (CHX-­‐A”-­‐DTPA)	   (0.4	  mg)	   in	  DMSO	   (40	  µL)	  was	  
added	  to	  the	  ED2	  solution	  (400	  µL)	  and	  the	  conjugation	  allowed	  to	  proceed	  at	  room	  
temperature	  for	  3	  h	  then	  overnight	  at	  4°C.	  Buffer	  exchange	  was	  then	  performed	  with	  
0.1	   M	   ammonium	   acetate,	   pH	   6	   and	   the	   final	   solution	   concentrated	   (5	   mg/mL).	  
Conjugation	  was	  assisted	  by	  Dr.	  MS	  Cooper.	  
	  
5.2.5 Radiolabelling	  ED2-­‐CHX-­‐A’’-­‐DTPA	  
111InCl3	  in	  0.05	  M	  HCl	  (Covidien,	  Petten,	  Netherlands)	  was	  added	  (47	  MBq,	  114	  µL)	  to	  
ED2-­‐CHX-­‐A”-­‐DTPA	   in	   ammonium	   acetate	   (120	  µL,	   2	  mg/mL)	   and	   incubated	   at	   room	  
temperature	   for	   20	   min.	   The	   radiolabelled	   antibody	   was	   analysed	   by	   size	   exclusion	  
HPLC	   by	   size	   exclusion	   HPLC	   using	   a	   BioSep	   SEC-­‐S-­‐2000	   column	   (Phenomenex,	  
Macclesfield,	  UK)	  with	  an	  isocratic	  mobile	  phase	  of	  0.1	  M	  phosphate	  buffer	  containing	  
2	   mM	   EDTA,	   pH	   7	   and	   a	   flow	   rate	   of	   1	   mL/min.	   The	   retention	   time	   of	   the	  
radioimmunoconjugate	  was	   typically	   7	  min	   and	   that	   of	   the	   unbound	   111In	   impurities	  





5.2.6 Preparation	  of	  99mTc-­‐ED3	  
200	  µL	  of	  protein	  G-­‐purified	  ED3	  (10	  mg/mL,	  PBS)	  was	  incubated	  with	  2µL	  of	  14.3	  M	  2-­‐
mercaptoethanol	   (Sigma	   Aldrich,	   Poole,	   UK)	   for	   30	   min	   at	   room	   temperature.	   The	  
solution	  was	  transferred	  to	  a	  PD	  MiniTrap	  G-­‐10	  column	  (GE,	  Chalfont	  St.	  Giles,	  UK)	  and	  
eluted	  with	  degassed	  PBS.	  0.2	  mL	  fractions	  were	  collected	  and	  OD280	  determined	  using	  
a	  BioPhotometer	  (Eppendorf,	  Cambridge,	  UK).	  Fractions	  with	  an	  OD280	  >5	  mg/mL	  were	  
pooled,	   aliquoted	   into	  20	  µL	   fractions,	   snap-­‐frozen	   in	   liquid	  nitrogen	  and	   stored	  at	   -­‐
80C	  until	  further	  use.	  
For	  radiolabelling,	  5	  µL	  of	  a	  reconstituted	  MDP	  kit	  (Medronate	  Draximage,	  Draxis,	  USA)	  
was	  added	  to	  20	  µL	  of	   freshly	  thawed	  reduced	  ED3,	   followed	  by	  200	  MBq	  of	  sodium	  
pertechnetate	  Tc-­‐99m	  in	  between	  20	  to	  40	  µL	  saline	  (kindly	  provided	  by	  Department	  
of	  Nuclear	  Medicine	  at	  Guys	  Hospital	  UK)	  then	  incubated	  at	  room	  temperature	  for	  15	  
min.	   Labelling	  efficiency	  was	  measured	  using	   thin	   layer	   chromatography	   strips	   (ITLC-­‐
SA)	   (Varian	   Medical	   Systems	   UK,	   Ltd.,	   Crawley,	   UK)	   with	   a	   mobile	   phase	   of	   0.1	   M	  
citrate	   buffer,	   pH	   5	   and	   analysed	   using	   a	   gamma-­‐ray	   TLC	   scanner	   (Lablogic,	   UK).	  
Labelling	   efficiency	   was	   assessed	   also	   by	   HPLC-­‐SEC	   using	   a	   BioSep	   SEC-­‐300	   column	  
(Phenomenex,	  Macclesfield,	  UK)	  with	  an	  isocratic	  mobile	  phase	  of	  100	  mM	  phosphate	  
buffer,	  pH	  7.0,	  at	  a	  flow	  rate	  of	  1	  mL/min	  and	  in-­‐line	  gamma	  detector	  (Lablogic,	  UK).	  	  
	  
5.2.7 ED2-­‐DTPA-­‐111In	  and	  99mTc-­‐ED3	  Serum	  Stability	  
10	  MBq	  of	  ED2-­‐DTPA-­‐111In	  and	  50	  MBq	  of	  99mTc	   labelled	  ED3	  were	  added	  to	  AB	  type	  
human	   serum	   (Sigma)	   or	   PBS	   (Gibco)	   at	   1:4	   v/v	   and	   incubated	   at	   37	   °C	   for	   20	   h.	  
Samples	  were	  analysed	  at	  0,	  3,	  6	  and	  20h	  by	  HPLC-­‐SEC	  using	  a	  BioSep	  SEC-­‐300	  column	  
(Phenomenex,	  Macclesfield,	  UK)	  with	  an	  isocratic	  mobile	  phase	  of	  100	  mM	  phosphate	  
buffer,	  pH	  7.0,	  at	  a	  flow	  rate	  of	  1	  mL/min	  and	  in-­‐line	  gamma	  detector	  (Lablogic,	  UK).	  
Serum	  stability	  was	  calculated	  as	  the	  area	  under	  the	  antibody-­‐bound	  activity	  peaks	  as	  





5.2.8 In	  vivo	  Imaging	  and	  Biodistribution	  of	  ED2-­‐DTPA-­‐111In	  and	  99mTc-­‐ED3	  
Imaging	   was	   performed	   using	   a	   nanoSPECT/CT	   small	   animal	   scanner	   (Bioscan	   Inc.,	  
Washington,	   USA)	   SPECT	   images	   were	   obtained	   using	   a	   4-­‐head	   scanner	   with	   1	  mm	  
pinhole	  collimators.	  Helical	  acquisitions	  were	  performed	  with	  24	  projections	  with	  the	  
time	   per	   projection	   adjusted	   so	   as	   to	   make	   overall	   scan	   time	   equal	   to	   45	   min.	   CT	  
images	  were	  obtained	  using	  45	  KVp	  X-­‐ray	  source,	  set	  with	  a	  500	  ms	  exposure	  time	  in	  
180	   projections	   lasting	   approximately	   10	   min.	   Images	   were	   reconstructed	   using	  
proprietary	  BioScan	  InVivoScope	  (IVS)	  software.	  	  
Adult	  male	  rats	  (Wistar,	  8	  –	  10	  weeks)	  were	  injected	  IV	  under	  anaesthesia	  (isoflurane,	  
VetOne,	  UK)	  with	  approximately	  2MBq	  ED2-­‐DTPA-­‐111In	  and	  50MBq	  99mTc-­‐ED3	  in	  500	  µL	  
(approx.	  1	  mg/mL;	  n	  =	  3).	  Each	  was	  recovered,	  culled	  at	  3	  h	  then	  imaged	  immediately.	  
After	  imaging	  standard	  biodistributions	  were	  performed.	  
Syringes	   (25G	  X	  16mm,	  Terumo)	  were	  weighed	  before	  and	  after	   injection,	  and	  serial	  
dilutions	  of	  1:4	  were	  performed	  with	  a	  starting	  100	  µL	  stock	  solution	  (containing	  both	  
ED2-­‐DTPA-­‐111In	  and	  99mTc-­‐ED3).	  After	  culling	  according	  to	  schedule	  1,	  the	  animals	  were	  
dissected	   and	   the	   following	   organs	   harvested:	   intestines,	   stomach,	   spleen,	   liver,	  
kidney,	   heart,	   lungs,	   blood	   (20	   µL),	  muscle,	   bone	   and	   tail.	   The	   tissue	   samples	   were	  
weighed	   and	   radioactivity	   counted	   using	   a	   gamma	   counter	   (LKB	   Wallac,	   Finland)	  
alongside	   standards.	   Both	   In-­‐111	   emission	   windows	   (110-­‐155,	   170-­‐185)	   were	  
measured	  at	  day	  1	  and	  at	  day	  4	  post-­‐experiment.	  Contribution	  of	  In-­‐111	  signal	  to	  Tc-­‐
99m	   emission	   was	   back	   calculated	   from	   day	   4	   counts	   and	   used	   to	   correct	   Tc-­‐99m	  
signal	  at	  day	  1.	  Injected	  dose	  was	  then	  calculated	  for	  each	  isotope	  from	  total	  activity	  in	  
each	  injected	  syringe	  minus	  activity	  counted	  in	  tail,	  and	  presented	  as	  the	  percentage	  of	  
injected	  dose	  per	  gram	  (%ID/g)	  of	  each	  tissue	  sample.	  
	  
5.2.9 Statistics	  
Uptake	   values	   were	   analysed	   for	   significance	   using	   a	   paired,	   2-­‐tail	   Student’s	   T	   test,	  





5.3.1 ED2	  and	  ED3	  Purification	  
ED2	  and	  ED3	  antibodies	  (against	  antigens	  CD163	  and	  Sn,	  respectively)	  were	  purified	  via	  
Protein	  G	   from	   culture	   supernatant	   of	   ED2	  hybridoma	   grown	   in	   IgG	  depleted	  media	  
and	   ED3	   ascites.	   Purified	  protein	  was	   of	   approximately	   150	   kDa	   (lanes	   2	   and	  4)	   and	  
following	   reduction	   showed	   fragmentation	  pattern	  characteristic	  of	   IgG	  with	  75	  kDa,	  
50	  kDa,	  25	  kDa	  bands	   (see	  Figure	  5.1).	  For	  ED2	  hybridoma,	  yields	  of	  between	  9	  –	  12	  
mg/L	  of	  unsupplemented	  media	  were	   recovered,	  whilst	  of	  8	  mL	  ED3	  ascites	  2	  mg	  of	  
antibody	  was	  recovered.	  
	  
Figure	  5.1	  Reduced	  and	  non-­‐reduced	  Protein	  G	  purified	  ED2	  and	  ED3.	  Antibody	  was	  isolated	  
from	   hybridoma	   supernatant	   (ED2)	   and	   ascites	   (ED3)	   using	   a	   Protein	   G	   column.	   Purified	  
antibodies	  were	   run	  as	  non-­‐reduced	   (ED2	   lane	  1;	  ED3	   lane	  3)	  and	   reduced	   (ED2	   lane	  2;	  ED3	  
lane	  4)	  on	  SDS-­‐PAGE.	  
	  
5.3.2 Immunohistochemistry	  
Purified	   antibodies	   were	   assayed	   for	   functioning	   by	   staining	   endogenously	   Sn	   and	  
CD163-­‐expressing	   splenic	   tissue.	   ED2	   heavily	   stained	   the	   red	   pulp	   (as	   distinguished	  
from	  the	  white	  pulp	  by	  less	  cell	  numbers/nuclearity	  evidenced	  by	  DAPI	  –	  see	  Figure	  5.2	  
A)	  whereas	  ED3	  localised	  with	  cells	  lining	  the	  periphery	  of	  the	  white	  and	  red	  pulp	  with	  







Figure	   5.2	   ED2	   and	   ED3	   staining	   of	   spleen.	   Rat	   spleens	  were	   incubated	  with	   ED2	   and	   ED3	  	  
overnight,	   followed	  by	  a	   fluorescent	   secondary	   (A	  and	  D	   for	   ED2	  and	  ED3,	   respectively)	   and	  
mounted	  with	   DAPI	  mountant	   (B	   and	   E	   for	   ED2	   and	   ED3,	   respectively).	   ED2	   antibody	   stains	  
Mφs	   heavily	   in	   the	   red	   pulp	   which	   can	   be	   distinguished	   from	   white	   pulp	   by	   less	   cell	  
numbers/nuclearity	   (identified	  by	  DAPI).	   ED3	  antibody	   identifies	  Mφs	  bordering	   the	   red	   and	  
white	   pulp	   regions,	   forming	   characteristic	   elliptical	   structures	   in	   the	   spleen.	   Merged	  
fluorophore	   and	   DAPI	   images	   are	   presented	   in	   panels	   C	   and	   F	   (ED2	   and	   ED3,	   respectively).	  
Magnification	  of	  50x	  for	  A	  to	  C,	  100x	  for	  D	  to	  F.	  
	  
5.3.3 Preparation	  of	  ED2-­‐CHX-­‐A’’-­‐DTPA-­‐111In	  
ED2	   was	   reacted	   with	   CHX-­‐A’’-­‐DTPA	   and	   radiolabelling	   of	   the	   resulting	  
immunoconjugate	   assessed	   by	   SEC	   radioHPLC.	   After	   20	  min	   incubation	   with	   111InCl3	  
100%	  of	  radioactivity	  is	  found	  associated	  with	  the	  antibody	  as	  shown	  by	  single	  peak	  in	  
radioHPLC	   chromatogram	   with	   a	   retention	   time	   of	   7	   min	   20s	   (see	   Figure	   5.3).	   The	  
column	  was	  inspected	  for	  residual	  activity	  using	  a	  geiger	  counter	  (900	  Series,	  Thermo	  
Fisher	  Scientific,	  UK)	  to	  assay	  qualitatively	  any	  activity	  trapped	  on	  the	  column.	  Column	  






Figure	   5.3	   Radiolabelling	   ED2-­‐CHX-­‐A’’-­‐DTPA.	   The	   immunoconjugateED2-­‐	   CHX-­‐A’’-­‐DTPA	   was	  
labelled	  with	  111In	  and	  analysed	  by	  SEC	  radioHPLC.	  All	  activity	  was	  associated	  with	  antibody	  (t	  =	  
7	  min	  20s	  –	  (A))	  and	  111InCl3	  signal	  absent	  (t	  =	  11	  min	  30	  sec	  -­‐	  (B)).	  
	  
5.3.4 Preparation	  of	  99mTc-­‐ED3	  
ED3	   was	   partially	   reduced	   by	   incubation	   with	   2-­‐mercaptoethanol,	   stored	   in	   frozen	  
aliquots	   then	   radiolabelling	   performed	   by	   addition	   of	   pertechnetate	   with	   freshly	  
reconstituted	   MDP	   kit.	   Radiolabelling	   was	   assessed	   by	   SEC	   radioHPLC	   with	   PBS	   as	  
eluent	  and	  ITLC	  using	  citrate	  buffer	  (pH	  5,	  0.1	  M).	  SEC	  radioHPLC	  recorded	  three	  peaks	  
with	   97%	  of	   activity	   eluted	   at	   7	  min	   20	   sec,	   corresponding	   to	   antibody	   fraction,	   2%	  
activity	  eluted	  at	  10	  min	  45	  sec	   (representing	  either	  radiolabelled	  antibody	   fragment	  
or	   2-­‐ME	   chelated	   activity),	   and	   1%	   activity	   at	   17	  min	   20	   sec,	   corresponding	   to	   free	  
pertechnetate	  (see	  Figure	  5.4	  A).	  ITLC	  shows	  98%	  activity	  associated	  with	  protein	  (Rf	  =	  
0)	  and	  2%	  as	  unbound	  (either	  free	  or	  colloidal	  –	  see	  Figure	  5.4	  B),	  corresponding	  to	  a	  





Figure	  5.4	  Direct	  labelling	  of	  ED3.	  Following	  disulphide	  reduction,	  ED3	  was	  labelled	  with	  99mTc.	  
Samples	   were	   injected	   on	   a)	   SEC	   radioHPLC	   showing	   elution	   of	   majority	   activity	   with	   the	  
antibody	  (t	  =	  7	  min	  20	  sec,	  97%)	  and	  two	  minor	  peaks	  (t	  =	  10	  min	  45	  sec,	  2%;	  t	  =	  17	  min	  20	  sec,	  
1%).	  B)	  ITLC	  showed	  the	  presence	  of	  radiolabelled	  protein	  (Rf	  =	  0,	  98%)	  and	  free	  pertechnetate	  
(Rf=1,	  2%).	  
	  
5.3.5 111In-­‐CHX-­‐A’’-­‐DTPA-­‐ED2	  and	  99mTc-­‐ED3	  Serum	  Stability	  
99mTc-­‐ED3	   was	   incubated	   in	   the	   presence	   of	   serum	   or	   PBS	   overnight	   and	   stability	  
assayed	   by	   SEC	   radioHPLC.	   In	   the	   presence	   of	   PBS	   alone,	   ED2-­‐CHX-­‐A’’-­‐DTPA-­‐111In	  
shows	  increased	  dissociation	  over	  time	  (from	  96%	  to	  86%	  labelled	  protein	  over	  20	  h),	  
however	  not	  as	  markedly	  as	  directly	   labelled	  ED3	   (from	  90%	  to	  75%	   labelled	  protein	  
over	  20	  h	  -­‐	  see	  Table	  5.5)	  indicating	  the	  greater	  stability	  of	  the	  immunoconjugate.	  Both	  
radiolabelled	   antibodies	   demonstrate	   similar	   stability	   in	   the	   presence	   of	   serum.	  
Example	   traces	   of	   both	   antibodies	   at	   20	   h	   in	   the	   presence	   of	   serum	   or	   PBS	   are	  








Figure	   5.5	   Serum	   stability	   of	   ED2-­‐DTPA-­‐111In	   and	   99mTc-­‐ED3.	   Antibodies	   were	   labelled	  
according	   to	   2.3.3,	   incubated	   in	   either	   mouse	   serum	   or	   PBS	   and	   stability	   assessed	   by	   SEC	  
radioHPLC.	   Percentage	   bound	  was	   assessed	   by	   comparison	   of	   bound	   activity	   to	   that	   of	   free	  
activity	  peaks.	  
	  
Figure	  5.6	   SEC	   radioHPLC	  analysis	  of	   ED2-­‐DTPA-­‐111In	  and	   99mTc-­‐ED3	   serum	  stability	   at	   20	  h.	  
Both	  antibodies	  were	  incubated	  in	  the	  presence	  of	  PBS	  (99mTc-­‐ED3	  =	  A;	  ED2-­‐DTPA-­‐111In	  =	  B)	  or	  
serum	  (99mTc-­‐ED3	  =	  C;	  ED2-­‐DTPA-­‐111In	  =	  D)	   for	  20	  h	  at	  37°C	  then	   injected	   into	  SEC	  radioHPLC	  
system.	  Percentage	  bound	  was	  assessed	  by	  comparison	  of	  bound	  activity	  (integral	  of	  7	  min	  10	  
sec	  and	  6	  min	  45	  sec	  peaks	  for	  ED2	  and	  ED3,	  respectively)	  to	  that	  of	  free	  activity	  (integral	  of	  10	  































5.3.6 In	  vivo	  ED2-­‐CHX-­‐A’’-­‐DTPA-­‐111In	  and	  99mTc-­‐ED3	  
Rats	  were	  culled	  3	  h	  post	  injection	  of	  ED2-­‐CHX-­‐A’’-­‐DTPA-­‐111In	  and	  99mTc-­‐ED3	  followed	  
by	   whole	   body	   imaging	   performed	   using	   nanoSPECT/CT.	   Imaging	   revealed	   co-­‐
localisation	  of	  ED2	  and	  ED3	  in	  the	  spleen	  and	  liver,	  with	  ED2	  additionally	  accumulating	  
in	  the	  bone.	  99mTc	  was	  also	  observed	  in	  the	  bladder	  (see	  Figure	  5.7).	  	  
	  
Figure	  5.7	  Simultaneous	  nanoSPECT/CT	  imaging	  of	  ED2-­‐CHX-­‐A’’-­‐DTPA-­‐111In	  and	  99mTc-­‐ED3	  
in	  a	  wistar	   rat.	  Rat	  injected	  IV	  with	  ∼2	  MBq	  ED2-­‐CHX-­‐A’’-­‐DTPA-­‐111In	  and	  ∼50	  MBq	  99mTc-­‐ED3	  
then	   imaged	  at	  3	  h	  post	   injection.	   (A)	  ED2-­‐CHX-­‐A’’-­‐DTPA-­‐111In	  signal;	   (B)	   99mTc-­‐ED3	  signal;	   (C)	  
Fused	   ED2-­‐CHX-­‐A’’-­‐DTPA-­‐111In	   and	   99mTc-­‐ED3	   signal.	   Upper	   panel:	   whole	   body	   acquisition,	  
lower	  panel:	  pelvis	  acquisition.	  
Biodistributions	  were	  performed	  on	  animals	   culled	  at	  3	  h	  post	   injection	  of	  ED2-­‐CHX-­‐
A’’-­‐DTPA-­‐111In	  and	  99mTc-­‐ED3	  (see	  Figure	  5.8).	  Both	  111In	  and	  99mTc	  showed	  comparable	  
accumulation	   in	   the	   spleen,	   liver,	   bone	   and	   heart.	   99mTc	   additionally	   showed	  
significantly	  higher	  accumulation	  in	  the	  kidney	  (p	  <	  0.001),	  lungs	  (p	  =	  0.013),	  urine	  (p	  =	  










Figure	  5.8	  Biodistribution	  of	   ED2-­‐CHX-­‐A’’-­‐DTPA-­‐111In	   and	  99mTc-­‐ED3	   in	   8	  week	  old	  wistar	  
rats	   (n=3).	  Rats	  were	   injected	   IV	   into	   the	   tail	  vein	  with	  ∼2  MBq   ED2-­‐CHX-­‐A’’-­‐DTPA-­‐111In	  and	  ∼50	  MBq	  99mTc-­‐ED3	  then	  culled	  at	  3	  h	  post	  injection.	  Organs	  harvested,	  weighed	  and	  gamma	  
counted.	  Radioactive	  uptake	  in	  organs	  is	  presented	  as	  the	  percentage-­‐injected	  dose	  per	  gram	  
per	  organ.	  A:	  Full	  biodistribution.	  B:	  Rescaled	  to	  a	  max	  of	  10	  %ID/g	  of	  A	  to	  see	  biodistribution	  
of	  lower	  activity	  organs	  (error	  represents	  a	  standard	  deviation	  of	  n	  =	  3)	  
Organ-­‐to-­‐blood	  ratios	  (see	  Figure	  5.9)	  showed	  significantly	  elevated	  uptake	  of	  ED2	   in	  
spleen	   (p	   =	   0.030)	   and	   bone	   (p	   =	   0.041)	   as	   compared	   to	   ED3	   and	   higher,	   albeit	   not	  







































Figure	   5.9	   Organ-­‐to-­‐blood	   ratio	   of	   ED2-­‐CHX-­‐A’’-­‐DTPA-­‐111In	   and	   99mTc-­‐ED3	   in	   8	   week	   old	  
wistar	   rats	   (n=3).	   Representation	   of	   biodistribution	   data	   from	   figure	   6.7	   as	   organ-­‐to-­‐blood	  
ratio.	  A:	  full	  biodistribution,	  B:	  zoom	  of	  biodistribution	  to	  view	  low	  activity	  organs.	  
	  
5.4 Discussion	  
ED2	   hybridoma	   was	   grown	   using	   the	   Celline	   CL350	   system	   followed	   by	   Protein	   G	  
extraction	  resulted	  in	  yields	  comparable	  to	  the	  SER4	  hybridoma	  (see	  chapter	  2),	  whilst	  


























































function	  was	  assayed	   in	   vitro	  by	   immunohistochemistry,	  which	   confirmed	  binding	   to	  
discrete	  Mφ	   subpopulations	   in	   the	   spleen	   identified	   as	   red	   pulp	  Mφs	   and	  marginal	  
metallophilic	  Mφs	  for	  ED2	  and	  ED3,	  respectively	  (Dijkstra,	  Dopp	  et	  al.	  1985).	  
When	  deciding	  upon	  the	  radioisotope	  to	  label	  ED2	  with	  it	  was	  taken	  into	  account	  that	  
although	   endogenous	   CD163	   could	   provide	   an	   antigen	   sink	   for	   circulating	   ED2,	  
allowing	  imaging	  at	  a	  relatively	  earlier	  time	  point	  for	  an	  intact	  antibody	  (as	  with	  anti-­‐
CD169	  SER4	  antibody	   in	  mice	  –	   see	   chapter	  3)	   significant	  amounts	  of	   soluble	  CD163	  
(sCD163)	  could	  bind	  to	  ED2	  in	  the	  circulation	  and	  eliminate	  the	  endogenous	  sink	  effect	  	  
(Moller,	   Peterslund	   et	   al.	   2002).	   The	   preparation	   of	   111In-­‐labelled	   ED2	   permitted	  
imaging	  over	  several	  days	  so	  as	  to	  allow	  blood	  clearance	  of	  any	  sCD163-­‐bound	  ED2	  and	  
offered	   the	   chance	   to	   image	   99mTc-­‐labelled	   ED3	   simultaneously.	   Additionally,	   the	  
availability	  of	  established	  protocols	  in	  immunoconjugate	  production	  made	  preparation	  
routine	  (Cooper,	  Sabbah	  et	  al.	  2006).	  
The	  development	  of	   in	  vitro	  radiolabelling	  assays	  for	  ED2	  and	  ED3	  was	  obstructed	  by	  
the	   availability	   of	   rat	   ED2	   antigen	   (CD163)	   as	   well	   as	   the	   limited	   resource	   of	   ED3	  
antibody.	   As	   yet	   no	   recombinant	   form	  of	   rat	   CD163	   is	   available,	   nor	   has	   a	   cell	   type	  
been	  induced	  to	  express	  CD163.	  Preparation	  of	  affinity	  purified	  CD163	  using	  sepharose	  
column	   functionalised	   with	   ED2	   has	   been	   performed,	   however	   a	   low	   recovery	   of	  
approximately	   100	   µg	   antigen	   from	   60	   spleens	  was	   reported	   (Fabriek,	   Polfliet	   et	   al.	  
2007).	   Induction	   of	   ED3	   antigen	   (CD169)	   has	   been	   shown	   using	   the	  Mφ	   cell	   line	   R2	  
after	  incubation	  with	  dexamethasone	  and	  various	  cytokines	  (vandenBerg,	  vanDie	  et	  al.	  
1996).	  Due	  to	  limited	  amounts	  of	  ED3	  available	  it	  was	  decided	  to	  not	  pursue	  this	  cell	  
based	   assay.	   Based	   upon	   the	   behaviour	   of	   SER4	   in	   mice	   (see	   chapter	   3)	   it	   was	  
determined	   that	   an	   in	   vivo	   based	   assay	   could	   be	   performed,	   wherein	   uptake	   to	  
endogenous	  populations	  of	  Mφs	  (particularly	  in	  the	  spleen)	  would	  indicate	  functioning	  
of	  radiolabelled	  ED2	  and	  ED3.	  	  
Whole	   body	   imaging	   revealed	   antibody	   uptake	   as	   expected	   from	   histological	   data	  
(Dijkstra,	  Dopp	  et	  al.	  1985).	  ED2	  showed	  tracking	  to	  the	  spleen,	  liver	  and	  bone	  marrow	  
due	  to	  CD163	  expression	  by	  red	  pulp	  Mφs,	  Kupffer	  cells	  and	  RBMMs	  as	  the	  target	  cell	  




of	  mice	  (and	  humans)	   in	  that	   it	   is	  not	  endogenously	  expressed	  by	  RBMMs.	  Thus	  ED3	  
showed	  only	  uptake	   to	   the	   spleen	  and	   liver.	   In	   this	  way	  whole	  body	   imaging	  of	   ED2	  
more	   resembled	   the	   distribution	   pattern	   of	   SER4	   in	   mice	   than	   ED3	   in	   rats.	   To	   our	  
surprise,	   ED2-­‐DTPA-­‐111In	   did	   not	   display	   prolonged	   circulation	   time	   of	   conventional	  
radiolabelled	  IgG	  but	  instead	  exhibited	  rapid	  blood	  clearance	  similar	  to	  that	  of	  anti-­‐Sn	  
antibodies	   (i.e.	   ED3	  and	  SER4).	   The	   levels	  of	   circulating	   sCD163	   in	   rats	  has	  not	  been	  
determined,	   so	   this	   effect	   may	   represent	   an	   absence	   of	   circulating	   sCD163	   or	  
alternatively	  it	  may	  be	  that	  ED2	  is	  raised	  to	  an	  epitope	  outside	  of	  sCD163	  structure	  but	  
instead	  located	  on	  the	  membrane	  bound,	  extracellular	  portion	  of	  CD163.	  
Additionally	  the	  choice	  of	  radiolabel	  can	  influence	  targeting	  properties	  and	  distribution	  
of	  activity.	  Non-­‐specific	  hepatic	  uptake	  by	  of	  immunoconjugates	  is	  a	  clinically	  relevant	  
feature	   that	   limits	   the	   use	   of	   radiolabelled	   antibodies	   in	   imaging	   disease	   processes	  
involving	   the	   liver	   (Bander,	   Trabulsi	   et	   al.	   2003;	   Bhattacharyya	   and	   Dixit	   2011).	  
Although	   the	   exact	   nature	   of	   this	   uptake	   has	   yet	   to	   be	   elucidated,	   both	   antibody	  
(Morris,	   Divgi	   et	   al.	   2005)	   and	   radioisotope-­‐specific	   (Vallabhajosula,	   Kuji	   et	   al.	   2005)	  
effects	  have	  been	  shown	  to	  influence	  this	  uptake.	  In	  this	  way,	  ED2-­‐DTPA-­‐111In	  imaging	  
exhibits	  non-­‐specific	  as	  well	  as	  specific	  uptake	  (mediated	  by	  the	  radiolabel	  and	  target	  
antigen	  on	  Kupffer	  cells,	  respectively)	  to	  the	  liver,	  confounding	  the	  amount	  of	  specific	  
uptake	  in	  this	  organ.	  Use	  of	  a	  directly	  labelled	  antibody,	  as	  with	  ED3,	  would	  avoid	  this	  
uptake	   and	   instead	   result	   in	   accumulation	   of	   activity	   in	   the	   bladder.	   This	   effect	   is	  
thought	  to	  be	  due	  to	  transchelation	  to	  cysteine	  in	  the	  bladder,	  which	  has	  the	  benefit	  of	  
decreasing	  blood	  pool	  activity	  (see	  Chapter	  3),	  and	  is	  observed	  in	  the	  imaging	  of	  99mTc-­‐
ED3.	  
The	  distribution	  patterns	  of	  ED2	  and	  ED3	  in	  the	  liver	   indicate	  apparent	  heterogenous	  
localisation	   of	   their	   respective	   Mφ	   populations,	   as	   illustrated	   by	   99mTc-­‐ED3	   signal	  
observed	   from	   regions	  absent	   from	  ED2-­‐DTPA-­‐111In.	   Similarly,	   faint	   99mTc-­‐ED3	  can	  be	  
seen	   in	   the	   femoral	   and	   tibial	   space,	   whereas	   distinct	   signal	   is	   observed	   from	   ED2-­‐
DTPA-­‐111In	   in	   these	  regions.	  This	   is	  consistent	  with	   the	  presence	  and	  absence	  of	  ED2	  
and	  ED3	  positive	  Mφs	  (respectively)	  from	  the	  bone	  marrow	  (see	  above)	  but	  also	  with	  
the	  same	  pattern	  observed	  in	  synovial	  lining	  of	  the	  joint	  space	  (Verschure,	  Vannoorden	  




Biodistribution	  data	  reproduced	  the	  expected	  distribution	  pattern	  with	  highest	  %ID/g	  
for	   spleen	   then	   liver	   for	  both	  ED2-­‐DTPA-­‐111In	  and	   99mTc-­‐ED3.	  Raw	  %ID/g	  values	  were	  
similar	  for	  both	  ED2-­‐DTPA-­‐111In	  and	  99mTc-­‐ED3	  in	  the	  spleen.	  With	  ED3	  absent	  from	  this	  
compartment	  coupled	  with	  imaging	  data	  that	  indicated	  no	  specific	  uptake	  in	  the	  bone	  
marrow	  by	   99mTc-­‐ED3	  whereas	  ED2-­‐DTPA-­‐111In	   showed	  definite	  uptake,	   the	   influence	  
of	  contaminating	  blood	  pool	  was	  taken	  into	  consideration.	  With	  approximately	  a	  two	  
fold	   increase	   of	   blood	   pool	   for	   99mTc-­‐ED3	   compared	   to	   ED2-­‐DTPA-­‐111In	   (in	   line	   with	  
greater	  antigen	  sink	   for	  ED2)	   it	  was	   reasoned	  more	  perfused	  organs	   (such	  as	  spleen,	  
liver	   and	   bone	   marrow)	   would	   exhibit	   higher	   levels	   of	   non-­‐specific	   uptake	   due	   to	  
contaminating	  blood	  pool	  signal.	  Representing	  biodistribution	  data	  as	  organ-­‐to-­‐blood	  
ratios	   revealed	   significantly	   higher	   specific	   uptake	   of	   ED2-­‐DTPA-­‐111In	   compared	   to	  
99mTc-­‐ED3	  in	  the	  spleen,	  which	  is	  in	  line	  with	  the	  relative	  abundances	  of	  CD163	  and	  Sn	  
positive	  Mφs	   in	   the	   spleen	   (Dijkstra,	   Dopp	   et	   al.	   1985).	   Additionally,	   organ-­‐to-­‐blood	  
ratios	  identified	  the	  significantly	  higher	  uptake	  of	  ED2-­‐DTPA-­‐111In	  in	  the	  bone,	  which	  is	  
expected	  because	  of	  expression	  of	  CD163	  but	  not	  Sn	  in	  rat	  bone	  marrow	  Mφs.	  
	  
5.5 Summary	  
In	   this	   chapter	   the	   development	   of	   two	   anti-­‐Mφ	   imaging	   agents	   based	   upon	   the	  
antibodies	   ED2	   (anti-­‐CD163)	   and	   ED3	   (anti-­‐CD169,	   Sn)	   was	   reported.	   The	   imaging	  
agents	   were	   designed	   to	   include	   orthogonal	   isotopes	   to	   permit	   the	   simultaneous	  
imaging	  of	  two	  different	  Mφ	  cell	  populations	  simultaneously.	  Due	  to	  time	  constraints	  
and	  resources	   in	  vitro	   characterisation	  of	  both	  radiotracers	  was	   limited,	  with	  binding	  
validated	  by	  in	  vivo	  tracking	  to	  target	  organs.	  Both	  antibodies	  displayed	  extravasation	  
corresponding	   to	   degree	   of	   antigen	   sink,	   in	   which	   ED2	   showed	   the	   more	   rapid	  
clearance,	   and	   with	   each	   agent	   permitting	   early	   imaging	   time	   point	   for	   an	   intact	  
antibody.	   The	   data	   are	   encouraging	   and	   supports	   the	   pursuit	   of	   in	   vitro	  
characterisation	  of	  both	  agents,	  and	  warrant	  their	  application	   in	  the	  study	  of	  disease	  
processes	  in	  which	  Mφ	  balance	  is	  critical,	  such	  as	  rheumatoid	  arthritis	  and	  cancer.	  




6 Chapter	  6	  	  Summary	  
This	  thesis	  proposed	  that	  radiolabelled	  anti-­‐Sn	  antibody	  could	  be	  used	  to	  image	  Mφ	  in	  
vivo.	  To	  this	  end,	  we	  have	  shown	  that	  a	  radiotracer	  based	  on	  the	  direct	  labelling	  of	  the	  
anti-­‐Sn	   antibody	   SER4	  with	   99mTc	  was	   able	   to	   bind	   to	   recombinant	   target	   antigen	   in	  
vitro	   using	   a	   radioHPLC	   assay,	   and	   that	   in	   vivo	   the	   tracer	   tracked	   to	   the	   expected	  
tissues	  in	  which	  endogenous	  Sn	  is	  expressed.	  Using	  a	  model	  of	  transplant	  rejection,	  we	  
demonstrated	   that	   it	  was	  possible	   to	   image	   the	   recruitment	  of	  Sn	  positive	  Mφ	   in	  an	  
acutely	  rejecting	  transplant	  as	  compared	  to	  a	  tolerated	  transplant.	  The	  specific	  identity	  
of	  these	  Mφ	  was	  not	   identified	  and	  future	  studies	  should	  seek	  to	  characterise	  these,	  
which	   could	   be	   achieved	   by	   flow	   cytometry	   analysis	   based	   on	   a	   panel	   of	   known	  
phenotypic	  markers.	  From	  	  a	  basic	  science	  point	  of	  view,	  it	  is	  of	  interest	  to	  know	  if	  Sn	  is	  
a	   functional	   participant	   in	   these	   Mφ	   populations,	   which	   has	   been	   shown	   previous	  
adaptive	  immune	  responses,	  or	  if	  Sn	  is	  simply	  a	  passive	  marker	  for	  inflammatory	  Mφ.	  
Whether	  Sn	   is	  functional	  could	  be	   investigated	  by	  conducting	  transplants	  onto	  Sn	  KO	  
background	  mice,	  or	  via	  blocking	  Sn	  with	  antibody,	  however	  neither	  approach	  would	  
determine	  if	  the	  influence	  of	  Sn	  is	  exerted	  locally	  in	  the	  rejected	  heart	  or	  systemically	  
in	  lymphoid	  tissue.	  From	  a	  more	  clinical	  perspective,	  identifying	  if	  Sn	  has	  a	  functional	  
role	   in	   rejection	  may	   provide	   a	   therapeutic	   strategy	   for	   treating	   this	   disease.	  When	  
also	   considering	   imaging,	   the	   ability	   of	   the	   probe	   to	   measure	   the	   response	   to	  
treatment	  would	  be	   informative	  upon	   the	  possibility	  of	   Sn	   imaging	  as	  a	   clinical	   tool.	  
Further	  on,	  although	  acute	  graft	   rejection	  events	  represent	  a	  significant	  outcome	  for	  
transplant	   recipients,	   it	   is	   the	   monitoring	   of	   chronic	   rejection	   that	   will	   have	   the	  
greatest	  impact	  as	  this	  is	  the	  chief	  cause	  of	  transplant	  rejection.	  Therefore,	  imaging	  of	  
Sn	  in	  a	  chronic	  transplant	  rejection	  model	  is	  a	  natural	  step	  from	  from	  these	  results.	  
The	   preliminary	   data	   collected	   during	   residence	   in	   the	  Wu	   Lab	   using	   a	   PET	   isotope	  
labelled	  anti-­‐Sn	  antibody	  generated	  the	  novel	  result	  that	  bone	  marrow	  Sn	  expression	  is	  
upregulated	  following	  response	  to	  localised	  irradiation,	  and	  that	  this	  could	  be	  imaged.	  
With	  scant	  data	  related	  to	  the	  roles	  of	  this	  particular	  Mφ	  subset,	  this	  represents	  some	  




significance	   of	   this	   result,	   establishing	   whether	   Sn	   upregulation	   relates	   to	   Mφ	  
recruited	   for	   the	   clearance	   of	   the	   debris	   resulting	   from	   irradiation	   or,	   more	  
speculatively,	  whether	  these	  Mφ	  are	  re-­‐establishing	  the	  haemopoietic	  niche,	  of	  which	  
they	  are	  critical	  components,	  in	  order	  to	  resume	  haematopoiesis.	  With	  the	  finding	  that	  
inhibition	   of	   CSF-­‐1	   signalling	   was	   able	   to	   abrogate	   this	   response	   then	   subsequent	  
investigation	   could	   seek	   to	   examine	   the	   cellular	   constituents	   of	   treated	   and	   non-­‐
treated	  mice	  and	   relate	  whether	   clearance	   is	   impeded.	   Simultaneously,	   the	   levels	  of	  
HSC	  colony	  forming	  units	  could	  be	  used	  to	  determine	  whether	  HSC	  are	  being	  retained	  
or	   released	   systemically	   in	   response	   to	   irradiation,	   and	   then	   this	   data	   may	   be	  
correlated	  with	   levels	   of	   Sn	   expression	   in	   the	   irradiated	   tissue.	  However,	   this	  would	  
not	  ascribe	  whether	  increased	  HSC	  retention	  is	  occurring	  specifically	   in	  the	  irradiated	  
tissue.	  	  
Sn	   expression	  was	   also	   found	   on	   a	   population	   of	   cells	   expressing	  markers	   of	  MDSC.	  
Although	   the	   possibility	   that	   Sn	   may	   include	   MDSC	   confounds	   its	   use	   as	   a	   Mφ-­‐
restricted	  marker,	  it	  also	  suggests	  another	  avenue	  for	  its	  function	  in	  vivo.	  Following	  the	  
observation	   that	  MDSC	   are	   recruited	   to	   the	   tumour	   environment	   following	   localised	  
irradiation	   and	   that	   these	   cells	   assist	   in	   tumour	   development	   (personal	  
communication,	   Lily	   Wu),	   as	   well	   as	   the	   enrichment	   of	   bone	   marrow	   Sn	   in	   the	  
proximity	  of	  an	  irradiated	  tumour	  that	  also	  express	  MDSC	  markers	  suggests	  an	  origin	  
for	   these	   infiltrating	   cells.	   Where	   MDSC	   are	   characterised	   by	   considerable	  
heterogeneity,	   the	   identification	   of	   Sn	   as	   a	   cell	   surface	   marker	   may	   represent	   the	  
identification	  of	  a	  specific	  subset	  with	  tumour	  promoting	  capacity.	  The	  significance	  of	  
this	  finding	  needs	  to	  be	  established	  but	  at	  present	  points	  to	  a	  novel	  cellular	  expression	  
of	  Sn.	  
We	  finally	  showed	  the	  feasibility	  of	  using	  antibodies	  targeted	  to	  different	  Mφ-­‐specific	  
antigens	   for	   simultaneous	   imaging	   of	   two	   different	  macrophage	   populations	   in	   rats.	  
Leading	   on	   from	   this	   a	   study	   examining	   the	   relative	   merits	   of	   these	   antibodies	   in	  
imaging	  Mφ	  recruitment	  during	  various	  disease	  models	  would	  be	  a	   logical	  next	  step.	  




arthritic	   induction	   using	   histological	   examination,	   repetition	   of	   this	  work	  with	  whole	  
body	  imaging	  would	  be	  a	  suitable	  experiment	  to	  assess	  the	  validity	  of	  this	  approach.	  
Apart	   from	  addressing	   the	  questions	   raised	  by	   the	   specific	   studies	  performed	  during	  
this	  thesis,	  the	  initial	  data	  supports	  the	  investigation	  of	  Sn	  targeting	  for	  imaging	  Mφ	  in	  
man.	  With	  the	  availability	  of	  anti-­‐human	  Sn	  antibody	  (HSN-­‐1),	  the	  next	  stage	  would	  be	  
the	   humanisation	   of	   this	   mouse	   background	   protein	   and	   production	   of	   it	   in	   GMP	  
facilities.	  With	  Sn	  expression	  identified	  on	  circulating	  monocytes	  the	  utility	  of	  strategy	  
may	  be	  restricted	  to	  binding	  to	  this	  cell	  population	  and	  subsequent	  imaging	  after	  their	  
extravasation	   from	   the	  vascular	   system.	   In	   this	  manner	   it	  would	  present	  as	  a	   similar	  
agent	   to	   Leukoscan,	   a	   radiolabelled	   antibody	   targeted	   to	   granulocytes.	  However	   the	  
different	   trafficking	   properties	   of	   the	   target	   cells,	   namely	   granulocytes	   tracking	   to	  
acute	   inflammation	   versus	   monocyte	   trafficking	   to	   chronic	   inflammation,	   could	   be	  
especially	  informative,	  for	  example	  in	  conditions	  such	  as	  atherosclerosis.	  If	  levels	  of	  Sn	  
on	  circulating	  monocytes	  were	  not	  found	  to	  be	  significant	  then	  anti-­‐human	  Sn	  imaging	  
could	  be	  a	  means	  of	  targeting	  inflammatory	  Mφ	  as	  observed	  in	  the	  preclinical	  findings	  
recorded	  here.	  
Future	   work	   focussed	   on	   preclinical	   studies	   may	   also	   involve	   the	   development	   of	  
engineered	  antibody	  fragments.	  The	  advantages	  of	  such	  proteins	  are	  often	  found	  with	  
site	  specific	   labelling	  to	  be	  able	  to	  produce	  uniform,	  reproducible	  imaging	  agents	  but	  
also	  for	  increasing	  antibody	  clearance	  and	  thus	  reducing	  imaging	  time	  points.	  Although	  
SER4	  showed	  exceptionally	  high	  clearance	  for	  an	  intact	  antibody,	  blood	  activities	  were	  
still	  relatively	  high	  during	  imaging.	  By	  dropping	  this	  further,	  the	  influence	  of	  blood	  pool	  
could	  be	  reduced	  whilst	  keeping	  the	  time	  between	  injection	  and	  imaging	  short.	  	  
In	   conclusion,	   this	   thesis	   has	   proposed	   anti-­‐Sn	   imaging	   as	   a	  means	   of	   identifying	   by	  
whole	   body	   imaging	   Mφ	   populations	   in	   vivo,	   and	   with	   the	   potential	   to	   track	   their	  
appearance	   during	   disease	   processes.	   By	   showing	   targeting	   to	   Sn	   Mφ	   in	   wild	   type	  
animals	   and	   during	   different	   disease	   models	   the	   validity	   of	   Sn	   targeting	   for	   in	   vivo	  
imaging	   has	   been	   established.	   Along	   with	   future	   studies	   examining	   the	   role	   of	   Sn	  
expressing	   cells	   in	   the	   specific	   systems	   that	   were	   covered	   during	   the	   course	   of	   this	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